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RÉSUMÉ 
Les vecteurs lentiviraux (LVs) sont considérés comme des véhicules de transfert prometteurs 
pour des applications en thérapie génique. Cependant, il y a un manque évident de stratégies de 
production efficaces et transposables à grande échelle. En effet, les techniques actuelles de 
production ne pourront pas suffire à la génération du nombre de LVs nécessaires pour les 
évaluations en phases cliniques et éventuellement pour leur commercialisation en cas de succès 
des essais. 
Dans ce travail, nous avons tout d’abord fait le point sur les méthodes actuelles de production des 
LVs et fait ressortir leurs contraintes intrinsèques. Jusqu’à ce jour, la production routinière de 
LVs se fait presqu’exclusivement à petite échelle avec des cellules adhérentes. Il est clair que ce 
mode de production ne sera pas suffisant pour répondre aux demandes futures en LVs. Afin de 
faciliter les essais cliniques et la production de LVs à des fins thérapeutiques après certification 
par les autorités de règlementation, il apparaît important de mettre au point de nouvelles 
stratégies de production à grande échelle et permettant l’obtention de vecteurs à hautes 
concentrations. 
Une technologie de production de LVs par transfection transitoire de cultures en suspension de la 
lignée cellulaire HEK293 a été développée. Dans ce procédé transposable à grande échelle, 
l’opération en mode perfusion a permis de résoudre la problématique associée à la faible stabilité 
fonctionnelle des LVs. La combinaison de plusieurs approches, incluant la transfection à haute 
densité cellulaire, la sélection de formulations avancées de milieux de culture et l’ajout de 
butyrate de sodium en tant qu’additif activateur d’expression, a permis d’augmenter 
significativement les productivités volumétriques et spécifiques. Ainsi, il a été  possible 
d’augmenter de 100 fois le taux de LVs fonctionnels, que ce soit à petite ou à grande échelle, 
permettant d’atteindre des titres fonctionnels maximaux en LVs avoisinant les 108 unités de 
transduction (tu)/mL. 
Les cinétiques de production ont été évaluées en utilisant plusieurs méthodes de quantification 
des LVs. Ainsi, on a pu observer que les titres maximaux en LVs fonctionnels sont atteints deux 
jours après transfection. Ces résultats ont également démontré que la qualité des LVs produits (la 
qualité étant définie ici comme le rapport entre le nombre de LVs fonctionnels et le nombre de 
LVs totaux) était généralement faible : de l’ordre de 1 à 4 % du nombre de particules virales 
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totales (mesurées comme le nombre de génomes viraux associés aux particules virales) étaient 
fonctionnelles. Une variation de ce pourcentage au cours du temps a été observée suite à l’ajout 
de butyrate de sodium après transfection. Des expériences complémentaires ont permis de 
démontrer que la qualité des LVs pouvait être améliorée en réduisant le temps de séjour des 
particules virales dans le milieu de culture et donc en opérant à plus hauts débits de perfusion. 
Enfin, nos résultats ont mis en évidence que la cytotoxicité des protéines membranaires VSV-G 
pouvait être une limitation possible aux rendements de production dans ce système. 
Les cinétiques de production des LVs en bioréacteur ont été caractérisées grâce à l’utilisation 
d’un suivi en ligne du signal de permittivité. Les mesures de permittivité ont permis de suivre des 
évènements tels que le bourgeonnement des vecteurs viraux ainsi que la variation des propriétés 
diélectriques des cellules productrices suite au relargage des  particules virales. L’évolution de la 
permittivité a été analysée et reliée à la cinétique de production des LVs afin d’identifier quatre 
phases caractéristiques post-transfection.  
La caractérisation détaillée du système des LVs, effectuée avec des méthodes de quantification 
hors-ligne et des outils de suivi en ligne, a mis en lumière plusieurs stratégies permettant un 
meilleur suivi du procédé ainsi que l’optimisation de celui-ci. 
La stratégie de production qui a été établie fut dès lors basée sur la transfection à des 
concentrations cellulaires élevées couplé à un mode de perfusion à haut débit. Cette approche, qui 
a permis d’obtenir des LVs fonctionnels à de hautes concentrations, pourrait facilement être 
adaptée à la production d’autres constructions de LVs.  
Les stratégies de production développées dans ce travail ont permis de générer des titres viraux 
avoisinant les 1010-1011 tu/L, ce qui correspond à des titres totaux de l’ordre de 1012-1013 
génomes viraux (vg)/L dans les surnageants de production. Les cinétiques de production et 
l’évolution du procédé sont bien documentées, ce qui permettra de guider les optimisations 
futures. En plus de faciliter la production de LVs, ce procédé pourrait être transférable à des 
installations manufacturières, afin de permettre l’évaluation et l’utilisation de ces vecteurs dans 
des essais cliniques.  
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ABSTRACT 
Lentiviral vectors (LVs) are promising delivery vehicles for applications in gene therapy. Yet, the 
field still relies on inefficient and non-scalable production strategies. Current production methods 
will become a limitation in later clinical evaluation phases and for commercialization when large 
amounts of LVs need to be generated.  
In this work, we first reviewed current LV production methods and point out the constraints 
intrinsic to these protocols. To date, routine LV production is almost exclusively performed in 
small scale systems using adherent cells. These protocols will not be able to satisfy the 
anticipated future demands in LVs. For their widespread testing in clinical settings and for the 
production of LV-based therapeutics after their approval, novel scalable production strategies are 
needed to robustly produce these vectors at high yield.  
An optimized protocol for LV production was developed using a HEK293 cell line grown in 
suspension cultures. In this scalable process, production in perfusion mode addressed the low 
stability of functional LVs. Several strategies such as transfection at high cell density, selection 
of advanced medium formulations and addition of the expression-enhancing additive sodium 
butyrate resulted in significant improvements of volumetric and specific productivity. The overall 
yield in functional LVs was increased by 100-fold and similar results were obtained for small and 
bioreactor scale cultures, reaching maximum functional LV titers in the range of 108 transducing 
units (tu)/mL. 
The production kinetics under improved conditions was then analyzed employing several LV 
quantification methods. After transfection, highest functional LV titers were reproducibly found 2 
days post-transfection. The results also showed that LV quality, as the ratio of functional to total 
LV particles was generally low with only 1-4 % of the total viral particles (measured as the 
number of viral genomes) being functional, i.e. having the ability to transfer genetic information. 
This ratio was not constant over time when sodium butyrate was added after transfection. LV 
quality was also increased at higher harvest rates. Our results also indicate that the cytotoxic 
effects of VSV-G might be limiting for further yield improvements of the current LV production 
system. 
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LV production kinetics was also characterized using online monitoring of the permittivity signal 
in bioreactor productions. Permittivity measurements are valuable for identification of events 
such as budding of viral vectors as dielectric properties of the producing cells are affected during 
the viral release process. The evolution of the permittivity signal was analyzed and linked to the 
LV production kinetics to identify four key process transition phases after transfection which are 
characteristic of LV production. 
The in depth process characterization of the LV system with offline LV quantification methods 
and online tools provided several avenues for process monitoring and further process 
optimization. 
The developed LV production strategy is based on high cell density transfection. The approach 
delivers LVs at high yield in a timely manner and should be easily adaptable to other LV 
constructs.  
The strategies developed in this work provide unprecedented yields of 1010-1011 tu/L, 
corresponding to 1012-1013 viral genomes (vg)/L of production supernatant. Production kinetics 
and process evolution are well characterized, which will guide future yield optimization. As it 
facilitates the production of LVs, the developed process should thus enable the evaluation and use 
of these vectors as a therapeutic and should be an attractive option to generate LV for future 
clinical trials. 
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CONDENSÉ EN FRANÇAIS 
La thérapie cellulaire et la thérapie génique sont des secteurs très prometteurs pour le traitement 
de plusieurs maladies potentiellement mortelles et pour lesquelles peu de traitements alternatifs 
existent. Le traitement des anomalies génétiques, du cancer et certaines stratégies de vaccination 
font partie des applications les plus importantes. La thérapie génique a été développée sur la base 
de progrès considérables accomplis au cours des vingt dernières années lors de recherches 
menées sur les maladies génétiques (Rosenzweig 1999). Le principe général repose sur 
l’introduction d’une copie fonctionnelle d’un gène défectueux ou absent dans une cellule, afin 
d’éliminer la maladie engendrée par ce dernier (McTaggart et Al-Rubeai 2002).  
 
Pour assurer le transfert de l’information génétique, des véhicules permettant de livrer des 
transgènes de façon efficace et sécuritaire au sein des cellules cibles sont requis. Ces véhicules 
(ou vecteurs) peuvent être d’origine virale ou non. Des vecteurs viraux ont été développés à partir 
de différentes souches virales naturelles.  
 
L'essor de la thérapie génique a été considérablement ralenti à cause d'incidents survenus durant 
les programmes d'évaluation clinique. Malgrè tout, près de 1500 essais cliniques ont à ce jour été 
effectués avec des résultats expérimentaux démontrant un avenir prometteur pour les vecteurs 
viraux. Ainsi, la première commercialisation d’un vecteur viral en tant qu’agent thérapeutique a 
été autorisée en Chine en 2007. 
 
Les vecteurs lentiviraux (LVs) sont considérés comme l’un des véhicules de transfert les plus 
prometteurs pour les applications en thérapie génique. Les LVs sont la plus récente des classes de 
vecteurs et sont conçus à partir du virus d’immunodéficience humaine de type 1 (VIH-1). Ces 
vecteurs sont néanmoins dépourvus des propriétés pathogéniques du VIH-1, ne peuvent ni se 
répliquer ni transférer des gènes viraux, et ne sont pas reconnus par le système immunitaire des 
patients. Ils conservent par contre leur capacité de transférer des transgènes (Throm, Ouma et al. 
2009). En comparaison avec d’autres vecteurs viraux, ils offrent divers avantages, tels que la 
possibilité d’accueillir une longue séquence de nucléotides, la capacité à transduire des cellules 
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ne se divisant pas, ainsi qu’une expression longue et stable du transgène (Cockrell et Kafri, 
2007).  
 
Jusqu’à present, les LVs ont démontré leur potentiel en thérapie génique et sont utilisés dans au 
moins 25 études cliniques (D’Costa, Mansfield et al. 2009). Le premier essai clinique utilisant 
des LVs a été approuvé en 2002. Plusieurs autres traitements contre des maladies infectieuses et 
génétiques utilisant des LVs sont actuellement en cours, ont été approuvés ou sont en préparation 
(D’Costa, Mansfield et al. 2009). Les LVs sont donc un outil important pour le developpement 
d’avancées significatives dans le traitement de nombreuses pathologies. Celles-ci regroupent les 
maladies neurodégénératives, telles que l’adrénoleucodystrophie (ALD) et la maladie de 
Parkinson ainsi que la β-thalassémie et sa forme plus sévère, la drépanocytose. Enfin, le 
traitement de certains cancers, après transduction de cellules ayant des fonctions immunologiques 
manquantes chez le patient, est également une approche thérapeutique pour laquelle des essais 
cliniques sont développés (D’Costa, Mansfield et al. 2009). 
 
L’utilisation des LVs est jusqu’à présent limitée exclusivement à des applications ex vivo sur les 
cellules des patients. Les approches in vivo doivent tenir compte du large tropisme cellulaire des 
LVs pseudotypés avec la glycoprotéine G du virus de la stomatite vésiculaire (VSV-G). Ce large 
tropisme empêche le ciblage du vecteur à un type cellulaire bien défini, suscitant des inquiétudes 
quant à la possibilité de transduction non-spécifique de cellules telles que les cellules 
dendritiques, souches et germinales.  
 
Bien que les stratégies basées sur les LVs présentent un large potentiel pour de nombreuses cibles 
thérapeutiques, leur utilisation intensive est fortement tributaire de la capacité de produire ces 
vecteurs en grandes quantités. Actuellement, la production des LVs à haut rendement demeure 
une contrainte à l’application clinique des stratégies thérapeutiques élaborées experimentalement. 
Les méthodes actuelles de production couramment employées présentent de faibles rendements et 
de nombreuses limitations en terme de mise à l’échelle puisqu’elles reposent sur la culture de 
cellules adhérentes. Les protocoles de production des LVs demeurent largement empiriques; les 
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procédés ne sont généralement pas bien caractérisés au niveau de la productivité cellulaire, des 
titres maximums pouvant être atteints, des cinétiques de production, du temps de récolte optimal 
et de la stabilité du vecteur. Il semble donc évident que ces méthodes de production rudimentaires 
ne soient pas directement adaptables à une production à grande échelle, car la robustesse et la 
reproductibilité de ces procédés est insuffisante pour la fabrication industrielle des LVs. En effet, 
les techniques actuelles de production ne pourront pas suffire à la génération du nombre de LVs 
nécessaires pour les évaluations en phases cliniques et éventuellement pour leur 
commercialisation. 
 
L’objectif principal de cette thèse est l’identification des paramètres critiques pour la production 
de LVs dans des cultures de cellules HEK293 en suspension, permettant ainsi le développement 
d’un procédé transposable à plus grande échelle et la production de LVs à hautes concentrations. 
Les méthodes actuelles de production de LVs souffrent de faibles rendements et il reste plusieurs 
questionnements au niveau de la productivité et des étapes de production. La caractérisation de 
ces différentes étapes reste à faire. Il est, par ailleurs, attendu que le rendement fonctionnel des 
LVs avec ce système peut être amélioré de façon significative à l’aide d’un suivi en ligne et hors 
ligne et d’un contrôle des paramètres critiques du procédé.  
 
Le but ultime de cette recherche est d’identifier, de suivre et de contrôler des paramètres critiques 
qui déterminent la production efficace des LVs et qui permettent le développement d’un procédé 
robuste et transposable à grande échelle. Plus spécifiquement, ces travaux visent:  
1) L’identification des conditions du procédé qui ameliorent la productivité des LVs et le 
développement d’une stratégie d’optimisation détaillée en vue d’améliorer  les techniques 
actuellement utilisées pour la production de LVs  
2) La caractérisation des cinétiques de production pour guider l’identification de stratégies 
permettant une succession d’opérations robustes et optimisées 
3) La mise en évidence de liens entre les cinétiques de production virale et des mesures 
effectuées en ligne afin de permettre le suivi en temps réel du procédé 
xiii 
 
Dans ce travail, nous présenterons tout d’abord une revue de la littérature approfondie, qui couvre 
les propriétés des systèmes LVs actuels, ainsi que leur quantification et qui fait le point sur les 
méthodes actuelles de production, tout en soulignant les contraintes intrinsèques de celles-ci.  
 
Jusqu’à ce jour, la production routinière de LVs se fait presqu’exclusivement à petite échelle avec 
des cellules cultivées en adhérence. Néanmoins, des améliorations significatives ont été obtenues 
à ce niveau. En effet, bien qu’ils soient longs, fastidieux et sujets à une grande variabilité, les 
protocoles actuels de production utilisant des flacons statiques (T-flasks) permettent tout de 
même d’obtenir des concentrations suffisantes pour supporter des recherches à petite échelle. 
Toutefois, en raison de la large gamme de protocoles de production et de méthodes de 
quantification retrouvés dans la littérature, il s’avère difficile de comparer les résultats provenant 
des différents groupes de recherche. De plus, les approches d’optimisation s’appuyant sur des 
principes de génie biochimique sont rarement retrouvées dans la littérature couvrant le sujet. Les 
procédés existants ne sont donc pas adaptés pour répondre aux demandes futures en LVs. Afin de 
permettre des essais cliniques et la production de LVs à des fins thérapeutiques, il apparaît 
primordial de mettre au point de nouvelles stratégies efficaces de production à grande échelle et 
permettant avec obtention de vecteurs à hautes concentrations. 
 
Dans ce travail, une stratégie de production de LVs par transfection transitoire a tout d’abord été 
développée avec des cultures de la lignée cellulaire HEK293 en suspension. Dans ce procédé 
facilement transposable à grande échelle, il est apparu que la production en mode perfusion 
permettait de résoudre la problématique associée à l’instabilité fonctionnelle des LVs.  
Par la suite, plusieurs stratégies comme la transfection à haute densité cellulaire, la sélection de 
formulations avancées de milieu de culture et l’ajout de butyrate de sodium en tant qu’additif 
stimulant l’expression ont permis d’augmenter significativement les productivités volumique et 
spécifique. 
 
Plus spécifiquement, l’utilisation d’une approche de transfection à haute densité cellulaire a 
permis d’augmenter la productivité volumique par un facteur cinq. Par la suite, une optimisation 
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des conditions de transfection transitoire au polyéthylènimine (PEI) dans un milieu plus 
performant a permis de doubler le rendement de la méthode. Les meilleurs résultats ont été 
obtenus avec un ratio massique en PEI:DNA de 2:1 et 0.4-0.6 µg d’ADN total/ 610  cellules 
utilisées pour la transfection dans le milieu de culture HyClone SFM4Transfx-293 (HyQ) 
medium. Cette technique a permis de réduire les effets cytotoxiques du PEI et d’augmenter le 
rendement de la méthode. Il est à noter que de toutes les conditions évaluées, l’ajout de butyrate 
de sodium a eu l’effet le plus significatif sur le titre fonctionnel, en augmentant de quinze fois le 
rendement total. Ainsi, il a été possible d’augmenter de plus de 100 fois le taux de LVs 
fonctionnels, que ce soit à petite ou à grande échelle, permettant ainsi d’atteindre des titres 
maximums avoisinant les 108 unités de transduction (tu)/mL dans le surnageant non-concentré. Il 
a également été démontré que le procédé est transposable à la culture en bioréacteur tout en 
conservant un rendement similaire, et ce jusqu’à une échelle de 3 L. Les résultats suggèrent 
qu’avec ce procédé à haut rendement, une seule production dans une unité pilote permettrait de 
produire la quantité de LVs requises pour la réalisation d’essais cliniques de phase I.  
 
Dans le cas du système modèle étudié, pour obtenir un rendement total de l’ordre de 0.5 à 1x1010 
tu à petite échelle, la meilleure stratégie consisterait à effectuer la production à une densité 
cellulaire d’environ 5 à 10x106 c/mL en effectuant 2 changements de milieu par jour. Ces 
conditions permettraient ainsi d’obtenir de hauts rendements totaux, tout en préservant la qualité 
des LVs. Les surnageants cellulaires pourraient ensuite être congelés pour de futures étapes de 
purification ou être directement concentrés par ultracentrifugation. 
 
À l’échelle de bioréacteur et pour l’obtention de rendements supérieurs à 1x1011 tu, le choix 
d’opérer avec changement(s) de milieu dépend fortement de la possibilité d’effectuer 
adequatement les étapes de purification subséquentes, ainsi que de l’importance accordée à la 
qualité des LVs.  
 
Changer l’équivalent de deux volumes de réacteur par jour (2 VVD) permet d’obtenir des LVs de 
qualité supérieure par rapport à une production réalisée à 1 VVD. Des LVs en quantité deux fois 
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plus importantes sont retrouvés dans le surnageant à 2 VVD, mais la période de conservation à 
4°C est limitante en raison de l’instabilité des vecteurs. En outre, la congélation de larges 
volumes est difficilement réalisable. Ainsi, c’est la  stratégie de purification qui doit dicter si la 
production avec de nombreux échanges de milieu est avantageuse ou non.  
 
Il est important de noter que les rendements totaux en LVs sont fonction du système d’expression 
et du transgène d’intérêt; les rendements absolus peuvent dès lors significativement différer des 
valeurs observées pour le modèle utilisé dans ce travail. Nous avons décrit une démarche 
générique de production de LVs pouvant s’appliquer pour l’amélioration des constructions de 
LVs et leur évaluation à petite et à grande échelle. La stratégie de perfusion à plus grande échelle 
peut également faciliter le développement des technologies reliées, telles que le passage à grande 
échelle des procédés de purification qui était initialement limité par l’incapacité de générer de 
grands volumes de surnageant contenant des LVs concentrés.  
 
Toutefois, même en utilisant des conditions améliorées de production, la productivité cellulaire 
spécifique en vecteurs viraux fonctionnels demeure faible (60-120 tu/cellule). Nos résultats ont 
d’ailleurs permis de mettre en évidence que les rendements de production dans ce système sont 
limités par les effets cytotoxiques de VSV-G. Si ces observations sont confirmées avec d’autres 
systèmes d’expression, le développement et l’utilisation de lignées cellulaires stables serait alors 
questionnable, puisque la production des LVs par ces systèmes pourrait également être limitée 
par les effets toxiques de VSV-G.  
 
La production de LVs est également fonction de la disponibilité des nutriments dans la culture. 
Toutefois, un travail plus approfondi est requis pour comprendre l’influence de l’état métabolique 
des cellules sur les rendements de production. Des résultats préliminaires ne permettaient pas de 
déterminer si le procédé actuel était limité par des contraintes d’ordre métabolique ou par une 
efficacité de transfection à haute densité cellulaire. 
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Les cinétiques de production à petite échelle et en bioreacteur ont été évaluées initialement en 
utilisant les méthodes de quantification des LVs. Les titres maximaux en LVs fonctionnels ont 
été observés deux jours après transfection. Ces résultats ont également montré que la qualité des 
LVs, définie comme étant le rapport entre le nombre de LVs fonctionnels et le nombre de LVs 
totaux, était généralement faible, soit à peine 1 à 4 % du nombre de particules virales totales 
(mesurées comme le nombre de génomes viraux). Une variation de ce pourcentage au cours du 
temps a été remarquée suite à l’ajout de butyrate de sodium après transfection. La qualité des LVs 
a pu être également améliorée via des taux de récoltes plus élevés.  
 
Les méthodes actuelles de quantification représentent une contrainte importante pour le 
développement du procédé, puisqu’elles sont pour la plupart longues, fastidieuses et génèrent des 
résultats très variables. Il y a un urgent besoin de standardisation et de nouvelles méthodes de 
quantification pour les vecteurs lentiviraux sont requises. Pour ce faire, la précision et la rapidité 
des différentes méthodes sont des paramètres critiques à considérer. Actuellement, la 
quantification du titre des LVs par la RT-PCR semble être l’approche directe la plus efficace afin 
d’obtenir un nombre total de particules. Au niveau des méthodes indirectes, nos résultats ont 
révélé l’importance de contrôler le nombre de passages cellulaires afin de diminuer 
significativement la variabilité des mesures de titres de LVs fonctionnels. 
 
Afin de permettre le suivi en temps réel du procédé de transfection transitoire, il est nécessaire 
d’identifier des outils d’analyse en ligne capables de détecter le relargage et les cinétiques de 
production des vecteurs viraux. De tels outils facilitent grandement le développement des 
procédés, supportent leur optimisation et l’implantation de la démarche PAT (« Process 
Analytical Technologies »). Cette dernière vise à soutenir  l’innovation dans les procédés 
pharmaceutiques, en vue d’améliorer les critères de production et d’assurance de qualité. Cette 
démarche vise donc à améliorer la robustesse des procédés et à faciliter le contrôle en ligne de la 
qualité du produit. Les cinétiques de production en bioréacteur ont pu être suivies en cours de 
culture grâce à une mesure en ligne de la permittivité. L’évolution de la permittivité a ainsi 
permis d’identifier quatre phases de transition caractéristiques associées à la production de LVs 
après transfection. Les résultats du suivi en ligne ont reflété d’une manière reproductible les 
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cinétiques de production des LVs pour plusieurs productions en bioréacteur, utilisant des 
conditions d’opération différentes. Des changements relatifs pendant la phase de production ont 
montré une corrélation avec le rendement total en termes de génomes viraux de ces productions 
en bioréacteur. Les mesures de permittivité ont permis de suivre des évènements tels que le 
bourgeonnement des vecteurs viraux ainsi que la variation des propriétés diélectriques des 
cellules productrices suite au relargage de particules virales. Cette technologie constitue donc un 
bon outil pour le criblage des conditions d’opération et la caractérisation du procédé.  
 
La caractérisation détaillée du système des LVs, effectuée avec des méthodes de quantification 
hors-ligne et des outils de suivi en ligne, a mis en lumière plusieurs stratégies permettant un 
meilleur suivi du procédé ainsi que l’optimisation de celui-ci. Les améliorations les plus 
significatives peuvent être espérées au niveau moléculaire, telles qu’une augmentation de la 
stabilité des LVs fonctionnels, une diminution de la cytotoxicité de l’enveloppe ou encore des 
stratégies de régulation de VSV-G. Des enveloppes de LVs alternatives ont été décrites dans le 
but de les utiliser pour l’obtention des titres viraux plus élevés (Verhoeyen et Cosset 2004; 
Cronin, Zhang et al. 2005). Par contre, les LVs qui ne sont pas pseudotypés avec VSV-G sont 
limités à des applications et à des cibles cellulaires spécifiques.  
 
D’autres possibilités pour améliorer le procédé sont également envisageables au niveau du choix 
des conditions opératoires. Une meilleure caractérisation du métabolisme des cellules HEK293 
dans le milieu HyQ permettrait de développer des stratégies d’alimentation permettant 
d’augmenter la densité cellulaire lors de la transfection, sans perte de productivité spécifique. Dès 
lors, il semble nécessaire d’effectuer des études métaboliques et des travaux portant sur 
l’optimisation du milieu afin d’augmenter les taux de LVs produits. Par exemple, des 
concentrations potentiellement inhibitrices en lactate ont été observées lors des cultures en 
perfusion. En raison du manque de méthodes simples et fiables pour quantifier les LVs, il est 
recommandé de réaliser cette étude en utilisant des systèmes de transfection pour lesquels la 
production protéique peut être plus facilement mesurée.  
Des travaux portant sur la production de vecteurs rétroviraux suggèrent que le contenu lipidique 
cellulaire joue un rôle critique dans la production des vecteurs (Merten 2004; Coroadinha, Alves 
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et al. 2006; Coroadinha, Ribeiro et al. 2006; Coroadinha, Silva et al. 2006). Comme la 
concentration en lipides dans les vecteurs produits semble déterminer leur stabilité, il serait 
intéressant d’étudier spécifiquement les effets de la concentration en lipides du milieu de culture 
sur la production et la stabilité des LVs (Beer, Meyer et al. 2003; Carmo, Faria et al. 2006; 
Coroadinha, Alves et al. 2006). Aussi, d’autres études pourraient porter sur l’exploitation des 
signaux en temps réel pour des fins de contrôle et de réglage du procédé. Par exemple, le signal 
de permittivité pourrait être utilisé pour contrôler directement le taux de récolte. L’alimentation 
en milieu pourrait également être contrôlée en fonction du signal de permittivité avant 
transfection, ce qui permettrait de minimiser la consommation du milieu de culture et la 
formation de métabolites toxiques. 
Les stratégies développées dans ce travail ont permis de générer des titres viraux avoisinant les 
1010 à 1011 tu/L, ce qui correspond à des titres de l’ordre de 1012 à 1013 génomes viraux (vg)/L 
dans les surnageants non-concentrés de cultures. Les cinétiques de production et l’évolution du 
procédé sont bien documentées, ce qui permettra de guider les optimisations futures. Le procédé 
développé rend ainsi possible l’évaluation et l’utilisation de ces vecteurs en tant que thérapie et 
pourra être une option intéressante pour la production future de LVs à des fins cliniques.  
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1 
INTRODUCTION 
Background 
Gene and cell therapy are fields holding tremendous promises as they offer therapeutic strategies 
for a wide variety of diseases. To date, approximately 1500 gene therapy clinical trials have been 
completed, are ongoing or have been approved (Edelstein, Abedi et al. 2007; 
http://www.wiley.co.uk/genetherapy/clinical/). A first gene therapy product has now been 
approved in China (Peng 2005). The treatment of genetic dysfunctions, cancer and vaccination 
strategies are at the forefront of possible applications. Gene therapy is based on the significant 
progress that has been made in understanding the genetic basis of several diseases over the last 20 
years (Rosenzweig 1999). Its original principle is defined as the introduction of a normal 
(functional) copy for the correction of a defective or missing gene to eliminate disease symptoms 
(McTaggart and Al-Rubeai 2002).  
All gene and many cell therapy approaches require the use of gene transfer vehicles (vectors). An 
ideal vector allows for the safe and efficient transfer of genetic information to the patient. Non-
viral or viral vectors are used as delivery vehicles. The latter were found to be extremely efficient 
and have been consequently more extensively studied. The respective advantages of each viral 
vector are a function of the underlying biology of the virus that determines the main vector 
characteristics such as immunogenicity, packaging capacity, expression of the transgene, 
infectivity and cellular or tissue tropism. 
Although conceptually straightforward, the practical development of gene therapy interventions 
remains challenging. A fatal incident during a gene therapy clinical trial occurred at the turn of 
the century and led to the death of one patient in a study conducted in 1999 (Raper, Chirmule et 
al. 2003). Only a few months later the results of a different trial where 3 out of 10 treated patients 
suffering from a severe immune deficiency (SCID-X1) developed leukemia several years after 
the treatment, were made public (Hacein-Bey-Abina, Von Kalle et al. 2003). However, in all 
treated patients, this study provided proof of principle that gene therapy can work. These 
incidents and other results from ineffective gene therapy clinical trials marked important setbacks 
for the entire field (Steinbrook 2007; Iaccino, Schiavone 2008). The scientific community also 
remains sceptical on the effectiveness of the first commercialized gene therapy intervention in 
China, partly due to the difficulty in comparing the clinical outcomes (Ma, Shimada et al. 2009). 
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As a consequence, research in the gene therapy area mainly shifted back from clinical 
applications to experimental research (Müller-Röber, Hucho et al. 2008). The main focus in the 
gene therapy field is now on designing better vectors with the goal to overcome the disadvantages 
of these early-generation gene delivery vehicles. 
Lentiviral vectors (LVs) are one of the most recently developed forms of virus-derived gene 
delivery vectors. LVs were designed based on the biology of human immunodeficiency virus-1 
(HIV-1). For that purpose, the molecular architecture of HIV-1 was dramatically altered to 
remove pathogenic properties, avoid replication of the vector and emergence of replication 
competent lentiviruses (RCLs) but conserve its natural ability for gene transfer. LVs are therefore 
replication-deficient, do not transfer any viral genes and recipients lack a pre-existing immune 
response to the vector (Throm, Ouma et al. 2009). In comparison to other viral vectors, they offer 
several advantages, including a large packaging capacity, the ability to transduce non-dividing 
cells and a stable, i.e. life-long, transgene expression (Cockrell and Kafri 2007).  
To date, LVs have already demonstrated their potential for gene therapy in clinical studies and 
are under investigation in approximately 25 clinical trials (D’Costa, Mansfield  et al. 2009). The 
first clinical trial using LVs was approved in 2002. Several others targeting infectious and genetic 
diseases are currently in progress, have been approved or are in preparation (D’Costa, Mansfield 
et al. 2009). Interestingly, HIV infection is to date one of the preferred targets in ongoing clinical 
trials using LVs, exemplifying that the system came a long way since its initial development. 
These therapies are based on RNA interference (RNAi) and delivery of an anti-HIV payload gene 
into autologous CD4+ T lymphocytes with the goal to inhibit HIV-1 replication (D’Costa, 
Mansfield et al. 2009).  
LVs hold much promise for a wide range of applications. Disease targets that are currently under 
investigation comprise neurodegenerative disorders such as adrenoleukodystrophy (ALD) and 
Parkinson’s disease, β-thalassemia and its more severe form, sickle cell anemia. Cancer therapy, 
after transduction of cells with immune functions, is another promising area in which clinical 
trials are in development (D’Costa, Mansfield et al. 2009). 
To date, LVs are almost exclusively limited to ex vivo administration into patient cells. In vivo 
approaches face the challenge that the widely used vesicular stomatitis virus glycoprotein G 
(VSV-G) pseudotyped LVs have a wide tropism, which renders a targeted delivery to a certain 
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cell type impossible and raises concerns on transduction of off-target cell types such as dendritic, 
stem and germ cells. 
Research Problem, Hypothesis and Objective 
Although LV-based strategies hold great promise for a wide variety of targets, their extensive use 
highly depends on the ability to efficiently generate these vectors in large amounts. To date, LV 
mass production remains an important constraint for the translation of therapeutic straegies to the 
clinic. Current routine LV production methods have low yields and are limited in terms of their 
scalability. Protocols to produce LVs are largely empirical and the processes are generally not 
well characterized with cellular productivity, peak titers, production kinetics, optimum harvest 
points and vector stability being only rarely determined. It can be anticipated that these current 
rudimentary protocols are not readily amenable to large scale production and that they would 
result in insufficient process robustness to support industrial manufacturing.  
The driving hypothesis of this work is that the identification of critical parameters for the 
production of LVs in suspension-grown HEK293 cells allows for the development of a scalable 
process delivering LVs at high yield. Current LV production methods suffer from low yields as 
several issues that determine productivity in a critical manner are not sufficiently addressed by 
the process strategy. Also, it is believed that the functional LV yield of this system could be 
improved significantly by online and offline monitoring and controlling the critical process 
parameters that dictate productivity.  
The overall objective of this work is to identify, monitor and/or control parameters that are 
critical for the efficient generation of LVs and that allow for the development of a scalable and 
robust production process. More specifically, this work aims to:  
1) identify process conditions resulting in enhanced LV productivity to propose and develop 
a detailed optimization strategy for the improvement of the current state of the art of LV 
production 
2) characterize the production system and its kinetics to guide strategies that will help in 
defining a robust and optimized operation of the process 
3) link the viral release and production kinetics to the results from online permittivity 
measurements to allow for monitoring and supervision of LV production in real-time  
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Thesis Structure 
The thesis can be divided in four main parts: 
1) an extensive literature review (chapter 1)  
2) a methodology section (chapter 2) 
3) the development of a scalable process delivering high yields (chapter 3) 
4) the characterization of the LV production process (chapters 4 and 5) 
The first chapter was published as a review article entitled “Recent progress in lentiviral vector 
mass production” in the Biochemical Engineering Journal. In this paper, current strategies for 
LV production are critically assessed and compared.  
The set of methods used during this research project is described in detail in chapter 2 
“Methodology for scalable LV production and process characterization”. This chapter also 
comprises a short summary and error assessment of LV quantification methods. 
Chapter 3 was published as a research article entitled “Development of a scalable process for 
high-yield lentiviral vector production by transient transfection of HEK293 suspension 
cultures” in the Journal of Gene Medicine. The paper describes an optimization strategy that 
translated to improvements in LV yields by 100-fold under scalable operating conditions. In this 
approach, production in perfusion mode was successfully used to continuously harvest functional 
LV thereby addressing the critical problem of low LV vector stability.  
In chapter 4, entitled “Characterization of lentiviral vector production kinetics using offline 
quantification methods” the process kinetics was assessed to further characterize the production 
system and to identify intrinsic limitations and further possible optimization strategies. In chapter 
5, the application of permittivity measurements for real-time monitoring of LV production is 
presented. The chapter is entitled “Monitoring lentiviral vector production kinetics using 
online permittivity measurements” and has been submitted to the Journal of Biotechnology. 
Finally, complementary experiments are summarized in the appendices. This last section is 
divided in four parts. A preliminary study on LV stability in culture supernatants can be found in 
appendix I. Process limits and operating windows of high cell density LV production by transient 
transfection are presented in appendix II. Appendix III is presented as a draft manuscript entitled 
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“Practical applications of online permittivity signals: characterization of HEK293 batch growth 
and identification of metabolic shifts” and introduces permittivity measurements as real-time 
monitoring tool for mammalian cell cultures. Appendix IV finally summarizes additional relevant 
experimental observations that are not integrated in the main chapters of the thesis. 
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CHAPTER 1 LITERATURE REVIEW: RECENT PROGRESS IN 
LENTIVIRAL VECTOR MASS PRODUCTION 
1.1 Article Presentation 
The goal of this thesis is to improve current production methods of lentiviral vectors in order to 
develop strategies that will be applicable for LV mass production for clinical trials and 
commercialization. This chapter provides a critical review of studies reporting LV production and 
summarizes the progress which was made in the field since HIV-1 based LVs were first described 
in 1996. The performance of routine and advanced protocols is compared and it is pointed out 
that the LV production methods currently in place are limited in terms of their scalability. The 
review thus allows understanding the constraints of current LV production strategies and 
emphasizes the need for improved and scalable production strategies that are later presented in 
this thesis. 
1.2 Recent Progress in Lentiviral Vector Mass Production  
Sven Ansorge1,2, Olivier Henry2 and Amine Kamen1,2 
1
: National Research Council Canada, Biotechnology Research Institute,  6100 Royalmount 
Avenue, Montréal, Québec H4P 2R2, Canada; 2: École Polytechnique de Montréal, C.P. 6079, 
succ. Centre-ville, Montréal, Québec H3C 3A7, Canada 
1.2.1 Abstract 
Lentiviral vectors (LVs) are promising tools for gene and cell therapy. They are presently used in 
several clinical trials as in vivo or ex vivo gene delivery vectors. However their mass production 
remains a challenge and might limit their potential therapeutic use. New robust and scalable 
processes are required for industrial production of these vectors.  
In this review, we focus on the assessment of current LV production methods and evaluate the 
most critical limitations with a focus on scalability. The key properties of LVs are described and 
their inherent advantages and disadvantages discussed. A brief overview of the quantification 
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methods generally used to characterize vector production is also provided as well as indications 
on downstream processing and basic regulatory aspects.  
The recent developments in the field including production in serum-free suspension cell cultures 
indicate that LV production is now amenable to industrial manufacturing using reliable large-
scale processes.  
1.2.2 Introduction 
Worldwide, more than 20 clinical trials are currently investigating the use of lentiviral vectors 
(LVs) for gene delivery targeting a variety of diseases (http://www.wiley.co.uk/ 
genetherapy/clinical/). In particular the ability of LVs to transduce non-dividing cells render them 
an important tool for the treatment of neurological and lympho-hematological disorders 
(Quinonez and Sutton 2002; Salmon and Trono 2002; Azzouz, Kingsman et al. 2004; Cockrell 
and Kafri 2007). LVs provide efficient delivery, integration and long-term expression by 
establishing a stable provirus in target cells (Quinonez and Sutton 2002). These properties led to 
a widespread use in research and clinical environments for in vitro and in vivo gene transfers 
(Cockrell and Kafri 2007).  
With the increasing use of LVs in translational research programs, scalable, effective and robust 
LV production processes become of critical importance. Processes that can be swiftly transferred 
to manufacturing sites once LV-based vectors are ready for use in approved clinical trials are 
needed. As demonstrated for other viral vectors-based therapeutics, these processes are a 
fundamental requirement for the successful advancement of LV-based therapeutic interventions 
(Wright 2009). Current production methods do, however, not meet these requirements, show only 
low yields and are typically not easily scalable (Stewart, Leroux-Carlucci et al. 2009).  
This review focuses on the mass production of LVs to provide sufficient material for clinical 
trials. Current production methods are compared, in particular for their scale-up potential, with 
respect to robust LV manufacturing. First, we briefly summarize the most important properties of 
lentiviruses as those determine LV functions, expression kinetics and vector stability. Then we 
introduce the different methods for LV quantification, compare production strategies and provide 
general indications on LV downstream processing methods and regulatory aspects. Since LV 
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systems based on human immunodeficiency virus (HIV)-1 are by far the most advanced to date, 
we will focus on this vector family.  
LV elements are encoded by several plasmid constructs or expression cassettes (Fig 1.1). Vector 
particles are assembled in trans from constructs without most viral cis-acting sequences. The 
packaging construct codes for the core and enzymatic components of the usually HIV-1 derived 
virion. A second construct is responsible for expression of the viral envelope which is most 
commonly VSV-G (envelope construct). The viral cis-acting sequences are delivered by an 
expression cassette which encodes for the transgene of interest (transfer vector construct). These 
constructs need to be simultaneously expressed in a respective producer cell. We briefly 
summarize the most important properties and functions of these constructs and refer to extensive 
and more detailed reviews wherever possible.  
Most recent LV production systems use 3rd generation plasmid constructs (Dull, Zufferey et al. 
1998; Vigna and Naldini 2000; Quinonez and Sutton 2002) (Fig. 1.1 A). Whereas tat-dependent 
systems may result in mobilization of vectors upon transfer of gag-pol and env or HIV-1 
superinfection (Bukovsky, Song et al. 1999), tat is removed in these constructs and its function 
replaced by a heterologous strong promoter (e.g. CMV). The accessory gene nef can be removed 
from LV constructs pseudotyped with the most commonly used pH-independent envelopes 
(Aiken 1997; Luo, Douglas et al. 1998; Chazal, Singer et al. 2001).  
VSV-G is by far the most often used LV envelope (Fig. 1.1 B). This envelope protein has been 
already used in retroviral vector (RV) constructs to broaden vector tropism (McClure, Marsh et 
al. 1988; Akkina, Walton et al. 1996). Using an unknown, but ubiquitously found receptor on 
animal cells, the uptake of VSV-G pseudotyped LV then takes place by a receptor-mediated 
endocytic pathway (Coil and Miller 2004). VSV-G increases particle resistance to shear forces 
allowing vector particle processing by ultracentrifugation and its presence increases the 
thermostability of LVs produced by transient transfection (Aiken 1997; Carmo, Dias et al. 2009). 
However, LVs pseudotyped with VSV-G produced in human cells are inactivated by human 
serum complement (DePolo, Joyce D. Reed et al. 2000), and alternative envelopes for clinical in 
vivo applications of LVs have been suggested. Pseudotyping with other envelopes has been 
extensively reviewed elsewhere (Verhoeyen and Cosset 2004; Cronin, Zhang et al. 2005). To 
address the limitation of the widely used VSV-G pseudotyped LVs to transduce quiescent cells in 
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the G0 phase of the cell cycle, recent findings indicate that LVs pseudotyped with measles virus 
glycoproteins and CXCR4-tropic HIV envelope are able to transduce quiescent T cells 
(Ramezani and Hawley 2002; Frecha, Costa et al. 2008). Other pseudotypes allow for the 
targeted transduction of certain organs, subsets of cells in tissue, or impart the vector with neural 
retrograde transport properties (Sena-Esteves, Tebbets et al. 2004; Verhoeyen and Cosset 2004; 
Wong, Azzouz et al. 2004).  
The third construct (transfer vector) contains the required cis-acting sequences (3’ and 5’ LTR, 
packaging signal (Ψ), rev responsive element (RRE)) and typically a reporter gene such as GFP 
that can be replaced by the therapeutic transgene of interest (Fig. 1.1 C). Tat-independent 3rd 
generation packaging plasmids are most often employed in combination with self inactivating 
(SIN) vectors (Miyoshi, Blomer et al. 1998; Zufferey, Dull et al. 1998; Iwakuma, Cui et al. 
1999). These constructs render transcription of full length RNA unlikely even in the presence of 
viral proteins. The desired transgene is expressed of an internal, heterologous promoter. These 
vectors reduce the risk of RCL formation (Miyoshi, Blomer et al. 1998; Iwakuma, Cui et al. 
1999). Without titer loss, it is possible to insert a transgene with a size of ~8 kb in current 3rd 
generation transfer vectors. Several conserved regions are included in current constructs to 
improve LV functionality. The woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE) significantly improves transgene expression when situated in the 3’ untranslated region 
of the coding sequence (Zufferey, Donello et al. 1999; Cockrell and Kafri 2007). The central 
polypurine tract (cPPT), the central termination sequence (CTS) and the polypurine tract (PPT) 
incorporated in central or 5’ vector location and adjacent to the 3’LTR, respectively, prime and 
terminate plus strand proviral DNA synthesis following reverse transcription of viral RNA, 
resulting in elevated transduction efficiencies (Follenzi, Ailles et al. 2000; Sirven, Pflumio et al. 
2000; Zennou, Petit et al. 2000; Zennou, Serguera et al. 2001; Cockrell and Kafri 2007).  
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1.2.3 Lentiviral Vectors 
1.2.3.1 Molecular Basis of LVs  
1.2.3.1.1 General Properties of Lentiviruses 
Lentiviruses form a more complex subclass of retroviruses, with HIV being the most prominent 
and best studied member. Other viruses of this group include SIV (simian immunodeficiency 
virus), EIAV (equine anemia virus), FIV (feline immunodeficiency virus) and BIV (bovine 
immunodeficiency virus). Lentiviruses are RNA viruses in which the genome is packaged into a 
capsid surrounded by a membranous envelope. The capsid contains the viral RNA genome and 
three enzymes required for virus replication (reverse transcriptase, integrase and protease). The 
host-cell derived membrane envelope is protruded with an envelope glycoprotein. This envelope 
protein is responsible for the binding and entry into the target cell. Upon infection by membrane 
fusion with the host cell and viral uncoating, viral RNA and the enzymes necessary for reverse 
transcription of the viral RNA and for integration of the viral cDNA are released. The RNA is 
then reversely transcribed and integrated into the host genome, with a preference for integration 
within active transcription units (Schröder, Shinn et al. 2002; Wang, Ciuffi et al. 2007). At the 
end of the virus life cycle, the full-length viral RNA genome is transported out of the nucleus, 
captured by the gag polyprotein, subsequently packaged, and the virus buds off the cell 
membrane. The lentiviral provirus sequence is subsequently transferred to progeny during cell 
division.  
Lentiviruses can infect nondividing cells, i.e. unlike oncoretroviruses, they are independent of 
cellular division to import their genetic information into the host cell. A preintegration complex 
of several proteins is formed after infection that allows translocating the genetic information into 
the nucleus (Amado and Chen 1999). Lentiviruses induce chronic and slowly progressive 
diseases (‘lenti’ means slow), typically associated with infection of macrophages, a terminally 
differentiated cell type (Vigna and Naldini 2000).  
Mature lentiviral particles have a relatively large diameter of 90–130 nm (Higashikawa and 
Chang 2001; Li, Kimura et al. 2005; Segura, Kamen et al. 2006). Lentiviral particles have a mass 
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of ~ 8105.2 ×  Da and present a density of 1.16 g/mL in sucrose density gradients (Vogt and 
Simon 1999).  
An infectious wildtype lentiviral particle (e.g. HIV-1) contains a diploid single-stranded positive 
sense RNA genome with cis- and trans-acting sequences. Cis-acting are non-coding sequences 
that are required for viral RNA synthesis, packaging, reverse transcription and integration. The 
trans-acting sequences encode for the major structural viral components (gag), lentivirus-specific 
enzymes (pol), accessory proteins and the virus envelope (env) (Quinonez and Sutton 2002). 
These three open reading frames are a characteristic of all retroviruses. After translation, the 
polyproteins are proteolytically cleaved to form the structural and enzymatic components of the 
virus. Lentiviruses also contain the regulatory genes rev and tat. Rev acts as a virally-encoded 
post-transcriptional activator (Desmaris, Bosch et al.) and is critical for viral replication 
(Ramezani and Hawley 2002; Lever, Strappe et al. 2004). The second regulatory gene, tat, is a 
transactivator that enhances the transcriptional activity of the 5’ long terminal repeat (LTR) by 
100-500 fold. Furthermore, the accessory genes vpu and nef increase viral release and enhance 
the viral ability to escape the immune system. Vif (virus infectivity factor) overcomes an 
endogenous cellular inhibitor of viral replication and viral protein R (vpr) causes G2 cell-cycle 
arrest, the cell-cycle phase in which the expression of viral products seems to be optimal 
(Quinonez and Sutton 2002). 
1.2.3.1.2 Development of LVs for Gene Delivery 
The main motivation for the development of LVs was to complement the successful features of 
(onco)retroviral vectors (RV). These include the integration in the chromatin, the absence of 
transferred viral genes and the lack of pre-existing immunity in the recipient. These features were 
sought to be combined with the lentivirus-specific ability to infect nondividing cells such as T 
and hematopoetic stem cells (Throm, Ouma et al. 2009). Lentiviral vectors are a promising tool 
to treat diseases like blood-cell disorders, stem cell defects, storage and metabolic diseases 
(Quinonez and Sutton 2002; Kohn 2007). LVs do not transfer the genes for viral packaging 
proteins and have a low pro-inflammatory activity (Follenzi, Santambrogio et al. 2007). They 
were used in the  study of neurological diseases by in vivo gene transfer to the central nervous 
system of rodents and primates (Kordower, Bloch et al. 1999; Watson, Kobinger et al. 2002; 
Jakobsson and Lundberg 2006). As LVs are able to efficiently transduce antigen-presenting cells 
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and in particular dendritic cells with tumor-associated antigens, cancer immunotherapy is another 
promising application (MacGregor 2001; Breckpot, Dullaers et al. 2003; Dullaers, Meirvenne et 
al. 2005; Wang, He et al. 2006; Breckpot, Aerts et al. 2007; Lejeune, Truran et al.). Other 
research applications have been extensively reviewed elsewhere (Quinonez and Sutton 2002; 
Cockrell and Kafri 2007). 
The LV technology has already been evaluated in phase I clinical trials targeting T cells to 
express an anti-HIV gene and had a promising outcome (Schonely, Afable et al. 2003; 
Slepushkin, Chang et al. 2003; Levine, Humeau et al. 2006; Kohn 2007). To date, most of the 
approved clinical trials using LVs are based on the ex vivo gene delivery to autologous cells 
(http://www.wiley.co.uk/genmed/clinical/). In particular, the in vitro transduction of 
hematopoetic stem cells seems to hold great promise for gene therapy applications in the near 
future (Chang and Sadelain 2007). 
LVs are based on the human pathogen HIV-1. Consequently, biosafety improvements were a 
central issue in the early development of LVs. They were originally designed as replication 
defective hybrid viral particles generated from the core proteins and enzymes of HIV-1 and the 
envelope (glycoprotein G) of a different virus, the vesicular stomatitis virus (VSV) (Naldini, 
Blomer et al. 1996; Naldini, Blomer et al. 1996; Vigna and Naldini 2000). The major goal in 
subsequent LV development was to increase biosafety by segregation of cis- and trans-acting 
sequences. This renders the formation of replication-competent lentiviruses (RCL) by 
recombination unlikely (Wu, Wakefield et al. 2000; Zufferey and Trono 2000; Ikeda, Takeuchi et 
al. 2003; Ni, Sun et al. 2005). 
The latest 3rd-generation self-inactivating (SIN) LVs include only 10 % of viral genomic RNA 
which is sufficient to ensure vector functionality (Ramezani and Hawley 2002). This was 
achieved after removal of all genes that are not essential for gene transfer, transduction into 
nondividing cells and sustained transgene expression. The biosafety concerns raised over 
lentiviral vectors have consequently been extensively addressed through improved vector design. 
Current LV constructs are as safe as RV (Lever, Strappe et al. 2004), and advanced LV constructs 
successfully prevent the formation of RCL (Escarpe, Zayek et al. 2003; Sastry, Xu et al. 2003; 
Miskin, Chipchase et al. 2005). Hence a safe use of LVs, as a gene delivery system in therapeutic 
applications, should be limited to a single transduction event without perturbation of the target 
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cellular genome. In this context, chromatin insulators were investigated as means to protect gene 
expression from neighboring enhancers or silencers and to reduce the risk related to viral 
integration (West, Gaszner et al. 2002; Sinn, Sauter et al. 2005; Hanawa, Yamamoto et al. 2009; 
Nielsen, Jakobsson et al. 2009).   
1.2.3.1.3 LV Expression Constructs 
LV elements are encoded by several plasmid constructs or expression cassettes (Fig 1.1). Vector 
particles are assembled in trans from constructs without most viral cis-acting sequences. The 
packaging construct codes for the core and enzymatic components of the usually HIV-1 derived 
virion. A second construct is responsible for expression of the viral envelope which is most 
commonly VSV-G (envelope construct). The viral cis-acting sequences are delivered by an 
expression cassette which encodes for the transgene of interest (transfer vector construct). These 
constructs need to be simultaneously expressed in a respective producer cell. We briefly 
summarize the most important properties and functions of these constructs and refer to extensive 
and more detailed reviews wherever possible.  
Most recent LV production systems use 3rd generation plasmid constructs (Dull, Zufferey et al. 
1998; Vigna and Naldini 2000; Quinonez and Sutton 2002) (Fig. 1.1 A). Whenever tat-dependent 
systems may result in mobilization of vectors upon transfer of gag-pol and env or HIV-1 
superinfection (Bukovsky, Song et al. 1999), tat is removed in these constructs and its function 
replaced by a heterologous strong promoter (e.g. CMV). The accessory gene nef can be removed 
from LV constructs pseudotyped with the most commonly used pH-independent envelopes 
(Aiken 1997; Luo, Douglas et al. 1998; Chazal, Singer et al. 2001).  
VSV-G is by far the most often used LV envelope (Fig. 1.1 B). This envelope protein has been 
already used in RV constructs to broaden vector tropism (McClure, Marsh et al. 1988; Akkina, 
Walton et al. 1996). Using an unknown, but ubiquitously found receptor on animal cells, the 
uptake of VSV-G pseudotyped LV then takes place by a receptor-mediated endocytic pathway 
(Coil and Miller 2004). VSV-G increases particle resistance to shear forces allowing vector 
particle processing by ultracentrifugation and its presence increases the thermostability of LVs 
produced by transient transfection (Aiken 1997; Carmo, Dias et al. 2009). However, LV 
pseudotyped with VSV-G produced in human cells are inactivated by human serum complement 
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(DePolo, Joyce D. Reed et al. 2000), and alternative envelopes for clinical in vivo applications of 
LVs have been suggested. Pseudotyping with other envelopes has been extensively reviewed 
elsewhere (Verhoeyen and Cosset 2004; Cronin, Zhang et al. 2005). To address the limitation of 
the widely used VSV-G pseudotyped LVs to transduce quiescent cells in the G0 phase of the cell 
cycle, recent findings indicate that LVs pseudotyped with measles virus glycoproteins and 
CXCR4-tropic HIV envelope are able to transduce quiescent T cells (Ramezani and Hawley 
2002; Frecha, Costa et al. 2008). Other pseudotypes allow for the targeted transduction of certain 
organs, subsets of cells in tissue, or impart the vector with neural retrograde transport properties 
(Sena-Esteves, Tebbets et al. 2004; Verhoeyen and Cosset 2004; Wong, Azzouz et al. 2004).  
The third construct (transfer vector) contains the required cis-acting sequences (3’ and 5’ LTR, 
packaging signal (Ψ), rev responsive element (RRE)) and typically a reporter gene such as GFP 
that can be replaced by the therapeutic transgene of interest (Fig. 1.1 C). Tat-independent 3rd 
generation packaging plasmids are most often employed in combination with self inactivating 
(SIN) vectors (Miyoshi, Blomer et al. 1998; Zufferey, Dull et al. 1998; Iwakuma, Cui et al. 
1999). These constructs render transcription of full length RNA unlikely even in the presence of 
viral proteins. The desired transgene is expressed of an internal, heterologous promoter. These 
vectors reduce the risk of RCL formation (Miyoshi, Blomer et al. 1998; Iwakuma, Cui et al. 
1999). Without titer loss, it is possible to insert a transgene with a size of ~8 kb in current 3rd 
generation transfer vectors. Several conserved regions are included in current constructs to 
improve LV functionality. The woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE) significantly improves transgene expression when situated in the 3’ untranslated region 
of the coding sequence (Zufferey, Donello et al. 1999; Cockrell and Kafri 2007). The central 
polypurine tract (cPPT), the central termination sequence (CTS) and the polypurine tract (PPT) 
incorporated in central or 5’ vector location and adjacent to the 3’LTR, respectively, prime and 
terminate plus strand proviral DNA synthesis following reverse transcription of viral RNA, 
resulting in elevated transduction efficiencies (Follenzi, Ailles et al. 2000; Sirven, Pflumio et al. 
2000; Zennou, Petit et al. 2000; Zennou, Serguera et al. 2001; Cockrell and Kafri 2007).  
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Figure 1.1 : Expression constructs for lentiviral vector production.  
To generate LVs, three to four constructs need to be expressed simultaneously in producer cells. 
Only relevant parts of the constructs are shown. 
(A): Lentiviral vector packaging constructs. Only constructs with advanced biosafety features are 
represented here, i.e. 1st generation constructs including the accessory genes vif, vpr and vpu are 
omitted. Whereas 2nd generation constructs are tat-dependent and in most cases only comprise a 
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single packaging plasmid, rev is placed on a second packaging plasmid in tat-independent 3rd 
generation constructs 
(B): Envelope constructs. In most LV systems, VSV-G is used as envelope protein, see text for 
details on alternative pseudotypes 
(C) Lentiviral transfer vector constructs. Early LV systems employed non-SIN vectors . In SIN 
vector systems, a deletion in the U3 region of the 3’LTR is transferred to the 5’LTR upon reverse 
transcription. Conditional SIN vectors provide additional safety and allow tissue specific 
transgene regulation (for review: [2]) or the inducible vector transcription in stable LV producer 
cell lines.  
CTS: central termination sequence; LTR: long terminal repeat; PBS: primer binding site; polyA: 
Polyadenylation site; Prom: Promoters such as CMV, EFIa, RSV or others; ψ: cis packaging 
signal; SA/SD: splice donor and splice acceptor site 
1.2.4 LV Particle Stability 
The stability of LVs is generally low, with a half-life of only 3-18 h at 37 °C (Higashikawa and 
Chang 2001; Watson, Kobinger et al. 2002; Croyle, Callahan et al. 2004). Nevertheless, they 
show a better stability than mouse RV (Mühlebach, Schmitt et al. 2003). The viral decay depends 
on the LV pseudotype and also the presence or absence of serum and is mainly driven by a loss 
of the capacity to perform reverse transcription (Watson, Kobinger et al. 2002; Croyle, Callahan 
et al. 2004; Carmo, Panet et al. 2008; Carmo, Alves et al. 2009; Carmo, Dias et al. 2009). LV 
stability is significantly increased at 4 °C. Only few studies investigated the effect of different 
parameters on the stability of VSV-G pseudotyped LV. Among the parameters tested were the 
influence of temperature, pH, freeze-thaw and different serum treatments (Higashikawa and 
Chang 2001; Croyle, Callahan et al. 2004). Lentiviral vectors were found to have a half-life of 
~10 h at 37 °C and were showing biphasic decay at 4 °C. After freeze-thaw, a half life of 3.8 
cycles was found for the first 5 rounds of treatment. LVs were stable at pH 7 and showed a 
marked decrease in stability at pH 6 or 8. The biphasic decay during multiple freeze-thaw cycles 
and temperature incubation is explained by the occurrence of two viral vector populations with 
different properties within the same vector preparation (Higashikawa and Chang 2001; Croyle, 
Callahan et al. 2004). LVs pseudotyped with amphotropic envelopes rapidly lose their infectivity 
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in non-optimized storage buffer formulations. Their stability can be increased significantly by the 
addition of serum, proteins such as albumin, lipoproteins and lipids (Carmo, Alves et al. 2009).  
1.2.5 Quantification of LVs 
Since this review focuses on production of LVs, it is essential for the understanding of the 
challenges and improvements in LV production processes and for a critical assessment of the 
yields reported in the literature, to provide an overview of quantification methods for LVs. These 
methods can be broadly divided in two categories: First, direct methods detect viral particles or 
major structural components in culture supernatants. Second, indirect methods or functional 
assays are most often cell-based biological assays that assess viral vector function after 
transduction of suitable target cells.  
1.2.5.1 Quantification of LVs in culture supernatants (direct methods) 
To assess the number of LV particles after production, methods for the direct quantification of 
LV components in supernatants are frequently employed. These assays comprise the 
quantification of viral RNA content (as RNA molecules or viral genomes (vg) per mL) by PCR 
(RNA titer), reverse transcriptase (RT) activity measurements (mU RT/mL) or quantification of 
the capsid protein CAp24 by ELISA (Eberle and Seibl 1992; Sastry, Johnson et al. 2002; Tonini, 
Claudio et al. 2004; Geraerts, Willems et al. 2006). The most common of these assays is probably 
the CAp24 ELISA although it is the least reliable for evaluation of functional vector particles and 
subject to high variability (Geraerts, Michiels et al. 2005; Ricks, Kutner et al. 2008). Results are 
typically reported as the mass amount of CAp24 protein per volume of supernatant (pg/mL) or as 
the calculated number of total/physical particles (TP/PP) (Naldini, Blomer et al. 1996; Farson, 
Witt et al. 2001; Beyer, Westphal et al.). Generally, only a small amount of the total produced 
viral particles is functional (Higashikawa and Chang 2001; Mitta, Rimann et al. 2005). All 
detection methods for total LV particles therefore largely overestimate functional titers. Various 
sources can additionally give false positive results in these assays, e.g. carryover of DNA from 
vector production (when estimating RNA titer) or unincorporated CAp24 that is not related to 
viral particles (ELISA), in particular when crude vector preparations are titered (Ricks, Kutner et 
al. 2008). Direct methods are consequently mainly used for normalization of vector preparations 
prior to transduction, for screening of high producer clones during the development of stable LV 
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packaging and producer cell lines, for vector optimization (Geraerts, Michiels et al. 2005) and to 
evaluate and validate the quality of vector preparations (via the ratio of functional to total LV 
particles). 
1.2.5.2 Functional assays (indirect methods)  
To assess the number of infectious particles, assays need to be performed after transduction of 
target cell lines. Typically, the cell line and exact protocol employed depend on the final 
application. For example, transduction-enhancing additives such as Polybrene® (PB) or cell cycle 
arrested (e.g. mitomycin C treated) cells (Chang, Urlacher et al. 1999) might be used in these 
assays. Transduction efficiencies are generally cell-line dependent. Functional titrations of LV 
preparations are consequently most often tested on two cell lines, using the cell line of interest for 
the final application (e.g. hematopoetic stem or other primary cells) and a universally used cell 
line with a well established protocol to allow for titer comparisons. Among the universally used 
cell lines which have been tested for transduction, HEK293 cell variants show a higher efficiency 
than HeLa and Mus dunni cells (Sastry, Johnson et al. 2002). Transduction efficiency is generally 
cell-line dependent with long term transgene expression depending on the characteristics of the 
transduced cell (Chang, Urlacher et al. 1999). Other candidates include the HT1080 (Böcker, 
Rossmann et al. 2007), NIH 3T3 (murine embryonic fibroblast) (Cronin, Zhang et al. 2005) and 
other cell lines that were tested for LV production such as TE671 human rhabdomyosarcoma 
cells (Chang, Urlacher et al. 1999) 
In general, transduction protocols need to be stringently standardized as minor modifications can 
result in significant titer differences. Vector titer can vary by up to 50-fold when modifying 
conditions of the transduction protocol such as inoculum volume (non-proportional effect on 
titer), type and number of target cells, vector stability and length of vector exposure to target cells 
(Zhang, Metharom et al. 2004). Transduction titers need to be estimated after dilution to ensure 
that the final MOI is <<1, resulting in a low percentage of transduced cells. This procedure 
minimizes the risk of multiple integrations in target cells and ensures assay linearity (Geraerts, 
Willems et al. 2006; Kutner, Zhang et al. 2009). Transduction assays also have inherent 
limitations because not each particle that transduces a target cell causes transgene expression. 
Expression from non-integrated vector forms can occur (Wu 2004; Nightingale, Hollis et al. 
2006), but only 10-18 % of the transduced RNA genomes integrate in host-cell DNA, with the 
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large majority being degraded after reverse transcription (Butler, Hansen et al. 2001; Van Maele, 
De Rijck et al. 2003). Transgene expression might also not be detectable if insertion takes place 
in regions of reduced transcriptional activity. Furthermore, transduction inhibitors like 
proteoglycans in non-purified material can negatively impact transduction efficiency (Le Doux, 
Morgan et al. 1996). 
Several days after transduction, the target cells are tested for LV gene transfer. The detection can 
be performed at several levels, quantifying cellular genomic DNA (proviral DNA), cellular 
mRNA or the target protein expression level. PCR methods offer the flexibility to detect LVs at 
all levels of their life cycle if suitable targets are selected. Common target sequences include well 
conserved regions in current HIV-1 vector constructs such as WPRE and LTR (Geraerts, Willems 
et al. 2006; Böcker, Rossmann et al. 2007). For a useful overview on PCR-based assays and other 
methods for LV quantification, extensive work is available (Delenda and Gaillard 2005; Sastry, 
Johnson et al. 2002; Geraerts, Willems et al. 2006). 
If a reporter gene such as GFP or β-galactosidase is present in the LV construct, a fast 
quantification by FACS analysis or fluorescence microscopy as GFP transducing units (gtu) or 
transducing units (tu) per mL is preferable (Kuate, Wagner et al. 2002; Geraerts, Willems et al. 
2006). Due to its simplicity, this method is the most popular mean to quantify functional LVs. 
When GFP is used, the method assumes that all integrated vectors create an expression that is 
above the detection threshold of assay. If only the percentage of GFP-positive cells is quantified, 
these assays are not sensitive for multiple transgene copies in target cells. The mean fluorescence 
intensity of transduced cells does, however, correlate with the GFP copy number per genome 
(Zhang, La Russa et al. 2004). Control transductions including LV inhibitors such as AZT should 
be used to rule out pseudo-transduction that is defined as false GFP-positive cells detected 
because of diffusion of GFP or transfer of GFP-encoding DNA (Liu, Winther et al. 1996; Nègre, 
Mangeot et al. 2000; Nash and Lever 2004). Other, less frequently used, methods include drug 
resistance assays in which results are reported as colony forming units (CFU)/mL) (Metharom, 
Takyar et al. 2000; Tonini, Claudio et al. 2004). 
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1.2.6 Production of LVs 
Production protocols for LVs were first described by transfecting adherent 293T cells with three 
different plasmids (Naldini, Blomer et al. 1996; Naldini, Blomer et al. 1996). Although the 
interest in these vectors in research and development steadily increased over the years, protocols 
for the production have undergone only slight modifications. Comparatively small quantities of 
vectors are required for standard research purposes. Conventional protocols can generate 
supernatants that lead after concentration to small volumes of LV preparations with titers of ~109 
tu/mL. This is sufficient for most in vitro experiments and for in vivo testing in small animal 
models (Klages, Zufferey et al. 2000). Protocols for the production of LVs are therefore still 
rudimentary, largely empirical and poorly standardized with the large majority based on 
production in adherent 293T cells, rendering a transfer to industrial mass production impractical. 
Although LVs mostly are and, in the near future, will be used for ex vivo transduction, the total 
vector amount for early phase clinical trials is in the range of at least 1011-1012 functional 
particles. Production in large batch preparations will also clearly be advantageous, minimizing 
the number of tedious quantification, RCL assays and other contaminants. With several 
candidates moving towards advanced clinical trials, there is consequently an increasing need of 
scalable production strategies. In the following sections, current protocols and strategies for the 
production of LVs will be reviewed and compared. 
Two production strategies for LVs are currently used: 1) transient transfection with several 
plasmid constructs and 2) expression of required vector components in stable, inducible 
packaging cell lines. The development of a stable packaging cell line is time-consuming but is 
generally expected to lead to higher yields. A significantly faster and cost-effective approach is 
transient gene expression/transfection. It offers advantages in terms of flexibility and overall 
process time. Improved scalable transfection protocols should allow producing enough material 
for phase I clinical trials (Derouazi, Girard et al. 2004; Ansorge, Lanthier et al. 2009). Both 
strategies will be discussed and compared in the following, in particular with respect to their 
large-scale applicability for the production of LVs. 
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1.2.6.1 Transient Transfection for the Production of LVs  
Transient transfection is defined as the unstable insertion of DNA into host cells. For in-depth 
reviews on transient transfection in mammalian cells, readers are referred to excellent work by 
others (Wurm and Bernard 1999; Baldi, Muller et al. 2005; Pham, Kamen et al. 2006). 
Commercially available cationic lipids (LipofectAMINE, FuGENE, 293fectin, etc.) are 
classically used in small-scale transfection experiments and result in high expression levels 
(Pham, Kamen et al. 2006). However, their elevated costs preclude their use for large-scale 
applications. Large-scale production is until now only economically feasible when using either 
calcium phosphate (CaPO4-) precipitation or polyethylenimine (PEI) mediated transfection.  
In the past, transfection was commonly regarded as a non-scalable technology. Its use in 
combination with suspension-grown cells has now been established for the large-scale production 
of biopharmaceuticals and viral vectors (Durocher, Perret et al. 2002; Geisse and Henke 2005; 
Park, Lim et al. 2006; Pham, Kamen et al. 2006; Durocher, Pham et al. 2007; Hildinger, Baldi et 
al. 2007). It is therefore an attractive alternative for the rapid production of recombinant proteins 
and viral vectors within 24-72 h (Naldini, Blomer et al. 1996; Wurm and Bernard 1999; Blesch 
2004). As medium exchange is necessarily required for CaPO4-precipitation, PEI is becoming the 
agent of choice for large-scale transfection campaigns (Pham, Kamen et al. 2006). Although it 
shows cytotoxic effects (Godbey and Mikos 2001; Kunath, von Harpe et al. 2003; Sun, Goh et al. 
2006), it offers advantages in terms of simplicity of use and compatibility with currently used 
media and is most suitable for large-scale applications as an exchange of medium is often not 
necessary (Pham, Kamen et al. 2006; Toledo, Prieto et al. 2009).  
Efforts are still needed to optimize the volumetric productivities of transient transfection 
protocols. One critical limitation is that current transfection protocols are confined to rather low 
cell densities of up to 6102 ×  c/mL (Derouazi, Girard et al. 2004) with most optimized protocols 
being in the range of only 61015.0 ×− c/mL at the time of transfection (Durocher, Pham et al. 
2007). In order to increase process yields, strategies that allow for operation at high cell density 
and/or an increase in cell specific productivity are needed (Ansorge, Lanthier et al. 2009).  
An advantage of transfection protocols for LV production is the possibility of using 
cytotoxic/cytostatic transgenes and/or vector components. This holds for many HIV-1 derived 
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proteins and for the commonly used VSV-G envelope glycoprotein (references in section 1.4.2 
and (Bartz, Rogel et al. 1996)). Various transgenes of interest and envelope glycoproteins with 
alternative cell tropisms can be tested within a short period of time. 
Table 1.1 compares published transfection protocols for LV production. The methods are divided 
into conventional and improved methods. Conventional methods include calcium phosphate-
based or cationic lipid-mediated transfection in adherent HEK293T cells cultured in serum 
containing standard medium (Follenzi and Naldini 2002). Improved methods encompass all the 
protocols which reported significant improvements, resulting in higher yields, better cost-
effectiveness or standardization.  
Several mammalian cell lines have been successfully used for LV production. Among those are 
several variants of HEK293 cells (293T and subvariants like FT and T/17, 293E6E, 293SF) but 
also COS-1, COS-7, CV-1, HeLa, HT1080 TE671 ((Chang, Urlacher et al. 1999; Ikeda, Takeuchi 
et al. 2003) and see Table 1.1). Compared to 293T, COS-7 and CV-1 were found to result in less 
efficient LV production (Reiser, Harmison et al. 1996; Smith and Shioda 2009). HeLa cells 
secrete less CAp24 for a given level of RNA expression than 293T and HT1080 (Ikeda, Takeuchi 
et al. 2003). In contrast, COS-1 have been described as an advantageous packaging host system 
for small scale production of high quality LVs. They adhere strongly to culture surfaces, 
producing packaging cell contamination-free supernatant after transfection with a higher amount 
of functional relative to total particles at similar titers (Smith and Shioda 2009). This system is 
therefore an interesting alternative for automated high throughput functional screens based on 
lentiviral vectors for which additional purification steps are impractical.  
HEK293 variants remain the most widely used host system for LV production. They are 
advantageous because of their human origin and provide a safe track record in the production of 
RV. It is possible to adapt HEK293 for growth in suspension and they show only a moderate 
dependence on accessory genes such as vif, vpu, nef to generate infectious virus (Garnier, Côté et 
al. 1994; Côté, Garnier et al. 1998; Farson, Witt et al. 2001). The cell density reported in the 
literature for LV production varies and depends on the employed production medium. In adherent 
cell cultures, optimal densities were found to be 7101.2 ×  cells/15 cm plate (18-24 h prior to 
transfection) (Sena-Esteves, Tebbets et al. 2004), whereas transfection of suspension cultures is 
typically performed at ~ 6101×  c/mL. Recently, LV production after transfection at high cell 
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density ( 6105×  c/mL) was described (Ansorge, Lanthier et al. 2009). Although these 
formulations will be an absolute necessity for LV mass production, serum and animal 
component-free media were only evaluated in a handful of publications (Reiser 2000; Sena-
Esteves, Tebbets et al. 2004; Segura, Garnier et al. 2007; Ansorge, Lanthier et al. 2009; Kuroda, 
Kutner et al. 2009). 
Other transfection agents than CaPO4 and PEI have been tested to generate LVs but either gave 
lower yields for multi-component lipid systems (Karolewski, Watson et al. 2003; Mitta, Rimann 
et al. 2005) or are not widely used because the associated costs are much higher than for 
protocols based on CaPO4 or PEI (Coleman, Huentelman et al. 2003). These methods are not 
suitable for mass production of LVs and are consequently not mentioned in Table 1.1. PEI has 
been only employed in recent work but was already demonstrated to give more reliable results 
(Segura, Garnier et al. 2007; Ansorge, Lanthier et al. 2009; Kuroda, Kutner et al. 2009; Toledo, 
Prieto et al. 2009). CaPO4 protocols can result in highly efficient transfection but results may be 
inconsistent when critical parameters are not stringently monitored. For example, slight shifts in 
pH, precipitation kinetics and impurities in starting material were shown to reduce transfection 
efficiency dramatically (Kuroda, Kutner et al. 2009; Toledo, Prieto et al. 2009). For PEI-based 
transfection, process conditions such as the PEI:DNA ratio and the amount of polyplexes per cell 
differ in the literature and seem to depend on the employed system (media, cell line, plasmid 
constructs, product) (Durocher, Perret et al. 2002; Derouazi, Girard et al. 2004; Backliwal, 
Hildinger et al. 2007; Durocher, Pham et al. 2007). Optimization of these parameters results in 
several-fold productivity improvements (Durocher, Perret et al. 2002; Ansorge, Lanthier et al. 
2009). 
Another important cost-driving factor for large-scale transfection protocols is the amount of DNA 
required to achieve efficient transfer of the genetic information to producer cells. Highly pure 
DNA preparations need to be employed, corresponding to spectrometric ratios of (260/280) nm 
superior to 1.8 (Tom, Bisson et al. 2007). Commercial kits are now widely accepted for plasmid 
purification and were demonstrated to result in similar LV titers compared to cesium chloride and 
ethidium bromide based protocols (Karolewski, Watson et al.). The amount of recombinant DNA 
used for the production of LVs is generally high for CaPO4-based methods, with a wide range 
from ~1-15 µg/ 6101×  cells. As the DNA mass to transfected cell ratio can be significantly 
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reduced using PEI, it appears also from that perspective to be the most cost-effective transfection 
agent, with only 0.4-3.5 µg of DNA/ 6101×  cells. Accordingly, recent protocols based on 
transfection in suspension cultures employ DNA amounts which are 20-30 fold lower than in 
conventional protocols (Segura, Garnier et al. 2007; Ansorge, Lanthier et al. 2009), thereby 
reducing costs and also the likelihood for RCL formation by recombination.  
The optimal mass ratio for multi-plasmid transfection with the LV constructs has been evaluated 
in a number of studies. It is a consistent finding that a higher mass ratio of transfer vector plasmid 
DNA compared to the other packaging components leads to highest titers (Mitta, Rimann et al. 
2005; Segura, Garnier et al. 2007). These ratios are, however, dependent on the respective vector 
constructs and vary in the literature (Table 1.1).  
LV titers generally decrease with increasing vector insert size and improved biosafety, with 3rd 
generation systems showing lower yields than 1st and 2nd generation constructs (Al Yacoub, 
Romanowska et al. 2007). Differences of several orders of magnitude have been reported for 
other envelopes than VSV-G that are possibly less cytotoxic (Sena-Esteves, Tebbets et al. 2004). 
Similar findings are reported for cases in which the transgene of interest shows cytotoxicity 
because high levels of transgene expression in LV producer cells are typical for VSV-G 
pseudotyped systems (Segura, Garnier et al. 2007). 
Assessing the cell-specific productivity is often difficult for LV production protocols. For 
production in adherent cells, the exact cell density at the time of transfection is rarely determined 
or productivity is reported based on the size of the culture dish only (Kuroda, Kutner et al. 2009). 
The cell density was therefore in several cases extrapolated and sometimes the volume of the 
harvested supernatants estimated to compare the yields of the different methods in Table 1.1. 
It was previously reported that the cell specific productivity after transfection is approximately 
50-500 fg CAp24/cell×d, resulting in average cell culture yields of 100-1000 ng CAp24/mL×d 
for 2-3 days, corresponding to 106-107 tu/mL after titration on HeLa cells (Farson, Witt et al. 
2001). These values are well in the range of the yields found for all studies that form a part of the 
present review, with average cell specific titers of 1-50 tu/cell×d. Only one study reported titers 
that are several orders of magnitude higher than these expected values, possibly due to the use of 
CHO K1 cells for titration or the concentration of LVs before titration (Mitta, Rimann et al. 
2005). 
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Remarks for Table 1.1 
1: if several culture media were tested, only best formulations are mentioned 
2: vector types: non-SN, SIN, conditional (cond.) SIN 
3: details: buffer system (CaPO4) or polymer type (PEI) 
4: Mass ratio of plasmid constructs for transfection: Envelope: Packaging 1: (Packaging 2): LV 
transfer vector 
5: if cell density at transfection is not determined, predicted cell density is given (from cell 
density before transfection); cell concentration only for protocols in suspension, if several cell 
densities were tested, only optimal density is mentioned 
6: if several additives, best conditions are mentioned only, largest reported scale mentioned 
7
 : positive signs for fully validated scale-up (maximum 3 degrees, negative sign for no validation 
of scale-up; - : no scale up validated (small-scale (culture dish or T-flask) only), +: scale up by 
increase in culture volume without increase in volumetric productivity, ++ : scaled up for large-
scale production, scalability limited, +++ readily scalable, bioreactor scale validated  
8: values were extrapolated or estimated (critical parameters like cell density at transfection or 
harvested LV-containing supernatant were not given); 
titer as virus concentration in non-concentrated culture supernatants; titers in tu/mL if not further 
specified, 
9: best three media formulation are shown 
10: more envelope constructs were tested, two constructs with highest titers are shown 
11: Advanced D-MEM medium: +2% fetal calf serum, (vii) and a culture additive containing 
0.01 mM cholesterol, 0.01 mM egg's lecithin and 1× chemically defined lipid concentrate 
12 : not clear if reported LV titers relate to non-concentrated culture supernatant or concentrated 
preparations after ultracentrifugation 
13: insert sizes from 4-7.5 kb were tested; titers decreased with vector construct insert size  
14: DMEM-0: DMEM without serum with high glucose concentration was used 
15: harvest continued until 168 hpt but low yields after 120 hpt 
 
 
 
1.2.6.2 Production of LVs with Packaging and Stable Producer Cell Lines 
Although transfection as a platform for LV production offers advantages in terms of flexibility 
and a short time to product, several intrinsic disadvantages hamper its use for LV mass 
production. These include variation in transfection efficiency when protocols are not optimized, 
costs associated to plasmid DNA production and additional quality control for the transfection 
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agents. The required transfection steps complicate the process compared to simple routine 
production processes of other biologics. Significant efforts are therefore undertaken to generate 
stable packaging and producer cell lines. Packaging cell lines express all LV components except 
the vector constructs and still require transfection for vector production. Stable producer cells 
express all necessary vector components and are consequently generated after introduction of the 
vector construct. The ideal LV producer cell line should be stable over extended culture periods, 
produce large quantities of LVs and preferably grow in suspension under serum-free conditions 
for easy scale-up (Kuroda, Kutner et al. 2009). It is a general expectation that, once established, 
stable producers will outperform transfection methods and deliver standardized production 
batches for optimized downstream processing of the produced material. Significant efforts have 
therefore been undertaken to establish stable packaging and producer systems. Table 1.2 
summarizes recent publications on stable LV packaging and producer cell lines. For this 
comparison, reports on systems lacking important biosafety features or exhibiting low yields and 
poor stability were not considered.  
Due to the cytotoxic and cytostatic effects of several LV vector components, in particular gag, 
rev and VSV-G (if selected as envelope protein), these components need to be tightly regulated 
when stably expressed in a cell line (Kaplan and Swanstrom 1991; Miyazaki, Takamatsu et al. 
1995; Sparacio, Pfeiffer et al. 2001; Quinonez and Sutton 2002). The basal expression of LV 
components in the ‘off-state’ hence needs to be below the cytotoxicity threshold (Sparacio, 
Pfeiffer et al. 2001).  
Most systems employ the tetracycline (Tet)-inducible system to achieve the required regulation 
(Kafri, van Praag et al. 1999; Farson, Witt et al. 2001; Ni, Sun et al. 2005). The classical systems 
are in off-state in the presence of doxycycline (dox), a tetracycline analog. The subsequent 
removal of dox induces expression of the LV components. The complete removal of dox is only 
easily feasible with adherent cells and induction takes typically several days until high expression 
levels are reached. These systems are hence not amenable to large-scale production. The 
counterpart to Tet-off systems, Tet-on, was consequently used to ease the scalability and 
practicability of induction (Broussau, Jabbour et al. 2008). Early classical Tet constructs were 
genetically (gene loss) or transcriptionally instable (gene silencing) after prolonged cultivation 
periods. The use of additives that are known to promote transcription such as sodium butyrate 
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have been used to circumvent this problem (Xu, Ma et al. 2001; Cockrell, Ma et al. 2006; 
Stewart, Leroux-Carlucci et al. 2009). Other approaches to achieve improved stability include 
multi-level regulation of the cytotoxic LV components to account for the commonly observed 
leakiness of the Tet system (Farson, Witt et al. 2001; Ni, Sun et al. 2005; Broussau, Jabbour et al. 
2008; Throm, Ouma et al. 2009). Alternatively to the Tet-inducible system, the insect derived 
ecdysone (Ecd) is used in several studies (Pacchia, Adelson et al. 2001; Sparacio, Pfeiffer et al. 
2001; Kuate, Wagner et al. 2002; Seraphin, Ralf et al. 2002). It is attributed with a lower basal 
expression, a higher level of induction and a faster peak expression after ponasterone A (an Ecd 
analog) addition but still needs to demonstrate its potential for high-yield LV production and 
requires further evaluation.  
Stable packaging cells are typically produced by transient cotransfection and subsequent selection 
of highly productive clones (Pacchia, Adelson et al. 2001; Cockrell, Ma et al. 2006; Stewart, 
Leroux-Carlucci et al. 2009). Alternatively, transduction with RVs or LVs can be used (Klages, 
Zufferey et al. 2000; Farson, Witt et al. 2001; Xu, Ma et al. 2001; Kuate, Wagner et al. 2002; 
Ikeda, Takeuchi et al. 2003; Broussau, Jabbour et al. 2008) as an efficient way to insert the vector 
construct in stable packaging cells. This approach results in more efficient expression of LV 
related proteins compared to transfection (Ikeda, Takeuchi et al. 2003). Transfected or transduced 
cells are then screened for gag, CAp24 expression or RT activity to select for the best producing 
clones, to generate LVs or to establish stable producers. With expression of vector RNA in 
producer cells being one of the major rate limiting steps for efficient LV production, serial 
transductions of packaging cell lines result in higher titers (Kafri, van Praag et al. 1999; Farson, 
Witt et al. 2001). SIN vectors are, however, difficult to insert stably into packaging cells with 
traditional, high-yield methods. Therefore, a third approach for the generation of stable 
producers, concatemeric array transfection, has been recently described. This method includes the 
generation of DNA structures (arrays) by in vitro ligation, containing multiple copies of SIN 
vector and drug resistance expression cassettes which are then transfected in stable LV packaging 
cells. This approach allows for the efficient generation of cell lines that stably express SIN LVs 
(Throm, Ouma et al. 2009). 
Challenges for the generation of stable LV producing cell lines include gene silencing, in 
particular for long term genetic stability of the constructs. Sufficient expression of rev is also 
29 
 
known to be critical for high-yield production (Ikeda, Takeuchi et al. ; Broussau, Jabbour et al. 
2008). 
Although not routinely reported, cell specific productivities for stable packaging cell lines and 
producers are more often found in the literature (Klages, Zufferey et al. 2000; Ikeda, Takeuchi et 
al. 2003). If not directly reported, it is in contrast almost impossible (because of the expansion of 
the producer cell population), to infer specific productivities for stable producers. The current 
stable systems give yields of 510 - 810  tu/mL with similar specific productivities compared to 
transient transfection. They also suffer from small production windows of a few days due to the 
cytotoxicity of the produced vector components. With the majority of current systems being 
VSV-G pseudotyped LV, in which self-infection of producer cells is a common observation, long 
production windows could increase the risk of recombination, might compromise genetic stability 
and are consequently not desired (Farson, Witt et al. 2001). 
Whereas cellular growth after transfection dilutes the transiently transferred genetic information 
over time, a stable cell line often leads to superior total yields at equal specific productivity when 
the cell population is expanded during production.  
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Remarks for Table 1.1 
1: name of packaging cell line 
2: vector types of producer cell line or packaging cell line (after tranfection/transduction) : non-
SIN, SIN, conditional (cond.) SIN 
3: +: stable producer generated, - no stable producer described 
4: positive signs for fully validated scale-up (maximum 3 degrees, negative sign for no validation 
of scale-up); - : no scale up validated (small-scale only (culture dish or T-flask)), +: scale up by 
increase in culture volume without increase in volumetric productivity, ++ : scaled up for large-
scale production, scalability limited, +++ readily scalable, bioreactor scale validated 
5: maximum titers, production window = length of production time with consecutive high titers 
6: clone-dependent decrease over prolonged cultivation observed  
7: no kinetics, one point titers only 
8: cell density neither reported nor possible to estimate  
9: cell specific productivity could not be calculated (neither cell densities at induction nor 
harvested volume reported 
 
1.2.6.3 Improvement of LV Production by Medium Additives 
Several process parameters govern the efficient generation of LVs. Despite the differences in the 
production methods, several compounds that are critical to achieve a high-yield LV production 
have been already identified and are used in several of the reviewed protocols (Tables 1.1 and 
1.2).  
1.2.6.3.1 Sodium Butyrate 
Gene silencing of at least some of the LV expression cassettes is a common observation after 
transient transfection and also in stable packaging and producer cell lines. The loss in expression 
can be dramatic with a decreased CAp24 production of 10-30 fold. As gene loss has been 
excluded as a possible reason, gene silencing is the most likely underlying mechanism (Kafri, van 
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Praag et al. 1999; Sparacio, Pfeiffer et al. 2001). Sodium butyrate in a concentration range of 2-
10 mM is well described as a powerful inducer of LV production. It causes hyperacetylation of 
histones, leading to higher transcription and increased expression of transfected DNA (Altenburg, 
Via et al. 1976; Kruh 1981; Gloger, Arad et al. 1985). It also stimulates the activity of the HIV-1 
LTR and CMV promoters (Gasmi, Glynn et al. 1999). When two strong promoters are close 
together, as in most 3rd generation vector constructs, sodium butyrate significantly reduces effects 
caused by promoter interference (Jaalouk, Crosato et al. 2006). It can consequently be used to 
boost LV production at least temporarily, leading to peak titers over a few consecutive days 
(Kafri, van Praag et al. 1999; Sparacio, Pfeiffer et al. 2001; Ansorge, Lanthier et al. 2009). 
Sodium butyrate was elsewhere reported to have a mixed effect on LV titers (Sena-Esteves, 
Tebbets et al. 2004), with no increase in titers of VSV-G pseudotyped particles but a marked 
increase for other pseudotypes. In conclusion, sodium butyrate only seems to have a major effect 
if the expression efficiency of the affected construct is non-optimal (Gasmi, Glynn et al. 1999). It 
acts on several levels, since increases in VSV-G mRNA, CAp24 expression and vector RNA 
levels are reported (Kafri, van Praag et al. 1999; Jaalouk, Crosato et al. 2006; Al Yacoub, 
Romanowska et al. 2007). Whereas no significant effects were found for any envelope construct 
at low concentrations (0.1 mM) (Al Yacoub, Romanowska et al. 2007; Ansorge, Lanthier et al. 
2009), it resulted in productivity improvements of 4-15-fold at higher concentrations of 5-20 mM 
(Karolewski, Watson et al. 2003; Ansorge, Lanthier et al. 2009). 
1.2.6.3.2 Chloroquine 
Chloroquine is an amine that raises the pH of endosomes and lysosomes. This increase in 
lysosomal pH may prevent the degradation of transfected DNA (Karolewski, Watson et al. 2003). 
Chloroquine is commonly used for LV and RV production (Park, Ohashi et al. 2000; Reiser 
2000; Mitta, Rimann et al. 2005; Al Yacoub, Romanowska et al. 2007; Kuroda, Kutner et al. 
2009). However, its effect depends on the transfection agent used, improving yields after calcium 
phosphate precipitation but resulting in reduced titers when PEI is used for transfection (Kuroda, 
Kutner et al. 2009).  
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1.2.6.3.3 Cholesterol and Lipids 
Enveloped viruses such as LVs, RVs, Influenza and Ebola bud from the membrane of an infected 
cell and thereby obtain a host-cell derived lipid bilayer. As various lipids show a heterogeneous 
distribution within cell membranes, it was hypothesized that sphingolipids and cholesterol 
segregate in cell membrane microdomains called membrane or lipid rafts. According to this 
theory, cholesterol stabilizes membrane rafts from which virus budding and also entry probably 
takes place (Chazal and Gerlier 2003). The lipid composition of different viral envelopes varies 
and suggests that some viruses bud from membrane rafts. These membrane rafts are highly 
dependent on cholesterol (Chazal and Gerlier 2003). Indeed, a disruption of lipid rafts by 
cholesterol depletion hinders HIV-1 particle production from cells and cholesterol depletion from 
viral particles reversibly impairs HIV-1 infection (Ono and Freed 2001; Popik, Alce et al. 2002). 
Significant lipid alterations are observed in infected cells compared to uninfected cells and the 
life cycle of HIV has also shown to be cholesterol-dependent. It was hypothesized that cellular 
cholesterol is an important requirement for the infectious form of the virus (Maziere, Landureau 
et al. 1994). Excess cholesterol is thus expected to increase the budding of enveloped viruses 
(Chazal and Gerlier 2003; Holm, Weclewicz et al. 2003; Mitta, Rimann et al. 2005). 
The addition of lipid cocktails is therefore a common strategy to improve the production yield of 
viral vectors based on budding virus forms. Cholesterol, lipid cocktail and also lipoprotein 
addition before transfection (>24 h) favors the budding of enveloped viruses and increases LV 
infectivity (Mitta, Rimann et al. 2005; Chen, Ott et al. 2009). 
Findings for RV suggest that the cellular lipid metabolism and content plays a critical role in 
vector production (Merten 2004; Coroadinha, Alves et al. 2006; Coroadinha, Ribeiro et al. 2006; 
Coroadinha, Silva et al. 2006). On the other hand, retroviral particle lability has been shown to 
parallel with viral membrane cholesterol content (Beer, Meyer et al. 2003; Carmo, Faria et al. 
2006; Coroadinha, Alves et al. 2006). To further optimize yields, studies are needed for LVs that 
decorrelate the cellular capacity of virus release and virus degradation or stability. 
1.2.7 Scalable Production Strategies and Process Operation 
For the development of a cost-effective LV production process, a scale-up should generally imply 
a larger culture volume and enhanced volumetric productivity. This is not the case when only the 
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number of production vessels or the surface area of adherent cultures (from T-flasks to roller 
bottles and cell factories) is increased (Merten 2004). Nevertheless, cell factories have been used 
to generate LV material for first clinical trials. The production of multi-liter volumes of LV 
supernatant is feasible with this approach but it is labor intensive and not cost-effective 
(Schonely, Afable et al. 2003). Similar efforts include the use of aerated high-performance flasks 
that suffer from similar limitations when compared to readily scalable suspension-based methods 
(Kutner, Puthli et al. 2009).  
Although many of the reports on LV production claim a large-scale applicability, most rely on 
adherent cell lines cultivated in standard serum-containing medium. These characteristics render 
the scalability of these processes challenging and cumbersome. Surprisingly, this problem is only 
rarely addressed in the literature. It can be expected that only bioreactor-based systems in which 
cells are grown on microcarriers (microspheric supports for adherently growing cell lines) or 
suspension-grown cell lines can satisfy future demands for LV mass production. Problems 
typically occurring with microcarrier cultures in large-scale cultures include the absolute need for 
bubble-free aeration and minimization of mechanical shear stress to allow for ideal growth on the 
surfaces (Merten 2004). The adaptation of stable packaging and producer cell lines to suspension 
and even microcarrier-based culture is additionally difficult because changes in cellular 
morphology and membrane properties during adaptation and/or serum reduction can lead to loss 
in viral productivity. Significant increases in LV yield will only be achieved by higher volumetric 
productivities. The yield of adherent cell cultures is by definition limited by the surface area of 
the culture dish or carrier. One study describes the scale-up of adherent cell cultures for LV 
production using fibrous discs (Throm, Ouma et al. 2009). This process, however, still requires 
discontinuous medium exchanges for induction and/or LV harvest. 
Suspension-grown cell lines should be preferable as they show the best and most straightforward 
scalability and allow the high-yield production of LVs by transfection at high cell density in 
shake flask and continuous bioreactor perfusion cultures (Segura, Garnier et al. 2007; Ansorge, 
Lanthier et al. 2009). When employing stable LV cell lines, it should be noted that the classical 
Tet-off system requires medium exchange and complete inhibitor removal, and is consequently 
difficult to scale-up. To avoid this problem, the generation of a stable packaging cell line in 
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serum-free suspension culture using the corresponding Tet-on regulation system has recently 
been described (Broussau, Jabbour et al. 2008). 
Only a handful of studies have addressed the scalability of LV production (Segura, Garnier et al. 
2007; Broussau, Jabbour et al. 2008; Ansorge, Lanthier et al. 2009; Throm, Ouma et al. 2009). 
Further efforts are required to improve these processes and ensure their effectiveness and 
robustness.  
Low final yields in non-optimized production systems and low LV stability complicate the 
establishment of viable industrial processes (Cruz, Almeida et al. 2000; Merten 2004). Perfusion 
processes with rapid and regular exchange of medium are consequently highly recommended for 
LV production. For adherent cell lines, microcarrier cultures are preferable whereas conventional 
stirred tank bioreactors operated in perfusion mode should be chosen for suspension-grown cell 
lines (Merten 2004). All systems need to ensure tight control of process parameters such as pH 
and osmolality to mainain LV infectivity (Higashikawa and Chang 2001; Torashima, Yamada et 
al. 2006). For RVs and LVs, processes in which the cell culture is maintained at 37°C and the 
harvested supernatant cooled down are advantageous (Cruz, Almeida et al. 2000; McTaggart and 
Al-Rubeai 2000; Ghani, Garnier et al. 2006; Ansorge, Lanthier et al. 2009). Process optimization 
at the bioprocess engineering level has been performed for RV (Cruz, Almeida et al. 2000) and 
will also be required for LV processes.  
1.2.8 LV Purification and Final Product Characterization  
In conventional protocols for LV production ultracentrifugation remains the concentration and 
purification method of choice (Naldini, Blomer et al. 1996; Reiser 2000; Follenzi and Naldini 
2002). This method is easily accessible and convenient for small-scale applications, providing 
high-titer preparations after one or several rounds of concentration. It is, however, greatly limited 
by the volume of the preparation and consequently not scalable. Scalable purification strategies 
are required to process supernatants from multi-liter production runs. As LVs share very similar 
structural, physical and biochemical properties with RV, the field can benefit from extensive 
reviews covering the topic (Braas, Searle et al. 1996; Lyddiatt and O'Sullivan 1998; Segura, 
Kamen et al. 2006; Rodrigues, Carrondo et al. 2007). In summary, suitable purification methods 
should remove contaminants, such as transduction inhibitors, host cell derived proteins, 
endotoxins and free DNA remnants while preserving vector functionality. Chromatography-based 
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methods such as anion exchange chromatography appear to be the most viable options for 
scalable purification (Scherr, Battmer et al. 2002; Slepushkin, Chang et al. 2003; Yamada, 
McCarty et al. 2003). In particular, Mustang Q anion exchange membrane chromatography was 
described as a promising technology in several studies (Marino, Kutner et al. 2003; Slepushkin, 
Chang et al. 2003; Ricks, Kutner et al. 2008; Kutner, Puthli et al. 2009). The downstream 
processing strategy to purify LV preparations for the first clinical trial has also been published, 
reporting an overall recovery of 30 % and demonstrating the feasibility to generate material for ex 
vivo use. RV and LV preparations can also be polished using size exclusion chromatography 
(Slepushkin, Chang et al. 2003; Transfiguracion, Jaalouk et al. 2003). Particular challenges for 
purification include the low stability of LV after multiple freeze-thaw cycles, at increased 
temperature and the narrow pH and osmolarity range for processing of the vector. The process 
steps and materials and methods for scalable LV mass production by current state of the art 
methods are presented in Figure 1.2.  
37 
 
 
 
Figure 1.2 : Flowchart of a scalable process for LV mass production.  
Materials and methods that are used comprise PEI-based transfection in bioreactors using 3rd 
generation packaging (Gag-Pol, Rev) and envelope (VSV-G) constructs and a self-inactivating 
(SIN) lentivector in serum- and animal-component-free medium. LV-containing supernatant is 
then continuously harvested from 1-4 dpt from the perfusion culture. Further processing of the 
supernatant includes sequential microfiltration with decreasing pore size (0.8/0.45 µm), followed 
by (membrane) anion-exchange chromatography and/or size exclusion for polishing. Final steps 
are a benzonase treatment to remove free DNA, buffer exchange for storage/final formulation and 
sterile filtration. Quality control assays as described in section 1.2.5 and 1.2.8 
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Before LV preparations can be used in clinical applications, a variety of regulatory aspects need 
to be considered. Detailed descriptions of the regulatory requirements are well beyond the scope 
of this review but would be found in the specialized reviews cited below. The first clinical trial 
using lentiviral vectors in humans gave important insights into the concerns of the regulatory 
agencies and how these can be addressed from a manufacturing and quality control perspectives 
(Slepushkin, Chang et al. 2003; Manilla, Rebello et al. 2005; Levine, Humeau et al. 2006). 
Extensive reviews dealing with the manufacturing of viral vectors might also provide helpful 
guidance on these topics (Lusky 2005; Mandel, Burger et al. 2008; Thorne, Takeya et al. 2009; 
Wright 2009). In general, current good manufacturing practice (cGMP) guidelines for the 
production of biologicals in the United States and Europe are defined by the respective regulatory 
agencies Food and Drug Administration (FDA/CBER) and European Medicines Agency 
(EMEA). Other sources include international regulations of the International Conference on 
Harmonisation (ICH) and the World Health Organization (WHO) or other country-specific codes. 
Particular concerns related to the use of lentiviral vectors in humans include vector mobilization, 
insertional oncogenesis and generation of RCL. A variety of respective assays has consequently 
been developed for quality control release testing of LV lots and transduced cellular products 
(Schonely, Afable et al. 2003; Manilla, Rebello et al. 2005). These assays comply with the 
standard approach for release testing of biopharmaceutical products by testing for safety, identity, 
strength, potency, purity and biological properties of the final product. 
To prevent vector mobilization after infection and rescue by wild-type HIV-1 helper virus, it was 
suggested that the clinical implementation of LVs should be mainly based on SIN vector 
constructs (Miyoshi, Blomer et al. 1998; Zufferey, Dull et al. 1998; Bukovsky, Song et al. 1999; 
Evans and Garcia 2000). Concerning insertional mutagenesis, recent data analyzing the 
integration patterns in the first LV-based clinical trial is now available, suggesting that LVs, in 
contrast to RVs, integrate into the entire intragenic region and do not favor integration near proto-
oncogenes and that no selective expansion of the transduced population occurred over time 
(Mitchell, Beitzel et al. 2004; Ciuffi, Mitchell et al. 2006; Wang, Levine et al. 2009).  
This LV construct will be further evaluated during a long term follow up of all patients involved 
in this trial (Manilla, Rebello et al. 2005). However, ongoing clinical trials might reveal if other 
modified lentiviral constructs, containing strong promoters, are intrinsically less likely to 
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transactivate cellular genes than RV or have other adverse effects (Montini, Cesana et al. 2006; 
Kohn 2007; Rossi 2009; Wang, Levine et al. 2009). 
Although the generation of RCL is unlikely, their occurrence would be fatal as a novel human 
pathogen would be generated. It is therefore required to perform rigorous testing for the 
emergence of RCL. The assay design is generally difficult, as a putative RCL is of unknown 
structure. A number of different assays to detect RCL has been proposed (Sastry and Cornetta 
2008). Some methods are most likely sensitive to RCL, such as assays targeting the VSV-G 
envelope or its DNA/RNA, CAp24 protein and HIV-1 gag DNA/RNA. Typical procedures of 
RCL assays therefore comprise the co-cultivation of HIV-1 permissive (indicator) cell lines, such 
as C8166-45 and MT4, with production cells and the final LV preparation for a period of several 
weeks to amplify possible RCL (Chang, Urlacher et al. 1999; Farson, Witt et al. 2001; Escarpe, 
Zayek et al. 2003). In parallel, a positive control is used in form of an attenuated HIV-1 and the 
supernatants tested for the presence of RCL. To date, no RCL emergence has been reported 
during production when advanced LV constructs were used (Escarpe, Zayek et al. 2003; Sastry, 
Xu et al. 2003; Schonely, Afable et al. 2003; Miskin, Chipchase et al. 2005). Only large 
production batches of ongoing and future clinical trials can however give insights on the RCL 
formation during large scale LV production.  
1.2.9 Remaining Challenges for Efficient LV Mass Production 
In the field of LV production, only limited basic bioprocess engineering principle-guided 
approaches have been reported. For example, optimal harvest times or kinetics of virus 
production are rarely reported and for current standard protocols the time of LV peak production 
is only rarely determined. Authors use different harvest points after transfection or induction with 
or without culture media exchange during production. Most studies therefore report results in 
which both, viral productivity and degradation or decay, are confounded (Beer, Meyer et al. 
2003). A deconvolution of these parameters needs to be achieved to allow for a rational 
optimization, ideally based on mathematical models.   
The assessment of cellular productivities (infectious or total viral particles per cell) is often 
difficult because protocol details such as cellular density or harvest volume are not reported. 
Whereas titers of up to 10-150 pg/cell have been reported for transient protein production, the 
specific productivity for high-yield LV systems is low, similar to other viral vectors that are 
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produced transiently (Wright 2009). For total LV particles, cell specific mass amounts of only 
0.8-8 pg/cell×day are typically reported, with only ~0.1-1 % of total produced LVs being 
functional (i.e. ~1-50 tu/cell) (Higashikawa and Chang 2001; Mitta, Rimann et al. 2005). In 
contrast, cell-specific yields for other viral constructs such as adenoviral and adeno-associated 
viral vectors are in the range of 103-104 IVP/cell (Kamen and Henry 2004; Aucoin, Perrier et al. 
2008). The production of other vectors is mostly based on systems that include several ‘rounds’ 
of infection. Transient transfection and the expression of transfected DNA constructs for LV 
production is probably less efficient compared to virus-based gene transfer (Elouahabi and 
Ruysschaert 2005; Collins 2006; Vaughan and Dean 2006). Stable systems suffer so far from 
similar productivity limitations and equally only allow for transient LV production with short 
production windows.  The impact of medium additives and for example the importance of the 
lipid metabolism suggests that media optimization strategies are needed to further improve LV 
yields. Therefore more work integrating recent progress in metabolic and process engineering is 
required to significantly increase the LV production yields. 
The many different protocols and methods for LV quantification are another challenge that 
complicate advances in process development. Whereas it is suggested that both functional and 
total vector particles are quantified, most methods are time-consuming and standardization is 
urgently needed. The field would highly benefit from the development and adaptation of fast 
quantification methods targeting the total and intact viral particles that have been described for 
other viral vectors (Transfiguracion, Bernier et al. 2001; Shen, Meghrous et al. 2002; 
Transfiguracion, Coelho et al. 2004; Transfiguracion, Bernier et al. 2008). 
A clinical use of LVs will require optimized formulations to prevent a rapid loss in viral activity. 
Additional studies in different buffer compositions on the stability of purified preparation of 
pseudotyped LVs are urgently needed. 
1.2.10 Summary and Conclusion 
In this review, we point out recent advances in the generation of LV. A comparison of existing 
protocols for LV production is generally difficult because of the difference in production systems 
and operating conditions. Nevertheless, significant improvements of conventional transfection 
protocols, increasing functional titers by several orders of magnitude, have now been reported 
(Karolewski, Watson et al. 2003; Mitta, Rimann et al. 2005). Optimization of production 
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parameters and the use of scalable suspension-based strategies can lead to improved volumetric 
yields of more than 100-fold and allow for cost-effective LV production (Mitta, Rimann et al. 
2005; Ansorge, Lanthier et al. 2009). 
The LV system remains a field that is in development and improvements in its molecular 
architecture will depend on the acceptance and success of ongoing clinical trials. The optimal LV 
system is not yet found and depends on the respective therapeutic application. The rising interest 
in non-integrating LV forms can serve as one example for the ongoing development in the field 
(Nightingale, Hollis et al. 2006; Wanisch and Yanez-Munoz 2009). Methods offering a high 
degree of flexibility such as transient transfection are consequently instrumental to respond to the 
demand in LVs.  
Stable systems will be of highest importance for LV production with regards to routine mass 
manufacturing of final commercial material. However, these systems are not yet widely used, 
probably because the overall benefit compared to transient transfection remains relatively 
modest. It is questionable if the efforts to produce a stable packaging cell line are beneficial in the 
early stages of an LV-based evaluation of a therapeutic strategy. Using different or modified 
vector components in early stages of LV vector development is often required and transient 
expression offers the appropriate flexibility, whereas a stable cell line strategy would require 
generation of a new cell line for each desired vector pseudotype (Ni, Sun et al. 2005). Both 
production strategies, transient transfection and stable packaging and producer cell lines, will 
therefore be used in parallel in the foreseeable future. 
For research applications, protocols using adherent cultures in T-flasks or culture dishes are 
sufficient, whereas readily scalable suspension-based approaches should be developed for pilot 
and large-scale productions. It would be preferable to have a scalable production system in place 
when preclinical studies and phase 1 clinical trial are being contemplated to avoid serious 
production constraints that might turn into a bottleneck in the latest clinical evaluation phases.  
There is still a possibility to further improve current LV production processes by several orders 
of magnitude. The yields of current LV systems could first of all be increased rationally by 
optimization of the harvest rate as function of vector stability in culture supernatants. Production 
at higher cell densities and optimized media formulations should further increase productivity of 
current processes. Finally, improvements in the molecular design of LV systems, targeting an 
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improved stability of the viral particles should allow for more efficient production. Although 
many aspects require further research and development efforts, recent advances in LV production 
should enable the cost-effective and simple mass production of clinical LV material under GMP 
conditions in the near future. 
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CHAPTER 2 METHODOLOGY FOR SCALABLE LV PRODUCTION 
AND PROCESS CHARACTERIZATION 
As indicated in the introduction, an optimization strategy was developed in this thesis to produce 
LV in a scalable manner. Here we describe in detail the methodologies that were used during this 
work.  
First, the selected approach for LV production is described. This includes production of 
LV in perfusion after transient transfection. Operation in perfusion mode was combined with the 
transient transfection technology previously developed within our group. Extensive experience 
with the transfection technology (Durocher, Perret et al. 2002; Durocher, Pham et al. 2007; Tom, 
Bisson et al. 2007) and earlier work (Segura, Garnier et al. 2007) demonstrating the feasibility of 
LV production in suspension culture formed the basis of this work.  
The analytical methods used to assess LV quantity and quality are then described in detail and 
compared. We then give details on the other analytical and monitoring tools that were employed 
in this work and provide a brief theoretical background when needed. These tools comprise both 
offline and online methods for measurement of cell counts, permittivity, biovolume, cell size and 
metabolite concentrations. 
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2.1 Production of Lentiviral Vectors 
2.1.1 Cell Culture 
The HEK293SF-3F6 cell line, originally developed for the production of adenoviral vectors, was 
used in this study (Côté, Garnier et al. 1998). This cell line is highly transfectable and grows in 
suspension under serum-free conditions. In most parts of this work, we refer to this cell line 
simply as HEK293. 
Several culture media were tested for their ability to sustain production of LV in suspension: Two 
formulations of LC-SFM (Côté, Garnier et al. 1998) were used in small-scale experiments: LC-
SFM L (LC-SFM + 0.1 % (v/v) lipid mixture (SIGMA, L-5146) (Pham, Perret et al. 2003) and 
LC-SFM GL (LC-SFM L supplemented with 0.5 % (v/v) gelatin peptone GPN3 (OrganoTechnie 
S.A. (La Courneuve, France)), (Pham, Perret et al. 2005)). For bioreactor experiments, LC-SFM 
L was supplemented with 0.1 % BSA (Celliance, Kankakee, IL); HyQSFM4TransFx293 (HyQ) 
(Hyclone, Logan, UT), a commercial medium specifically developed for transfection of HEK293 
cells was evaluated as a second media formulation (Tom, Bisson et al. 2007). Whenever indicated 
HyQ was supplemented with 5 % (v/v) of stock solution of the regular formulation of cell boost 5 
(CB5 reg) (Hyclone, Logan, UT) or a customized formulation of CB5 (CB5 mod) to obtain a 
fortified HyQ medium formulation (HyQ+). In contrast to CB5 reg, the latter formulation CB5 
mod was not found to be inhibiting the transfection. The CB5 stock solutions were prepared at 35 
g/L according to manufacturer’s instructions. In general, precultures were passaged using 
standard media (i.e. LC-SFM L or HyQ) every 2-3 days to keep the cells in their exponential 
growth phase. After a maximum of three months, new cells were thawed from the working cell 
bank. 
2.1.2 Transient Transfection 
The transfection protocol has been published in detail elsewhere (Tom, Bisson et al. 2007). A 
PEI:DNA mass ratio of 2:1 was found to be optimal for transient transfection of HEK293SF-3F6 
(Durocher, Perret et al. 2002; Pham, Perret et al. 2003). We used a GFP-encoding SIN transfer 
vector (pCSII-CMV5-GFPq), third generation packaging plasmids (pMDLg/pRRE#54 and 
pRSV-Rev) and a vector encoding the VSV-G envelope (pSVCMV-IN-VSVg) (Dull, Zufferey et 
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al. 1998; Broussau, Jabbour et al. 2008) for LV production in HEK293 cells (fig. 2.1). A plasmid 
mass ratio of 1:1:1:2 (VSV-G: Gag-Pol: Rev: Lentiviral Transfer Vector) was used for 
transfection according to previous results from our group (Segura, Garnier et al. 2007). Initial 
conditions involved transfection according to routine procedures using PEI-DNA complexes 
(polyplexes) with a total DNA amount of 1 µg/ 610  cells. Improved production conditions were 
then identified (chapter 3) with transfection at a cell density of 5x106 c/mL in HyQ medium, a 
total DNA amount of 0.4 µg/ 610  cells and the addition of sodium butyrate (5 mM) at 16 hpt. If 
not mentioned otherwise, improved production conditions comprised a medium exchange rate of 
1 “sequential discontinuous medium exchanges per day (DMD)” or 1 volume(s) of medium per 
reactor volume per day (VVD) in small scale and bioreactor cultures, respectively. 
Initial small scale experiments were performed using a constant concentration of PEI-DNA 
complexes with varying polyplex volumes, i.e. for transfection at 5x106 c/mL, 40 µg of DNA 
were used for transfection per shake flask (working volume of 20 mL), corresponding to a total 
DNA concentration of 20 µg/mL in the polyplex mixture. 
For some of the experiments presented in appendix II, the polyplex volume was maintained 
constant at 10 % of the final culture volume. Thus DNA and PEI concentrations were a function 
of the cell density at transfection and up to 4 times higher for transfection at 2x107 c/mL. 
Precultures for LV production experiments in HyQ+ were diluted in medium including 5 % (v/v) 
of CB5 mod (HyQ+) 2-3 d before transfection (see appendix II). Polyplexes were in all cases 
prepared in medium without supplement to avoid interference of medium components in HyQ+ 
and ensure comparability. After transfection, regular cell boost (CB5 reg) was used as feed (in 
bioreactor cultures) or for discontinuous medium replacement (in small-scale) starting at 24 hpt. 
For bioreactor cultures, polyplexes were prepared by manual shaking of the DNA-PEI mixture 
that corresponded to ~7-9 % of the final culture volume (i.e. 200-250 mL). 
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Figure 2.1 : LV production by PEI-based transient transfection. 
Simultaneous transfection of four different plasmids encoding for the essential LV components 
into HEK293 cells leads to generation of LV particles  
2.1.3 Stability and Harvest of LVs  
Preliminary results of experiments on LV stability in culture supernatants confirmed literature 
reports showing that LVs rapidly loose infectivity at standard production temperature. In these 
preliminary experiments, incubation at 37°C for ~12 h resulted in loss of ~50 % of functional 
titer whereas the viral infectivity decay was greatly reduced if the produced vectors were 
maintained at 4°C (figure 2.2). Further results on LV stability in culture supernatants are 
presented in appendix I. 
The production of HIV-forming proteins is initiated as early as 5-6 h after transfection (Jouvenet, 
Bieniasz et al. 2008). To maximize the yield in functional LVs and to address the low vector 
stability, a daily harvest of LV was thus performed starting 1 day post-transfection (dpt) in the 
starting set of operating conditions. 
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Figure 2.2: LV stability in cell free bioreactor supernatants. 
Supernatants were harvested from continuous bioreactor cultures at 2 and 3 days post-
transfection (dpt) and incubated at 4 and 37°C prior to GTA analysis  
2.1.4 LV Production in Small Scale Cultures 
To mimic perfusion conditions and continuous LV production in bioreactor scale at high cell 
density, an experimental approach using sequential medium replacement was used in small scale 
cultures. Few hours before transfection, the cell suspension was centrifuged (300×g, 5 min) and 
resuspended in fresh medium at the targeted cell density for transfection. This simplified protocol 
was used to facilitate the execution of experiments and increase the experimental throughput. LV 
harvest was then conducted using complete daily medium exchanges by centrifugation (300×g, 5 
min) starting 1 dpt (i.e. at 24, 48, 72 and 96 hours post-transfection (hpt)). With the exception of 
data presented in chapter 3, we refer to this approach as “sequential discontinuous medium 
exchanges per day (DMD)”. Initial conditions, as presented in chapter 3, include transfection at 
1x106 c/mL and 1 DMD. In improved production conditions, cell density at transfection was 
increased to 5x106 c/mL and medium was exchanged at 1 or 2 DMD. At 2 DMD, media was 
exchanged at 16, 24, 40, 48, 64, 72, 88 and 96 hpt. When LVs were produced at higher cell 
densities than 5x106 c/mL, centrifugation time and relative centrifugal force were increased from 
5 to 10 minutes and from 300 to 350×g, respectively. 
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Each medium exchange decreased the LV titers in supernatants to very low and in comparison 
insignificant values (fig. AIV.2). Each harvest only represents the production of LV which 
occurred from one harvest to the subsequent one, thereby greatly facilitating the analysis of 
production kinetics. 
After centrifugation, the LV-containing supernatants that had been harvested were filtered 
through 0.45 µm HT Tuffryn membranes (diameter of 25 mm) (Pall, Ann Arbor, MI) to remove 
residual cells and cellular debris and stored at -80°C until further analyses. In general, not more 
than 3 mL of supernatant were subjected to filtration. At cell densities >5x106 c/mL, increased 
backpressure was observed during filtration. In these cases, membranes with larger filtration area 
(diameter of 32 mm) or sequential filtration through 0.8 µm Supor membranes (diameter 32 mm) 
followed by 0.45 µm filtration (25 or 32 mm) was performed. None of these methods decreased 
functional LV titer compared to non-filtered supernatants (results not shown). Stocks of sodium 
butyrate were prepared at a concentration of 1 M from n-butyric acid (SIGMA, B-2503) and 
neutralized with 10 M NaOH. This stock solution was added directly to the cell culture to reach a 
concentration of 5 mM whenever indicated. A basic description of the LV production protocol 
can, in a slightly modified form, also be found in the literature (Segura, Garnier et al. 2010). 
2.1.5 LV Production in Bioreactor Cultures 
A similar bioreactor setup to the one used in this study has been described previously (Henry, 
Kamen et al. 2007). A schematic representation of the bioreactor setup is presented in fig. 2.3. 
Minor modifications compared to this setup were the following: agitation rate was set to 85 rpm, 
pH was controlled in the range of 7.1-7.2 by addition of CO2 via the surface or sodium 
bicarbonate solution (7.5 % (w/v)). The vessel (working volume 2.7 L) was equipped with probes 
to measure and control pH, DO and temperature. A Biomass System® (Fogale nanotech, Nîmes, 
France) as well as a Biomass Monitor 220 (Aber Instruments, Aberystwyth, UK) (standard in situ 
probes for 25 mm ports) were employed for the measurement of permittivity across the β-
dispersion frequency spectrum of ~0.1-10 MHz. In perfusion mode, cells were retained in the 
bioreactor using a 10 L acoustic filter (AppliSens, Schiedam, Netherlands) operated in backflush 
mode (full recycling of cell suspension into bioreactor at each backflush) with an interval of 30 
min and a run/stop ratio of 55/5 s. The use of acoustic filter technology for perfusion cultures of 
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mammalian cells has been extensively described in the literature (Trampler, Sonderhoff et al. 
1994; Henry, Dormond et al. 2004; Shirgaonkar, Lanthier et al. 2004).  
Bioreactor cultures were inoculated at cell densities around 5105×  cells/mL (viable cell count 
(vcc)). Perfusion was started after initial growth in batch mode at cell densities above 6101×  
cells/mL. Perfusion was initiated at 1 or 2 volume(s) of medium per reactor volume per day 
(VVD). After reaching the targeted cell density ( 6101×  vcc (starting conditions) or 61085 ×−  
vcc (improved production conditions) in perfusion mode, the culture was transfected by the 
addition of polyplexes and perfusion was stopped for 3 h. After transfection, the LV-containing 
supernatant was kept at 4ºC until clarification and sodium butyrate was added following the same 
procedure as in small scale. The harvested supernatant was filtered through a Supor double 
membrane with pore sizes of 0.8 and 0.45 µm (Pall, Ann Arbor, MI). Bioreactor samples were 
filtered according to the procedure described above (section 2.1.4). Clarified supernatants and 
samples were subsequently stored at –80ºC until further analyses. 
The DO was controlled at 40 % of air saturation by sparging pure oxygen in pulse mode into the 
culture at increasing flow rates (depending on the biomass content in the reactor). From the total 
oxygen volume sparged into the bioreactor, the oxygen sparging rate (OSR in mL/min) was 
calculated as an indicator of the volumetric oxygen consumption. 
A summary of the bioreactor cultures performed in this work can be found in table AII.2. 
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Figure 2.3 : Schematic representation of bioreactor setup and continuous operation for LV 
production.  
For all cultures, bioreactors were equipped with in situ sterilizable probes to measure pH, 
temperature (T), dissolved oxygen (DO) and permittivity (see section 2.5 and chapter 5). 
2.2 Analytical Methods for Assessment of LV Quantity and 
Functional Titers: Variability Assessment and Comparison of 
Quantification Methods 
To appreciate the challenges in LV production process development, it is fundamental to assess 
the intrinsic variability of LV quantification methods (see also section 1.2.5). This section first 
provides a short theoretical introduction on the quantification methods used in this work. We 
focus on practical constraints of the different methods and assess inter- and intra-assay variations. 
It is critical to determine the accuracy of each quantification method to decide whether or not 
differences in titers observed using modified production conditions are significant.  
Quantification methods can be generally divided in two categories: The techniques assess either 
1) LV quantity, i.e. total/physical particle titers or 2) functional LV titers. The ratio of functional 
vectors to total particles in a given preparation is an indicator of LV quality. 
Methods targeting total/physical particle titers are directly assessing the LV concentration in cell 
culture supernatants. The results largely depend on how a total/physical particle is defined by the 
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experimental approach, i.e. which part of the viral particle is quantified. The most widely used 
direct LV quantification methods, the CAp24 ELISA and quantitative RT-PCR, assess the 
concentration of major structural components such as the most abundant LV protein, the capsid 
CAp24, and the viral genetic information in culture supernatants, respectively. From these two 
methods, RT-PCR is best suited to measure the amount of total particles (VG titer) (Gerearts,  
Willems et al. 2006). It is known that after transfection without the Gag-Pol plasmid which is one 
of the main drivers of LV particle formation, viral RNA secretion is significantly reduced, 
corresponding to one thousandth of values from control transfections (Ikeda, Takeuchi et al. 
2003). Nevertheless, viral RNA can even be detected if no functional LV particles are present 
when the VSV-G construct is omitted during transfection (Geraerts, Willems et al. 2006). 
In contrast, the CAp24 ELISA (VP titer) can be affected by false positive results from free non-
viral related CAp24, is less reliable for evaluation of functional vector particles and also subject 
to high variability (Ansorge, Henry et al. 2010; Geraerts, Michiels et al. 2005; Ricks, Kutner et 
al. 2008). Nevertheless, the CAp24 ELISA remains to date the most widely used assay. 
Generally, all direct methods overestimate functional titers and indirect methods must therefore 
be used to quantify the number of functional LVs. Functional assays (indirect methods) assays 
determine viral vector function or transgene transfer after transduction of suitable target cells. 
Functional titers are a function of the respective transduction protocol. More specifically, 
functional LV titers are dependent on (see also section 1.2.5 and tables 1.1-2): 
• the target cell line and the culture conditions including the medium, 
• the addition of transduction-enhancing additives (e.g. Polybrene), 
• the cell cycle phase/arrest of target cells, 
• the transduction conditions such as inoculum volume and number of target cells, 
• the vector stability, length of exposure, 
• the transgene, its promoter, vector backbone, i.e. transgene expression efficiency, 
• the transduction detection method used in the assay. 
The assays are generally dependent on the final application in which LVs are intended to be used. 
In most cases, functional assays are consequently conducted on two cell lines: First, LV 
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preparations are titered on a universally used cell line using a standard protocol to allow for 
comparison of production yields. Second, a protocol including the cell line of interest for the final 
application is performed to predict gene transfer efficiency and the target dose. 
In the following, we will summarize the experimental approach of the three main quantification 
methods used in this work.  
 
2.2.1 Assays for the Determination of Total/Physical Particles 
2.2.1.1 LV Quantification by Quantitative RT-PCR  
Real-time quantitative PCR is widely used to quantify LVs. An excellent review on the topic 
(Delenda and Gaillard 2005) provides a comparison of existing methods, their constraints and 
pitfalls. Thus herein we give only a short summary on the topic and focus on the approach that 
was developed in the present work. In general, RT-PCR offers the flexibility to detect LVs at 
several levels, i.e. either by quantifying viral particles in supernatants (VG titer), the cellular 
genomic DNA after transduction (proviral DNA) or transgene mRNA levels after transduction to 
estimate the transgene expression level.  
The two most common approaches comprise VG titer and proviral DNA quantification (fig. 2.4).  
 
Figure 2.4 : Flow diagram comparing the two most common methods for LV particle 
quantification by RT-PCR, VG titer (1) and proviral DNA (2) quantification.  
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In this work, RT-PCR was exclusively used to assess VG titer as a measure of the total viral 
particle numbers. Several protocols employing different purification methods and primer targets 
have been published for that purpose. Table 2.1 summarizes recently published methods for VG 
titer determination.  
Based on this comparison, a quantification method was developed using commercially available 
kits for purification, DNAse treatment and RT-PCR. WPRE (woodchuck hepatitis virus 
posttranscriptional regulatory element) was chosen as primer target as it is present in most of the 
recent LV constructs and can be detected at all levels of the LV life cycle. In particular when 
estimating VG titer after transient transfection, carryover of DNA from vector production can 
lead to false positive results in RT-PCR assays. A DNAse treatment was therefore included into 
the sample preparation procedure prior to PCR analysis. Only the most recent protocols describe 
the use of an RNA standard to calculate the number of viral genomes per PCR reaction. 
Routinely used DNA standards do, however, neglect differences in the reverse transcription 
process. A RNA standard based on the LV transfer vector pCSII-CMV5-GFPq (section 2.1.2) 
was thus developed. 
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Table 2.1 : Comparison of RT-PCR based methods for VG titer quantification (direct method) 
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RT-PCR method used in this work (VG titer) 
The VG titer, i.e. the amount of total viral particles expressed as viral genomes (vg)/ml), was 
determined using a SYBR-Green I (SGI) quantitative RNA RT-PCR assay (Roche Applied 
Science, Laval, Qc). An in-house RNA standard was used to quantify LV in supernatants from 
production runs. The RNA standard was produced using the MEGASCRIPT kit (Applied 
Biosystems, Foster City, CA). For this purpose, WPRE from the LV transfer vector (pCSII-
CMV-GFPq) was cloned into pUC19 T7. The resulting plasmid pUC19 T7-LVWPRE was then 
linearized and in vitro transcribed. The transcript (RNA standard) with a length of 260 bases was 
purified (MEGACLEAR kit, Applied Biosystems, Foster City, CA), quantified by 
spectrophotometry, aliquoted at the final standard concentrations (1x109-1x104 copies/reaction) 
in DEPC-treated water and finally characterized (fig. 2.5). Specificity of the PCR reactions was 
confirmed by melting curve and agarose gel analysis. The lower detection limit of this method is 
in the range of 5x105 vg/mL. 
After RNA purification from LV-containing supernatants using the High Pure Viral RNA kit 
(Roche Applied Science, Laval, Qc), samples were treated with DNAse (DNA-free Kit, Applied 
Biosystems, Foster City, CA). RT-PCR was then performed in a Carousel-based LightCycler 
(Roche Applied Science, Laval, Qc) or a Mastercycler ep realplex system (Eppendorff, Hamburg, 
Germany). Primers (P1, P2) targeting a sequence in the WPRE sequence were selected using 
clone manager (Sci-Ed Software, Cary, NC). Each reaction had a volume of 20 µL with a 
concentration for each primer of 0.5 µM (P1: LVWPREF: AGT-TGT-GGC-CCG-TTG-TCA-
GG, P2: LVWPRER: AGG-CGA-GCA-GCC-ATG-GAA-AG), amplifying a sequence in the 
WPRE element of 249 bp. 
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Figure 2.5 : Characterization of in-house RNA standard and qualification of PCR method with 
process samples. 
(A) DNAse and RNAse treatment of RNA standard; (B) evolution of RNA standard PCR results 
after sequential freeze-thaw cycles, legend indicates number of cycles; (C) PCR analysis of 
bioreactor (run #5) samples without (- DNAse) and with (+ DNAse) DNAse treatment, arrows 
mark time of transfection; br: samples taken from bioreactor; hv: sample from the harvested cell-
free supernatant 
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Figure 2.5 presents the characterization of the RNA standard and qualification of the PCR 
method during a bioreactor production run. We observed that residual DNA in the preparation 
was insignficant as copy numbers were not affected by additional DNAse treatment. 
Additionally, RNAse treatment could bring the signal back to the baseline value of the negative 
control (fig. 2.5 A). The freeze-thaw stability of the RNA standard was evaluated after sequential 
freeze-thaw cycles (fig. 2.5 B). No significant loss in RNA copy number was found up to three 
cycles and we thus defined this number as a maximum after which the RNA standard aliquots 
were discarded. 
When comparing samples from bioreactor production with and without DNAse treatment prior to 
PCR, we found that it was in particular decreased during the first 24 hours post-transfection. In 
later process stages, the difference in VG titer of treated and non-treated samples was lower. This 
indicates that residual plasmid DNA was most likely the main reason for increased PCR signals 
and that the DNAse treatment successfully addressed the carryover of plasmid DNA after 
transfection (fig. 2.5 C). 
The inter-assay variability of the developed PCR method was very low and the results between 
different assays, based on the RNA standard curve, were highly reproducible (fig. 2.6, table 2.2). 
 
Figure 2.6 : Average standard curve from independent PCR analyses (n = 12); crossing point is 
identical to ct values shown in fig. 2.5 B 
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2.2.1.2 LV Quantification by CAp24 ELISA (VP titer) 
As briefly mentioned earlier, various sources such as unincorporated CAp24 that is not related to 
viral particles can lead to false positive results in CAp24 ELISA assays (ELISA), in particular 
when crude vector preparations are titered (Ricks, Kutner et al. 2008). In addition, CAp24 is 
released from cells after transfection even though no functional LV is present (Geraerts, Willems 
et al. 2006). 
In the present work, a commercial CAp24 ELISA kit was used according to the manufacturer’s 
instructions (QuickTiter Lentivirus Titer Kit (LV-associated HIV p24); Cell Biolabs Inc, San 
Diego, CA) to determine VP titer. The manufacturer of this kit claims that the sample preparation 
method allows quantifying of the LV Cap24 core protein only, i.e. free capsid protein is excluded 
from the measurement.  
Processing of samples according to this protocol was particularly tedious and time consuming. 
Only a limited number of process samples were therefore analyzed for comparison with the other 
LV quantification methods. A further disadvantage of the method is its restricted linear range 
(>1.5–50 ng/ml, average standard curve shown in fig. 2.7). The resulting extensive dilution of LV 
samples will likely affect reproducibility. 
 
Figure 2.7 : Average standard curve from independent CAp24 ELISA assays (n = 3). 
Remark: the regression coefficient was slightly higher (R2 = 0.99) when values until 25 ng/mL 
only were considered for the regression 
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2.2.2 Functional LV Titer Quantification by Gene Transfer Assay (GTA) 
For the assessement of functional LV titer, it is necessary to conduct indirect methods that allow 
for the quantification of the LV ability to transfer its genetic information to suitable target cells 
(section 1.2.5.2, 2.2). In this work, a gene transfer assay (GTA) using suspension-grown cells 
was used to quantify functional LVs. The method is simple, allowing for a high throughput while 
minimizing assay variability. For this purpose, HEK293E cells (clone 6E) were cultured in 
FreestyleTM 17 medium (Invitrogen). Transduction and titer determination was performed as 
previously described (Segura, Garnier et al. 2007). In brief, the target cells were diluted at the day 
of transduction to a cell density of 5.5x105 c/mL. Polybrene was directly added to the cell 
suspension at 8 µg/mL. After 15-30 min of incubation at 37°C, 0.9 mL of the cell suspension was 
loaded into each well of a 12 well plate and 0.1 mL of diluted LV containing samples were 
added. Two days later, the cells were harvested by centrifugation, resuspended in PBS and fixed 
by formaldehyde addition (final concentration of 2 %). The samples were then scored for GFP 
expression by FACS analysis. Functional LV titer was calculated using the formula: 
tu/mL = % GFP positive cells * dilution factor * cell count at time of transduction (c/mL) *assay 
volume (0.9 mL)/100 
The limit of detection of this assay is ~ 5101×  tu/mL. We used an in-house LV standard in all 
GTA experiments to assess inter-assay variability. All final titers were calculated relative to this 
LV standard that was found to be stable over a period of more than one year after storage at -
80°C in culture medium. The average standard concentration was calculated from independent 
GTA experiments (n = 40) and gave a standard deviation of 27.7 % (fig. 2.8).  
To confirm that GFP-expression was not the result of pseudotransduction, which is defined as 
detection false GFP-positive cells caused by diffusion of GFP or transfer of GFP-encoding DNA, 
control experiments with selected samples were performed in the presence of azidothymidine 
(AZT) (SIGMA, 100 µM). In all performed control experiments, the number of GFP-positive 
cells was at least reduced by 90 % compared to titration without AZT (figure AIV.3). In contrast, 
the addition of butyrate had no direct effect on LV titer quantification during the assay (fig. 
AIV.1). 
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The only disadvantage of the described method is the rather high detection limit of 1x105 tu/mL 
and the need for large volumes of LV containing samples. The approach is probably amenable to 
smaller volumes but this was not tested in this work as routine production conditions already 
resulted in sufficient volumes of detectable LV amounts.  
 
Figure 2.8 : Variation in functional LV titer of in-house GTA standard.  
Each bar represents the average value of one GTA assay; dashed line represents the average 
values from n = 40 independent assays; cell density at the time of transduction was on average: 
5.19 +/- 0.935 x105 c/mL 
2.2.3 Summary and Comparison of LV Quantification Methods 
In summary, available LV quantification methods are a considerable constraint for process 
development (see table 2.2 for a comparison of the different methods). All approaches are of high 
work intensity, limiting the number of samples that can be analyzed by a single operator per day. 
In-house standards were instrumental to evaluate variability of all non-commercial methods and 
allowed comparing the results of samples that were processed in independent assays. In general, 
the time to result using the different protocols is long, in particular for functional titer 
determination for which results are not available earlier than 2 days after viral transduction of the 
target cells. 
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As the FACS-based GTA assay is dependent on the expression of GFP in transduced cells, the 
low flexibility with respect to other LV constructs is the main limitation of the present approach. 
Although strictly controlled conditions for target cell transduction were used here, the observed 
inter-assay variability was nevertheless quite high. In this context, it was put forward by others 
that small variations in cell density and random integration are responsible for variations in LV 
titration assays (Geraerts, Willems et al. 2006; Zhang, Metharom et al. 2004). In this work, a 
reduced intra-assay variability compared to the inter-assay variability was observed. It is thus 
believed that the state of the target cell line, its passage number and history could have impacted 
the GTA results. This suggests that a stringent control of target cell line history could be 
evaluated to reduce assay variability. 
RT-PCR based methods are particularly promising for LV quantification as the time to result for 
VG titer determination is short and inter-assay variability is low. The results suggest the 
evaluation of RT-PCR for functional LV determination after target cell transduction (approach 2 
in fig. 2.4) as this might reduce the time to result of the GTA assay significantly and additionally 
provide the flexibility to use the same test for several LV constructs.  
In contrast, LV quantification by CAp24 ELISA was the least advantageous method suffering 
from a high variability, a long time to result and the highest labor intensity. This method remains 
nevertheless essential due to its specificity for the LV capsid protein, for comparison of results of 
different LV-based constructs and when PCR-based methods are not available.  
The detection limits of the quantification methods were not directly compromising the 
comparison of different production conditions for the model system. Routine starting conditions 
(chapter 3) already resulted in significant amounts of LVs that were detectable by GTA and PCR. 
However, it remains to be evaluated if this will hold for other LV constructs which are produced 
at lower yields. 
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Table 2.2: Comparison of LV quantification methods used in this work 
LV 
Quantification 
Assay/ assay 
parameter 
GTA PCR ELISA 
Method 
in-house, similar to 
previously described 
approach (Segura et al., 
2007) 
in-house/kit-based, 
see section 2.2.1.1 kit-based 
Assay standard 
in-house,  
aliquot from bioreactor 
run #2 
in-house, in vitro 
transcript of WPRE 
sequence 
kit-based 
Inter-assay 
variabilityI 
27.7 %, 
(n = 40) 
4 +/-1 % 
(n = 12) 
15 +/- 12.5 %X,  
(n = 3) 
Intra-assay 
variabilityII 
8 +/- 16 %,  
(n = 250) 
9 +/- 8 %  
(n = 9)VII; 
22 +/- 15 %  
(n = 17VIII) 
21 +/- 20 %,  
(n = 34) XI 
Time to result/ 
throughput per 
dayIII 
2 dVI, ~60 3-6 hIX, 40-50 2 d, 40-50 
Labor intensityIV + + - 
FlexibilityV + +++ ++ 
Detection limit 
(DL) 0.5-1x10
5
 tu/mL 5x105 vg/mL 1.95x107 vp/mL 
Remarks 
highest number of 
samples processed with 
this method 
most advantageous 
LV quantification 
method 
low number of 
assays was 
available for 
analysis 
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Remarks Table 2.2 : 
+++:  recommended/advantageous 
++: recommended but intrinsic constraints 
+:  significant intrinsic constraints 
-: not recommended 
I: standard deviation based on assay standards; n corresponds to the number of assays 
II: average standard deviation from duplicate analyses of identical samples (n = # of duplicates) 
III: maximum number of samples that can be analyzed by one trained operator per working day 
IV: results from duplicate analysis of identical samples using independent purification and DNAse treatment steps 
V: method flexibility concerning the analysis of varying LV constructs/particles 
VI: time to result could possibly be reduced by using advanced detection methods (PCR) 
VII: results from duplicate analysis by RT-PCR in a single assay 
VIII: results from duplicate analysis by RT-PCR (two assays) after purification with High Pure Viral RNA kit and 
DNAse treatment  
IX: depends on the number of samples (purification step is time-consuming if many samples need to be analyzed) 
X: standards at low concentrations with higher variations than at high concentrations 
XI: duplicate analysis at two different dilutions for each sample 
2.3 Sample Analyses  
Cell Counting and Cell Size Measurements 
Hemacytometer counts using erythrosine B dye exclusion were used to assess cellular density 
and viability. The volume weighted arithmetic mean cell diameter (d) was determined using a 
Z2™ Coulter Counter® (Beckman Coulter, Mississauga, ON) with an aperture diameter of 100 
µm, followed by analysis of the size distributions with the Accucomp® software package 
(Beckman Coulter). The upper and lower analysis limits were 7.31 and 23.8 µm, respectively. To 
calculate d, the distributions were plotted as volume (%) against cell diameter (µm). The lower 
analysis limit was then manually increased to select only that part of the distribution 
corresponding to viable cells for the calculation. 
Each value of d represents the average of at least two distributions. Using d and the viable cell 
count per mL (vcc), the biovolume (bv) was then calculated (chapter 5.2.3.4.1 and appendix III). 
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GFP measurement 
In the present work, the total expression of GFP in samples was quantified offline in 96 well 
plates using a SpectraMax Gemini EM plate reader (Molecular Devices, Sunnyvale, CA). 1x105 
cells were distributed in each well and fluorescence was measured at wavelengths of 485/538/495 
nm (excitation/emission/cutoff) after fixation with 4 % formaldehyde. One of the limitations of 
the method was that the total GFP expression signal is a function of the number of producer cells 
distributed in the well prior to measurement. Any variation in cell density (obtained from manual 
counting) is thus reflected in the GFP signal (unpublished observation). 
Metabolite Concentrations 
Virus-containing samples were filtered by centrifugation (13000 rpm for 5 min, Biofuge 
Hereaeus, pico) through Microcon Centrifugal Filter Devices (Ultracel YM-30) with a nominal 
molecular weight limit (NWL) of 30,000 prior to amino acid analysis by HPLC and/or metabolite 
analysis. 
Glucose, lactate, and ammonia assays were performed using the Biolyzer (Kodak, New Haven, 
CT). Amino acid concentrations in fresh media and supernatants were quantified by HPLC 
(Waters Alliance System, Waters Corp., Milford, MA) using a modification of the Waters 
AccQ.Tag method as describedin the literature (Cohen 2000; Pham, Perret et al. 2003; Kamen, 
Tom et al.  1991). 
2.4 Data Treatment and Calculation of Growth and Metabolic 
Rates and Productivity 
Growth and metabolic rates were calculated using standard equations (Henry, Dormond et al. 
2004) after filtering of the raw data (online and offline measurements). The calculation of 
specific rates was based either on the viable cell count (vcc) or the online dual-frequency 
permittivity signal (∆εFC). Offline raw data were fitted using the smoothing spline regression 
function of the kyplot software. Online data were treated with Matlab (The MathWorks, Natick, 
MA).  
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The cell-specific viral productivity for our experiments (tu/cell; vp/cell; vg/cell) was calculated 
by dividing the total produced LV particles after 4 days post-transection by the number of cells at 
the time of transfection. 
 
2.5 Permittivity Measurements 
The underlying theory on the dielectric properties of biological cells has been described in detail 
elsewhere (Kell et al. 1985; Harris and Harris 1987; Pethig and Kell 1987; Markx and Davey 
1999). In brief, when placed in an alternating electric field, polarization of the cells occurs due to 
their insulating plasma membrane (fig. 2.9).  
 
Figure 2.9 : Biological cells act like tiny capacitors in an electrical field 
This polarization or charge separation can be measured in terms of the permittivity of the cell 
suspension. Hence, intact biological cells act as tiny capacitors in electrical fields whereas cells 
with ruptured membranes theoretically do not contribute to the permittivity. Any given cell 
suspension shows a characteristic decrease in permittivity when applying alternating currents at 
increasing frequencies in the range of 0.1-10 MHz. This decrease, the β-dispersion, is caused by 
the polarization of cell membranes and can be defined by several dielectric parameters (details on 
the parameters are described in chapter 5). The permittivity is decreasing in the range of the β-
dispersion starting on a low frequency plateau that is produced by the complete polarization of 
the cell membrane whereas the high frequency plateau is due to the polarization of suspending 
medium or liquid where frequency is too high to cause polarization of the cell membrane. 
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Additional dispersions can be observed at lower and higher frequencies caused by different 
effects (Markx and Davey, 1999; Foster and Schwan 1989). 
However, only the β-dispersion is of relevance for biomass estimation as the permittivity signals 
observed in the low-frequency range of the β-dispersion can be used for biomass estimation. 
Generally, it is the biovolume or membrane enclosed volume fraction that is estimated by 
permittivity measurements. Several commercial systems are now available. All of these comprise 
in situ sterilizable probes that, in most cases, use a four-electrode probe design to reduce 
electrode polarization effects (Figure 2.10). The system then computes permittivity, conductivity 
and the β-dispersion parameters in real-time.  
Details on the measurement of permittivity and its related parameters and practical applications 
of the technology are further described in chapter 5 and appendix III. 
 
 
Figure 2.10 : Probe tip of a typical commercial permittivity-based biomass probe (shown here: 
Fogale Biomass System®) 
 
electrodes 
probe body 
electric field 
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CHAPTER 3 DEVELOPMENT OF A SCALABLE PROCESS FOR 
HIGH-YIELD LENTIVIRAL VECTOR PRODUCTION BY TRANSIENT 
TRANSFECTION OF HEK293 SUSPENSION CULTURES 
3.1 Article Presentation 
This chapter presents the journal article “Development of a scalable process for high-yield 
lentiviral vector production by transient transfection of HEK293 suspension cultures”. This 
article was published in the Journal of Gene Medicine. This thesis aims to develop a production 
strategy suitable for the mass production of lentiviral vectors. To date, two complementary LV 
production methods exist: 1) the use of stable packaging or producer cell lines and 2) transient 
transfection. Transient transfection offers advantages in terms of flexibility and a short time to 
product. This strategy should therefore be ideal for the rapid production of clinical trial lots and is 
the focus of this work.  
The present paper describes the development of a scalable process for the high-yield LV 
production by transient transfection in perfusion cultures. The main hypothesis was that operation 
at high cell density would increase LV titers while production in perfusion mode could be used to 
recover functional LV and thus address the issue of low LV stability. Several strategies to 
increase specific and volumetric productity were employed in this work. Results suggest that, 
using this high-yield production process, LV could be generated in an efficient manner for phase 
I clinical trials in a single pilot scale bioreactor. 
In this work, we refer to results from two bioreactor runs that are presented in this paper as run #2 
(routine starting conditions) and run # 3 (improved production conditions). 
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3.2 Development of a Scalable Process For High-Yield Lentiviral 
Vector Production by Transient Transfection of HEK293 
Suspension Cultures  
Sven Ansorge1,2, Stéphane Lanthier1, Julia Transfiguracion1, Yves Durocher1, Olivier 
Henry2 and Amine Kamen1 
1
: National Research Council Canada, Biotechnology Research Institute, 
 6100 Royalmount Avenue, Montréal, Québec H4P 2R2, Canada  
2: École Polytechnique de Montréal, C.P. 6079, succ. Centre-ville, 
 Montréal, Québec H3C 3A7, Canada 
3.2.1 Abstract 
Background 
Lentiviral vectors (LVs) offer several advantages over other gene delivery vectors. Their 
potential for integration and long term expression of therapeutic genes render them an interesting 
tool for gene and cell therapy interventions. However, large scale LV production remains an 
important challenge for the translation of LV-based therapeutic strategies to the clinic. The 
development of robust processes for mass production of LV is needed.  
Methods 
A suspension-grown HEK293 cell line was exploited for the production of GFP-expressing LVs 
by transient Polyethylenimine (PEI)-based transfection with LV-encoding plasmid constructs. 
Using third-generation packaging plasmids (Gag-Pol, Rev), a VSV-G envelope and a self-
inactivating (SIN) transfer vector, we employed strategies to increase volumetric and specific 
productivity. Functional LV titers were determined using a flow cytometry-based gene transfer 
assay. 
Results and Discussion 
A combination of the most promising conditions (increase in cell density, medium selection, 
reduction of PEI-DNA complexes per cell, addition of sodium butyrate) resulted in significantly 
increased LV titers of more than 150-fold compared to non-optimized small-scale conditions, 
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reaching infectious titers of ~108 transducing units (tu)/mL. These conditions are readily scalable 
and were validated in 3 L-scale perfusion cultures.  
Conclusions 
Our process produces LV in suspension cultures and is consequently easily scalable, industrially 
viable and generated more than 1011 total functional LV particles in a single bioreactor run.  This 
process will allow the production of LV by transient transfection in sufficiently large quantities 
for phase I clinical trials in 10-20 L bioreactor scale.  
 
3.2.2 Introduction 
Lentiviral vectors (LVs) are an increasingly important tool for gene and cell therapy 
interventions. Each virus type offers an inherent set of properties for specific gene delivery 
applications (Kay, Glorioso et al. 2001). LVs offer advantages over other vectors such as their 
ability to transduce quiescent and non-dividing cells, the irreversible integration in the genome 
and a large packaging capacity (Quinonez and Sutton 2002). Compared to γ-retroviral vectors, 
LV do not show a preference for integration near transcription start sites (Montini, Cesana et al. 
2006). LVs have already been used in phase I clinical trials in which efficient and safe ex vivo 
gene delivery to T cells with good persistence in vivo was demonstrated (Levine, Humeau et al. 
2006; Kohn 2007).  
Readily scalable and cost-effective LV production is of primary importance to successfully 
implement LV-based therapy approaches in the clinic. As an example, for a phase I clinical trial, 
at least 11105×  functional LV particles would be required (MacGregor 2001). Although the 
interest in lentiviral vectors in research and development steadily increased over the years, 
protocols for their production have been given only minor attention. The processes still rely on 
the classical approach of transfecting adherent cell cultures (Naldini, Blomer et al. 1996; 
Coleman, Huentelman et al. 2003; Schonely, Afable et al. 2003; Slepushkin, Chang et al. 2003; 
Sena-Esteves, Tebbets et al. 2004; 2005; Warnock, Merten et al. 2006; Lejeune, Truran et al. 
2007; Bellintani, Piacenza et al. 2008; Kuroda, Kutner et al. 2009).  
To ease scale-up, attempts have been made to develop stable, inducible packaging or producer 
cell lines that stably express LV components. However, their generation, in particular for self-
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inactivating (SIN) vectors, resulted only in low yields (Kafri, van Praag et al. 1999; Klages, Zufferey 
et al. 2000; Sparacio, Pfeiffer et al. 2001; Ikeda, Takeuchi et al. 2003; Cronin, Zhang et al. 2005; Ni, 
Sun et al. 2005; Cockrell, Ma et al. 2006; Warnock, Merten et al. 2006; Broussau, Jabbour et al. 
2008; Throm, Ouma et al. 2009).  
Currently, transient transfection remains the only viable alternative to generate LVs, in particular 
for early phases of production campaigns. Transient transfection is a fast method for the production 
of sufficient amounts of viral vectors (Naldini, Blomer et al. 1996; Blesch 2004). The production of 
viral vectors by transient transfection in large-scale suspension cultures has recently been 
described by several independent studies (Durocher, Pham et al. 2007; Hildinger, Baldi et al. 
2007; Segura, Garnier et al. 2007). Transfection protocols also allow for the flexibility to use 
cytotoxic/cytostatic transgenes and/or vector components (Bartz, Rogel et al. 1996). Recently, it was 
demonstrated that PEI-based transfection leads to better reproducibility of LV production 
compared to common calcium phosphate-based protocols (Kuroda, Kutner et al. 2009). PEI also 
allows the production of LV in suspension culture by transient transfection without the need of 
medium exchange prior or after transfection, making the process scalable (Segura, Garnier et al. 
2007).  
The efficiency of transient transfection is highly culture medium dependent and seems to be a 
function of additives (e.g. anti-clumping agents) and nutrient availability before, during, and after 
transfection (Pham, Perret et al. 2003; Pham, Perret et al. 2005; Pham, Kamen et al. 2006). 
Enrichment of medium with peptones (or their addition after transfection) results in superior 
productivity following PEI-mediated transfection (Pham, Perret et al. 2003; Pham, Perret et al. 
2005). The presence and concentration of charged entities and polymers that interfere with 
transfection varies from one medium to another. In practice, the choice of media candidates for 
transfection is therefore limited. In many processes, the optimization of transfection protocols 
consequently results in significant productivity improvements (Durocher, Perret et al. 2002; 
Karolewski, Watson et al. 2003; Dormond, Meneses-Acosta et al. 2009). Transfection protocols 
for suspension cultures are typically performed in batch mode. A limitation of this approach is 
that common protocols are confined to rather low cell densities. Current studies report cell 
densities of up to 6102 ×  cells/mL (Derouazi, Girard et al. 2004) with most optimized protocols 
being in the range of 0.5- 6101×  cells/mL at the time of transfection (Durocher, Pham et al. 
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2007). As a result, efforts are still needed to optimize volumetric productivities of transfection 
protocols. 
A low half-life of 4-16 h is reported for LVs and retroviral (RV) vectors (Higashikawa and 
Chang 2001; Watson, Kobinger et al. 2002). This presents a challenge for the production of LV 
and RV vectors, rendering processes based on regular batch or fed-batch mode unattractive 
(Cruz, Almeida et al. 2000; Cruz, Goncalves et al. 2000; McTaggart and Al-Rubeai 2000). In a 
previous study, the issue of a low LV stability was addressed by producing LVs in batch 
replacement mode (Segura, Garnier et al. 2007). However, a transfer of this process to industrial 
operations is difficult (Geisse 2009). Perfusion mode using acoustic cell filter devices for cell 
retention has already been validated as an advantageous strategy for adenoviral and retroviral 
vector production (Ghani, Garnier et al. 2006; Henry, Kamen et al. 2007). It allows a rapid 
harvest of produced viral particles (Merten 2004) and also alleviates nutrient limitations, leading 
to higher specific productivity (Henry, Kamen et al. 2007).  
One important limiting step in LV production appears to be the expression of LV-related genes, 
possibly due to transcriptional silencing of the transfected plasmid DNA as observed for LV and 
RV packaging cell lines (Kafri, van Praag et al. 1999; Jaalouk, Eliopoulos et al. 2000; Ni, Sun et 
al. 2005). Therefore, the addition of n-butyric acid or its salt, sodium butyrate, in a concentration 
range of 5-20 mM is often described in LV and RV production protocols (Soneoka, Cannon et al. 
1995; Sakoda, Kasahara et al. 1999; Karolewski, Watson et al. 2003; Merten 2004; Sena-Esteves, 
Tebbets et al. 2004). Butyrate leads to higher transcription and increased expression of 
transfected DNA (Altenburg, Via et al. 1976; Kruh 1981; Gloger, Arad et al. 1985; Gasmi, Glynn 
et al. 1999; Davie 2003).  
In this study, we present a scalable process for the production of LV by transient transfection of 
suspension-grown HEK293 cells in perfusion cultures. The goal of this work was the 
development of a process that could be easily transferred to industrial bioreactor scale. We 
conducted a complete daily medium exchange after transfection starting 1 day post-transfection 
in small-scale experiments. This allowed harvesting of LV particles, removal of remaining 
polyplexes and also provided additional nutrients for the transfected cells. Overall, we 
demonstrate how the combination of several strategies to increase the productivity of the process 
(increase in cell density, medium selection, optimization of transfection conditions and addition 
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of the expression-enhancing additive sodium butyrate) led to an improvement in LV yield of 
more than 100-fold compared to non-optimized production conditions. Bioreactor perfusion 
cultures were then performed for validation of the conditions with a continuous medium 
exchange rate of one reactor volume per day. With these improved yields, the process can allow 
the production of LVs by transient transfection in sufficiently large quantities for phase I clinical 
trials in a single run using a pilot scale bioreactor. 
3.2.3 Materials and Methods 
3.2.3.1 Cell Culture 
The HEK293SF-3F6 cell line, originally developed for the production of adenoviral vectors, was 
used in this study (Côté, Garnier et al. 1998). This cell line is highly transfectable and grows in 
suspension under serum-free conditions. 
Several culture media were tested for their ability to sustain production of LV in suspension: Two 
formulations of LC-SFM (Côté, Garnier et al. 1998) were used in small-scale experiments: LC-
SFM L (LC-SFM + 0.1 % (v/v) lipid mixture (SIGMA, L-5146) (Pham, Perret et al. 2003) and 
LC-SFM GL (LC-SFM L supplemented with 0.5 % (v/v) gelatine peptone GPN3 
(OrganoTechnie S.A. (La Courneuve, France)), (Pham, Perret et al. 2005)). For bioreactor 
experiments, LC-SFM L was supplemented with 0.1 % BSA (Celliance, Kankakee, IL); 
HyQSFM4TransFx293 (HyQ) (Hyclone, Logan, UT), a commercial medium specifically 
developed for transfection of HEK293 cells was evaluated as a second media formulation (Tom, 
Bisson et al. 2007).  
Hemacytometer counts using erythrosine B dye exclusion were used to assess cellular density 
and viability.  
Stocks of sodium butyrate were prepared at a concentration of 1 M from n-butyric acid (SIGMA, 
B-2503) and neutralized with 10 M NaOH.  
3.2.3.2 Transient Transfection 
The transfection protocol has been published in detail elsewhere (Tom, Bisson et al. 2007). A 
PEI:DNA mass ratio of 2:1 was found to be optimal for transient transfection of HEK293SF-3F6 
(Durocher, Perret et al. 2002; Pham, Perret et al. 2003). We used a GFP-encoding SIN transfer 
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vector (pCSII-CMV5-GFPq), third generation packaging plasmids for Gag-Pol and Rev 
(pMDLg/pRRE#54 and pRSV-Rev) and a vector encoding the VSV-G enevelope (pSVCMV-IN-
VSVg) (Dull, Zufferey et al. 1998; Broussau, Jabbour et al. 2008). A plasmid mass ratio of 
1:1:1:2 (VSV-G: Gag-Pol: Rev: Lentiviral Transfer Vector) was used for transfection according 
to previous results from our group (Segura, Garnier et al. 2007). Experiments were conducted 
according to routine procedures using PEI-DNA complexes (polyplexes) with a total DNA 
amount of 1 µg/ 610  cells. Precultures were passaged every 2-3 days to keep the cells in their 
exponential growth phase. A few hours before transfection, the cell suspension was centrifuged 
(300×g, 5 min) and resuspended in fresh medium at the targeted cell density for transfection. In 
bioreactor experiments, the culture was grown to the targeted cell density in perfusion mode and 
transfected thereafter.  
3.2.3.3 Harvest of LVs, Plasmid Production 
As the production of HIV-forming proteins is initiated as early as 5-6 h after transfection 
(Jouvenet, Bieniasz et al. 2008), we conducted daily harvest of produced LV and a complete 
medium exchange by centrifugation (300×g, 5 min) starting 1 day post-transfection in small-
scale experiments. LV-containing harvests were filtered through 0.45 µm HT Tuffryn membranes 
(Pall, Ann Arbor, MI) to remove cell debris and stored at -80°C until further analysis. During 
bioreactor cultivations, the harvested supernatant was filtered through a Supor double membrane 
with pore sizes of 0.8 and 0.45 µm (Pall, Ann Arbor, MI).  
The four LV-encoding plasmid constructs (Segura, Garnier et al. 2007) were produced using an 
in-house anion-exchange purification method (St-Laurent et al., manuscript in preparation) or 
commercially available purification kits (QIAGEN Plasmid Giga Kit, Qiagen, Mississauga, ON).  
3.2.3.4 Viral Quantitation and Productivity 
Viral titer was determined using a flow cytometry-based gene transfer assay (GTA). For this 
purpose, HEK293E cells (clone 6E) were cultured in FreestyleTM 17 medium (Invitrogen). 
Transduction and titer determination was performed as previously described (Segura, Garnier et 
al. 2007). The limit of detection of this assay is ~ 5101×  tu/mL. We used an in-house LV standard 
in all GTA experiments to minimize inter-assay variability. All final titers were calculated 
relative to this LV standard that was found to be stable over a period of more than one year after 
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storage at -80°C in culture medium. The average standard concentration was calculated from 
independent GTA experiments (n = 21). We observed a standard deviation of ~30 % in these 
experiments (# of total LV standard tests = 115). To confirm that GFP-expression was not the 
result of pseudotransduction, control experiments with selected samples were performed in the 
presence of AZT (SIGMA, 100 µM). In all performed control experiments, the number of GFP-
positive cells was at least reduced by 90 % compared to titration without AZT (data not shown).  
The cell-specific viral productivity for our experiments (tu/cell) was calculated by dividing the 
total functional produced LV particles after 4 days post-trasnfection by the number of cells at the 
time of transfection. 
 
3.2.3.5 Bioreactor Cultures 
A similar bioreactor setup to the one used in this study has been described previously (Henry, 
Kamen et al. 2007). Minor modifications compared to this setup were the following: agitation 
rate was set to 85 rpm, pH was controlled in the range of 7.1-7.2 by addition of CO2 via the 
surface or sodium bicarbonate addition. The vessel (working volume 2.7 L) was equipped with 
probes to measure and control pH, DO and temperature and a Biomass Monitor 220 (Aber 
Instruments, Aberystwyth, UK) for the measurement of the culture capacitance. The DO was 
controlled by sparging pure oxygen in pulse mode. Cells were retained in the bioreactor using a 
10 L acoustic filter (AppliSens, Schiedam, Netherlands) operated in backflush mode (full 
recycling of cell suspension into bioreactor at each backflush) with an interval of 30 min and a 
run/stop ratio of 55/5 s. Bioreactor cultures were inoculated at cell densities around 5105×  
cells/mL. Perfusion was started after initial growth in batch mode at cell densities above 6101×  
cells/mL. The medium exchange rate was set in all experiments to one volume per day. 
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3.2.4 Results 
3.2.4.1 Small Scale Production of LV 
3.2.4.1.1 Production of LV at high cell density (HCD) 
We conducted small-scale shake flask experiments to identify improved LV production 
conditions. The goal was an increase in volumetric yield of the LV production process, targeting 
an operation at high cell density (HCD). In a first effort, we increased the cell density at the time 
of transfection from the routine cell density of 6101×  cells/mL to 6105×  cells/mL (fig. 3.1). The 
yields from transient transfection and the production of viral vectors are highly dependent on the 
physiological state of the cell culture (Pham, Perret et al. 2003; Pham, Perret et al. 2005; Pham, 
Kamen et al. 2006; Tom, Bisson et al. 2007). A cell density was hence chosen which could be 
supported by the selected medium and our chosen production strategy (daily medium 
replacement). When using the medium formulation LC-SFM L, we observed cell growth in batch 
mode up to a cell density of ~ 6105.2 ×  cells/mL. In perfusion mode at one medium exchange per 
day, the culture grew exponentially up to 7101×  cells/mL (data not shown). A cell density of 
6105×  cells/mL was consequently selected for the production of LV at HCD as it corresponded 
to early/middle exponential growth phase in perfusion mode under initial experimental 
conditions.  
We observed that it was possible to keep a constant specific productivity of ~2 tu/cell at HCD, 
thereby achieving higher volumetric titers (fig. 3.1 A). When transfecting at a cell density of 
6101×  cells/mL we reached maximum viral titers at 3 days post-transfection (dpt) of < 6101×  
tu/mL. At HCD, the LV titer was in the range of ~ 6105×  tu/mL. The cell density increased in 
both cases after transfection and viability remained high in all experiments until 4 dpt (>75 %) 
(fig. 3.1 B).  
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Figure 3.1 : Increase in cell density at transfection leads to higher viral titers at constant specific 
productivity in small scale experiments.  
Experiments were conducted at low (LCD) and high cell density (HCD) in LC-SFM L. A: viral 
titer. LCD (open bars), HCD (solid bars); B: cell density. total cell count (squares), viable cell 
count (triangles), HCD (solid symbols), LCD (open symbols) 
 
3.2.4.1.2 Medium Selection for LV Production and Optimization of 
Transfection Conditions 
We consequently pursued this strategy and tested several media for the transfection at HCD. We 
sought to identify a medium formulation devoid of inhibiting components that required no 
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complete exchange of medium by centrifugation prior to or after transfection. Medium exchange 
should primarily be used to harvest LV and maintain high cell densities. 
Although several commercial media formulations for transient transfection are available today, 
the choice of possible media candidates was limited, i.e. only a few media (LC-SFM L; LC-SFM 
GL; HyQ) showed the indispensable characteristics for this study: growth to high cell densities 
(with daily medium replacement) and ‘suitability’ for transfection (no interference with the 
transfection process itself). An additional preferable feature of possible media candidates was 
minimization/avoidance of animal-derived components. Preliminary growth tests revealed that 
cell growth was equivalent or superior in LC-SFM GL and HyQ (data not shown). Transfection 
was then performed at LCD and HCD in the three media candidates (fig. 3.2). LC-SFM GL was 
included to test if enriched medium formulations would be beneficial for LV production. GPN3 
is, however, an animal-derived component and was consequently not of interest for further 
development of the production process. Indeed, LC-SFM GL gave highest titers after transfection 
at HCD (6- 6108×  tu/mL) at 2 and 3 dpt. HyQ also showed high potential at LCD with a higher 
productivity of ~6 tu/cell. This high productivity could however not be transferred to HCD (~2 
tu/cell). A possible reason for the lower cell-specific titers at HCD was increased aggregation and 
formation of a cell ring at the shake flask wall starting 2 dpt (not shown). PEI is known to have 
toxic effects (Godbey and Mikos 2001; Kunath, von Harpe et al. 2003; Sun, Hia et al. 2008) and 
might have therefore indirectly induced this phenomenon. 
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Figure 3.2 : The effect of different culture media on the production of LVs. 
Experimental conditions were transfection at: HCD in LC-SFM L (solid grey bars), HCD in LC-
SFM GL (solid black bars), LCD in HyQ (open bars) and HCD in HyQ (hatched bars) 
 
Consequently, the impact of a reduction in polyplex amount was evaluated. Highest titers were 
observed when transfecting with 0.4-0.6 µg of total DNA/ 610  cells (data not shown). This 
modification of the transfection protocol allowed more than doubling maximum titers 3 dpt to 
~
6109 ×  tu/mL while using less than half of the total DNA amount for transfection (fig. 3.3). 
Because of the high potential of HyQ at LCD, the superior cell growth characteristics and 
medium properties (animal-derived component free medium), the optimization strategy was 
continued using HyQ.  
3.2.4.1.3 Effect of sodium butyrate on LV production 
In preliminary experiments, we evaluated the addition of sodium butyrate in batch cultures. We 
observed reduced cell growth of HEK293SF-3F6 at concentrations higher than 2 mM. At 
concentrations up to 5 mM, viability was however not significantly affected over a period of four 
days in preliminary batch cultures (data not shown). We therefore tested sodium butyrate addition 
after transfection at concentrations ranging from 0.1-5 mM (fig. 3.3). Sodium butyrate was added 
16 hours post-transfection (hpt) (Karolewski, Watson et al. 2003) and the concentration was kept 
constant after each subsequent medium replacement. Using this strategy, maximum LV titers of 
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810  tu/mL 2 dpt could be reached when adding butyrate at a concentration of 5 mM. The amount 
of produced LV decreased thereafter exponentially. Higher concentrations of butyrate could not 
significantly increase the yield of LV (data not shown).  
The kinetics of LV production under different experimental conditions was changed significantly 
when adding butyrate (compare fig. 3.2 and 3.3). In all experiments, LV could be detected 
starting 1 dpt. Without the addition of butyrate, maximum LV titers were observed 3 dpt. Before 
and after the maximum we found ~75 % (2 dpt) and up to 80 % (4 dpt) relative to the maximum 
titer for each experiment. When adding butyrate, the maximum in LV titer was found earlier (2 
dpt), with an exponential decrease of LV titer on the subsequent days (~50% after 3 dpt, ~20% 
after 4 dpt).  
The cell-specific viral productivity was in the range of 2-70 tu/cell in small scale experiments 
(table 3.1). Without the addition of butyrate, only ~2-6 tu/cell were produced. These numbers 
were increased up to 10-fold (~7.5-70 tu/cell) by the addition of butyrate at a concentration of up 
to 5 mM. At cell densities > 6105×  cells/mL, we observed a decrease in specific productivity 
(results not shown).  
 
Figure 3.3 : Effect of sodium butyrate addition at different concentrations on the production of 
LVs.  
All experiments shown were conducted in HyQ medium, at high cell density (HCD) and with 0.4 
µg of total DNA/ 610  cells. Concentration of butyrate is shown in the figure legend 
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3.2.4.2 Bioreactor Scale LV Production in Perfusion Mode 
In order to evaluate the scalability of the process, LV production was conducted in a lab scale 
bioreactor cultivation in perfusion mode (fig. 3.4). First, non-optimized production and 
transfection conditions were used. After transfection at a cell density of 6101×  cells/mL, 
perfusion was stopped for 3 h to allow for polyplex uptake. The harvested LV-containing 
supernatant was stored at 4°C and collected once per day for purification. After transfection at 
6101×  cells/mL, cell growth continued until the end of the experiment. Viability remained higher 
than 80 % during the whole experiment. Detectable amounts of LV were found in the bioreactor 
from 1-6 dpt. Maximum viral titers were reached at 3 dpt with ~ 5107 ×  tu/mL. The titers 
measured in the harvested supernatant followed the same profile as in the reactor, indicating no 
significant loss during storage at 4°C for (a maximum of) 24 h.  
 
 
Figure 3.4 : Production of LV in lab scale bioreactor perfusion system. 
Initial conditions were used (transfection at LCD in LC-SFM L). LV titer in harvest (solid 
diamonds), LV titer in reactor (solid triangles), total cell count (crosses), viable cell count (open 
triangles) 
 
After demonstrating the feasibility of LV production in perfusion mode, we validated the 
improved experimental conditions from small scale experiments (fig. 3.5). Perfusion was started 
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at a cell density of ~ 6102 ×  cells/mL and transfection was performed at ~ 6105.4 ×  cells/mL. 
Sodium butyrate was added 16 hpt at a concentration of 5 mM. Cell growth slowed down after 
transfection, reaching a maximum viable cell density of ~ 6106×  cells/mL 2 dpt. Viability 
remained high during the whole experiment (>80 %). Maximum LV titers of ~ 7108×  tu/mL were 
found 2 dpt in the bioreactor supernatant. Compared to non-optimized production conditions, an 
increase in maximum LV titers of ~100-fold was achieved. First viral release was observed 1 dpt, 
starting a few hours after the addition of butyrate.  
 
 
 
Figure 3.5 : Profile of LV production in perfusion culture under improved conditions. 
Improved experimental conditions were used (transfection at HCD in HyQ with total DNA 
amount of 0.4 µg of total DNA/ 610  cells), addition of butyrate 16 hpt. LV titer in harvest (solid 
diamonds), LV titer in reactor (solid triangles), total cell count (crosses), viable cell count (open 
triangles) 
 
A total of ~ 11105.3 ×  tu was produced in a single bioreactor run under improved  conditions, 
compared to ~ 9106×  tu when initial conditions were used (fig. 3.6). The improved production 
resulted in a ~75-fold increase in total functional particle yield after 4 dpt. The differences in 
production kinetics caused by butyrate addition were significant. An almost linear increase of the 
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total functional produced particles was found under initial experimental conditions from 1-3 dpt. 
In contrast, a steep increase was observed from 1-2 dpt when butyrate was added. The gain in 
produced LV particles was low in both experiments after 4 dpt.  
 
Figure 3.6 : Comparison of cumulative viral titers (total produced functional LV particles) of two 
bioreactor perfusion cultures. 
Initial experimental conditions (triangles, dashed line), improved conditions (solid circles, solid 
line) 
 
3.2.5 Discussion 
We describe here transient transfection at high cell density (HCD) without the need of 
discontinuous medium exchange before or after transfection. We could circumvent the cell 
density limitation of routine transfection protocols by producing LV in perfusion mode at HCD. 
Previously, transfection protocols at HCD have been reported (Backliwal, Hildinger et al. 2008; 
Sun, Hia et al. 2008). These protocols require however discontinuous concentration or dilution of 
the cell suspension before or after transfection (Baldi, Hacker et al. 2007; Backliwal, Hildinger et 
al. 2008). In the present study, media is continuously exchanged to harvest produced LV and 
alleviate nutrient limitations. The process is consequently industrially viable and readily scalable.  
The results from the comparison of different media suggest that the production of LV after 
transient transfection is dependent on nutrient availability. Enriched medium formulations (LC-
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SFM GL, HyQ) outperformed our standard medium formulation (LC-SFM L). These results 
substantiate previous findings demonstrating the improvement in transient transfection yields by 
nutrient additions (Pham, Perret et al. 2003; Pham, Perret et al. 2005; Pham, Kamen et al. 2006; 
Tom, Bisson et al. 2007). 
We observed that a significant decrease in polyplex amount leads to higher LV titers. Our results 
concur with findings from our (unpublished results) and other studies for calcium-phosphate and 
PEI-based transfection (Karolewski, Watson et al. 2003; Sena-Esteves, Tebbets et al. 2004; Sun, 
Hia et al. 2008; Kuroda, Kutner et al. 2009). Lower amounts of polyplexes probably minimize 
toxic effects of PEI, leading to higher productivity after transient transfection. Interestingly, other 
studies also found optimal LV and recombinant protein production at values of 0.4-0.6 µg of total 
DNA/ 610  cells for PEI-based transfection (Sun, Hia et al. 2008; Kuroda, Kutner et al. 2009). 
Whereas most transfection protocols do not take the number of transfected cells into account and 
report the quantity of transfection reagents on a volumetric basis (per volume of transfected cell 
suspension), the amount of polyplex used for transfection should therefore rather be calculated on 
a cell-specific basis. The DNA amounts used in the present study are significantly lower than 
what is routinely used in calcium-phosphate precipitation (Karolewski, Watson et al. 2003; Sena-
Esteves, Tebbets et al. 2004). This further improves the cost-effectiveness of the method used 
here.  
The significant impact of sodium butyrate on the production of LV underlines that this compound 
enhances the expression of limiting LV and retroviral (RV) gene products (VSV-G, viral 
packaging proteins and RNA) by increasing their transcription. Findings for RV indicate that 
butyrate in particular increases the production of packageable viral RNA (Olsen and Sechelski 
1995; Jaalouk, Crosato et al. 2006). Without the addition of butyrate, LV titers were possibly also 
in our case significantly lower because of transcriptional suppression of the viral RNA (Jaalouk, 
Crosato et al. 2006). The maximum titer was reached earlier and the decline in titer relative to the 
maximum was accelerated when butyrate was added. It therefore seems to have an impact on the 
expression kinetics. Optimal expression of all four plasmid constructs for LV production took 
place 2 dpt. The exponential decrease of LV titer a few days after the addition of butyrate might 
be caused by a loss of transfected producer cells, in turn due to the expression of the toxic LV 
104 
 
proteins (in particular VSV-G and gag). Another explanation could be that butyrate has a 
different effect on the expression of the LV required proteins over time.  
Comparing the results to literature findings, the LV titer and the cell specific productivity of 
functional LV after transient transfection were similar to what has been reported earlier by our 
group (Segura, Garnier et al. 2007). A comparison with results from other groups is generally 
difficult due to the variety of titration methods found in the literature. In addition, a comparison 
of cell-specific yields is not always possible since LV production protocols are often not 
providing all necessary values, e.g. the cell density at the time of transfection. Furthermore, 
differences in plasmid constructs might contribute to the variability in LV titers found in the 
literature. Using a 3-plasmid system, a yield of ~10 tu/cell was observed by others for LV 
production by transfection in adherent cells after 2-2.5 d (Kuroda, Kutner et al. 2009). This value 
is also well in the range of the present study for suspension-grown cells. In summary, the titers 
observed in the current study should be similar if not superior to what has been so far reported for 
protocols using adherent cells. 
Table 3.1 summarizes the impact of changes in small-scale production conditions based on the 
total functional particle yield from each experiment after 4 dpt. The most significant increase in 
production of LV particles was reached by butyrate addition (~15 fold). A combination of the 
most promising experimental conditions led to an overall increase in total functional LV particles 
of ~150 fold in small-scale experiments.  
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Table 3.1: Impact of change in small-scale production condition based on the cumulative titers  (total produced transducing particles 4 
days after transfection) 
 
The specific productivity was calculated based on the cell density at the time of transfection. 
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These conditions were then validated at the bioreactor scale, resulting in an increase of ~75-fold 
compared to a bioreactor production performed with non-optimized conditions. We observed 
similar LV titer trends in the bioreactor and harvested supernatant (stored at 4°C). These results 
are in-line with findings suggesting that LV have a much longer half-life at 4°C compared to 
37°C (Higashikawa and Chang 2001) and indicate that the continuous harvest of product 
addressed the issue of the low LV stability. 
The uptake of polyplexes was a fast process and resulted in production of LV one day after 
transfection. Transfection in perfusion mode is therefore feasible and an attractive alternative to 
alleviate the nutrient limitations in current protocols. Based on earlier results for the production 
of RV in bioreactor scale, we expected higher titers in bioreactor-scale compared to small-scale 
cultures due to constant and controlled culture conditions (Ghani, Garnier et al. 2006). We 
consequently attribute the lower LV yields in bioreactor scale to a less efficient transfection 
process. The use of acoustic cell filter should not directly influence LV titers but might cause an 
increased detrimental cellular aggregation before transfection, resulting in a less efficient plasmid 
transfer to cells. At this point, however, we can not exclude other possible explanations, in 
particular because lower yields for production of LV by transfection in bioreactor-scale (batch 
mode) compared to small-scale have also been reported earlier by our group (Segura, Garnier et 
al. 2007).  
3.2.6 Conclusions 
We describe here the development of a scalable process for the production of LV in bioreactor 
perfusion cultures by PEI-based transient transfection. Using a suspension-grown HEK293 cell 
line, a combination of several optimization strategies resulted in an improvement of LV yield of 
~150-fold compared to non-optimized production conditions. We were able to generate 
maximum LV titers in non-concentrated culture supernatants of ~ 810  tu/mL. We observed that 
yields after transient transfection were dependent on the selected production medium and the 
amount of polyplexes used for transfection. The addition of sodium butyrate was shown to alter 
the production kinetics of LV and improved the production by ~15-fold. Our improved 
production conditions include transient transfection at high cell density in a medium that allows 
transfection without the need of discontinuous medium exchange. These results were successfully 
validated in bioreactor scale.  
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Future work will investigate an optimized harvest rate in the bioreactor based on LV stability, a 
further improvement of transfection parameters and understanding of the LV production kinetics. 
To our knowledge this is the first study describing LV production in perfused suspension culture, 
resulting in an industrially viable process, i.e. without the need of discontinuous medium 
exchange (batch replacement) at any time of the process. 
The production process is easily scalable, cost-effective and in particular less laborious than other 
current LV production methods. It should allow for the production of LV in sufficient quantities 
for phase 1 clinical trials in 10-20 L perfusion bioreactor scale. 
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CHAPTER 4 CHARACTERIZATION OF LENTIVIRAL VECTOR 
PRODUCTION KINETICS USING OFFLINE QUANTIFICATION 
METHODS 
4.1 Introduction 
In routine production protocols, LV generation and degradation are confounded, rendering the 
analysis of production kinetics and evolution of LV quality (as the ratio of functional to total 
vector particles) difficult. These protocols involve one or two harvests at different time points 
after transfection from the supernatant of adherent cultures (see table 1.1; section 1.2.6). For a 
complete analysis of LV production kinetics generation and degradation processes would need to 
be deconvoluted. As described in chapter 3, LVs were harvested by sequential discontinuous 
medium replacement and continuous perfusion mode in small scale and bioreactor cultures, 
respectively. Using this production strategy, the released particles are either once or twice daily 
completely removed from the supernatant (small scale) or continuously harvested from the 
culture (bioreactor). This operation mode, in particular in bioreactor cultures, does not decouple 
the two processes (viral production and vector decay). It nevertheless facilitates the analysis of 
production kinetics in comparison to operation in batch mode.  
Each LV quantification method targets a specific property or structural component of the vector. 
In general, direct methods that are used for LV quantification largely overestimate functional 
titers (see also section 1.2.5). These methods are nevertheless instrumental for process 
development as they provide the means to assess virus yield, recovery and product quality, i.e. 
process efficiency. For the development of the production process, the main interest in comparing 
the results from functional assays (indirect methods) and total particle quantification (VG/VP 
titer) is the estimation of the quality of the produced LV preparation via the ratio of functional to 
total particles. Only a handful of studies report on the analysis of LV quality in final preparations 
and during production (Higashikawa and Chang 2001; Mitta, Rimann et al. 2005; Geraerts, 
Willems et al. 2006). For example, it was found that LV quality is dependent on the vector 
backbone and might vary if transfection conditions are not stringently controlled (Geraerts, 
Willems et al. 2006). 
116 
 
The successful production of a functional particle is only possible if all of its components are 
expressed simultaneously in a producer cell. It was expected that the comparison of production 
kinetics and LV quality would therefore provide: 
1) a better understanding of the transient nature of the production system, 2) important insights 
on why these kinetics were observed and 3) possible avenues for optimization of the LV 
production system.  
In this chapter, the previously described LV quantification methods (described in chapter 2) were 
used with the goal to further characterize LV production kinetics under improved production 
conditions in small scale and bioreactor cultures. In contrast, chapter 3 only contains production 
kinetics for functional LV titers based on GTA assays.  
First, this chapter presents the characterization of LV production kinetics after transient 
transfection in perfusion mode. A comparison of the results from several quantification methods 
is made to pull out similarities and differences in the evolution of vector titers after transfection. 
To that end, the experimental observations from small scale and bioreactor cultures under 
improved production conditions are analyzed. Second, the evolution of LV quality was 
investigated during production at different medium exchange rates. Its value was found to change 
significantly during the process and was a function of the production conditions such as medium 
exchange rate and sodium butyrate addition. Finally, the effect of butyrate on LV quality and 
production kinetics is evaluated and discussed. 
4.2 Results 
4.2.1 Comparison of LV Production Kinetics in Perfusion Mode 
4.2.1.1 Functional LV Titer Production Kinetics  
When producing LV using sequential medium replacement in small scale or continuous perfusion 
cultures, LV titers decreased exponentially after the maximum at 2 dpt. The LV production 
kinetics in perfusion mode was greatly affected by the addition of sodium butyrate and 
independent of cell density and medium composition with a maximum at 2 dpt (see figures 3.1-3 
and section 3.2.4.1). Without the addition of butyrate similar kinetics were observed independent 
of the medium composition with maximum functional titers at 3 dpt but only slightly smaller 
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values for 2 and 4 dpt. In contrast, transfection in batch cultures resulted in almost constant 
functional LV titers from 2-4 dpt (fig. 4.1).  
 
Figure 4.1: LV production in small scale at 1 “sequential discontinuous medium exchange per 
day (DMD) “ in comparison with production in batch mode. 
LV production in batch mode was performed after transfection at the same cell density of a 
culture taken from bioreactor run #3. 
 
Using improved LV production conditions (see section 2.1.4-5 for details) the kinetics for shake 
flask and bioreactor cultures was overall similar, with lower absolute values in bioreactor scale 
(fig 4.2). At 2 “sequential discontinuous medium exchanges per day (DMD)”, a faster decrease in 
transducing units was observed after the maximum in small scale cultures. 
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Figure 4.2 : Functional viral titer, quantified by gene transfer assay (GTA) in small scale and 
bioreactor experiments using improved production conditions  
(A) small scale results; average kinetics for experiments at 1 discontinuous medium exchange per 
day (1 DMD; n = 3) and 2 DMD (n = 6) are presented 
(B) bioreactor cultures, values correspond to a single culture performed at 1 and 2 VVD, 
respectively (run #3 and #4, see table 4.1 B) 
4.2.1.2 Production Kinetics of Total Particles Quantified by ELISA (VP Titer) 
Although only a limited number of CAp24 ELISA assays were performed for comparison of the 
different production conditions, the results gave consistent data (fig. 4.3). Maximum VP titers 
were observed at 3 dpt with 2x1010 vp/mL at 1 DMD (fig. 4.3 A). Slightly smaller values were 
found for 2 and 4 dpt. At a higher medium exchange rate, the titers were significantly reduced 
and a more distinct maximum was found at 3 dpt. In all conditions, the titers at 1 dpt were low or 
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even below the detection limit of the ELISA assay (for the chosen dilutions of the samples). 
Bioreactor cultures resulted in similar production kinetics (fig. 4.3 B). At 1 and 2 VVD, the 
maximum VP titer in those experiments was found at 3 dpt. 
 
Figure 4.3 : LV production kinetics quantified by CAp24 ELISA assay (VP titer) in small scale 
and bioreactor experiments using improved production conditions 
(A) small scale results, values correspond to single experiments at 1 and 2 DMD 
(B) bioreactor cultures, values correspond to a single culture performed at 1 and 2 VVD, 
respectively (run #3 and #4) 
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4.2.1.3 Production Kinetics of Total Particles Quantified by RT-PCR (VG 
Titer) 
In small scale experiments, the maximum in VG titer, i.e. the amount of lentiviral genomes 
quantified by RT-PCR, was found for medium exchange rates at 1 and 2 DMD at 2 dpt (fig. 4.4 
A). However, the differences with the values observed for subsequent production days were 
small. In contrast, bioreactor cultures were showing the VG titer maximum at a later time point, 
while only minor differences for the values from 2-5 dpt were again observed (fig. 4.4 B). In 
summary, the VG titer remained almost constant from its maximum until 5 dpt, independently of 
production scale and medium exchange rate. 
 
Figure 4.4 : LV production kinetics quantified by RT-PCR (VG titer) 
(A) small scale results; average kinetics for experiments at 1 discontinuous medium 
exchange per day (1 DMD; n = 3) and 2 DMD (n = 2) are presented 
(B) bioreactor cultures, values correspond to a single culture performed at 1 and 2 VVD, 
respectively (run #3 and #4) 
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4.2.1.4 Summary of LV Production Kinetics Results 
Table 4.1: LV titer kinetics in small and bioreactor scale   
(A) LV titer kinetics in shake flask cultures (small scale) 
         (B) LV titer kinetics in bioreactor scale  
A Functional titer (GTA) VP titer (ELISA)V VG titer (PCR) 
Operating 
condition/ 
parameter 
1 DMD II 2 DMD III 2 DMD, HyQ + IV 1 DMD 2 DMD 
2 DMD, 
HyQ + 1 DMD
V
 2 DMDVI 
2 DMD, 
HyQ + 
Time of 
maximum 
titer (dpt) 
2 1.7 1.7 2=3 2.67 2.67 2 1.68 n.a. 
LV titer at 
4 dpt (in % 
of max)I 
15 1.7 0.9 50 30 66 25 31 n.a. 
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B Functional titer (GTA) VP titer (ELISA) VG titer (PCR) 
Operating 
condition/ 
parameter 
1 VVD, 
run #3 
2 VVD, 
run #4 
2 VVD, 
HyQ +, 
run #5 
1 VVD, 
run #3 
2 VVD, 
run #4 
2 VVD, 
HyQ +, 
run #5 
1 VVD, 
run #3 
2 VVD, 
run #4 
2 VVD, 
HyQ +, run 
#5 
Time of 
maximum 
titer (dpt) 
2.1 1.67 1.67 3.1 2.78 n.a. 2.78 3.78VII 4.1VII 
LV titer at 
4 dpt (in % 
of max) I 
25 29 14.5 73 21 n.a. 72 100 100 
I: % of maximum titer is shown 
II: values represent average results of n = 3 independent experiments 
III: values represent average results of n = 6 independent experiments 
IV: values represent average results of n = 3 independent experiments 
V: values represent average results of n = 3 independent experiments  
VI: values represent average results of n = 2 independent experiments 
VII: almost constant values from 2-5 dpt all bioreactor cultures were performed only once at each operating condition 
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Table 4.1 compares LV production kinetics based on functional, VP and VG titer quantification 
in small and bioreactor scale. Functional vector titers found their maximum independent of 
operating condition and scale at around 2 dpt. Until 4 dpt, the functional titer then decreased 
dramatically to 1-15 % of its maximum value in small scale and 15-30 % in bioreactor cultures. 
In contrast, VP titer and VG titer were showing more uniform profiles from 2-4/5 dpt with almost 
constant values for that part of the production. Maxima in VP and VG titer were thus less clearly 
identifiable and in almost all cases found later than the highest concentration of functional LVs 
(also compare fig. 4.5 A). 
Figure 4.5 compares LV production kinetics of two of the performed bioreactor perfusion 
cultures at 1 and 2 VVD (run #3 and 4). First, these two examples demonstrate the reproducible 
kinetics that was observed after quantification with different methods (fig. 4.5 A). Second, the 
differences in kinetics from the three quantification methods are also well represented. In both 
cultures, the viable cell count (vcc) increased after transfection and reached a maximum at ~2 dpt 
(fig. 4.5 B). This maximum was observed at the same time than the maximum in functional LV 
particles. Total GFP expression above background levels was measured starting at 1 dpt. From 1-
3 dpt, the expression then increased linearly until 3 dpt after which it showed a smaller slope.  
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Figure 4.5 : Evolution of LV kinetics in bioreactor scale at 1 and 2 VVD 
(A) functional, VG and VP titer 
(B) vcc (the fit of offline cell counts taken 2-3 times daily is shown) and total GFP 
expression 
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4.2.2 Assessment of LV Quality Under Different Production Conditions  
Most studies reported low values of 0.3-8 % for the ratio of transducing units to RNA titer. Mitta 
et al. (2005) proposed the term VP (lentiviral particle performance), as the ratio of functional to 
VP titer (CAp24 ELISA), and observed a wider range (<0.01-70 %). It has, however, been 
questioned if the VP titer is suitable for calculation of LV quality, as other groups found that 
CAp24 ELISA assays are the least reliable method for prediction of LV titers (Geraerts et al. 
2006; Ricks et al. 2008). Routine protocols also measure free CAp24 in supernatants (Geraerts et 
al. 2006; Ricks et al. 2008). The results thus reflect CAp24 from viral particles alone only if 
purified samples are analyzed (Ricks et al. 2008); see section 1.2.5.1). Consequently, to calculate 
LV quality, we focused in the present work on the results from RT-PCR.  
The evolution of LV quality in a typical experiment under improved production conditions is 
represented in figure 4.6. At 2 dpt, when the maximum functional titer was reached, LV quality 
based on the ratio of GTA to RT-PCR was maximal at ~4 %. Its value then decreased at 3 and 4 
dpt (~ 3 and 2 %, respectively). For 2-4 dpt, a similar profile was observed for the LV quality 
based on the ratio of GTA to CAp24 ELISA. In contrast, the maximum was here already 
observed at 1 dpt. The ELISA results for samples at 1 dpt were, however, subject to high 
variability. 
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Figure 4.6 : Evolution of LV quality in typical small scale experiment using improved production 
conditions at 1 DMD. 
Values represent the average of several experiments (functional titer: n = 3; VG titer: n = 3; VP 
titer: n = 1) 
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4.2.2.1 Increased Perfusion Rate Results in Higher LV Quality 
 
Figure 4.7 : Comparison of LV quality evolution during small scale and bioreactor production at 
different medium exchange rates. 
All experiments were performed using improved production conditions 
(A) small scale production at 1 and 2 DMD 
(B) bioreactor production at 1 and 2 VVD (corresponding to run # 3 and #4) 
When medium exchange rate was increased to 2 DMD in small scale experiments (fig. 4.7 A), a 
higher LV quality was found from 1-3 dpt than at 1 DMD. Only towards the end of the 
experiment, LV quality was lower than at 1 DMD. These observations were generally confirmed 
in bioreactor scale (fig. 4.7 B), although the increase in LV quality was lower compared to what 
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was observed in small scale. In comparison, the number of total particles (VG titer) was similar 
in small and bioreactor scale. The difference in LV quality was thus caused by the higher 
functional titers in small scale experiments.  
4.2.2.2 Effect of Sodium Butyrate on LV Quality 
After observing that LV quality under improved production conditions was not constant during 
the experiment, the effect of sodium butyrate addition on the evolution of the ratio of functional 
to VG titers was investigated. Figure 4.8 presents the analysis of small scale experiments at 
increasing butyrate concentrations (0, 1 and 5 mM). While both, VG and functional titer 
increased after sodium butyrate addition, the effect on functional titer was much higher and 
resulted in an increase in LV quality from around 1 to 4 % at 2 dpt. The evolution of LV quality 
changed from a maximum at 3 dpt without butyrate to a maximum at 2 dpt when butyrate was 
added which was in both cases corroborating with the time point of maximum functional LV 
titer.  
 
 
Figure 4.8 : Effect of sodium butyrate addition at 16 hpt at different concentrations (0, 1, 5 mM). 
Data represent small scale transfections at 5x106 c/mL in HyQ medium 
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4.3 Discussion 
Overall, reproducible production kinetics was observed when butyrate was added to achieve high 
LV yields, i.e. under improved production conditions. Maximum functional LV titers were found 
at 2 dpt, followed by an exponential decrease at 3 and 4 dpt. In contrast, VG and VP titer showed 
smaller differences and almost constant values from 2-4 dpt. Nevertheless, the maximum in VP 
titer was constantly observed at 3 dpt whereas a reproducible maximum in VG titer could not be 
clearly identified.  
Also, it was demonstrated that LV quality (GTA : VG titer) varied during the production and was 
higher at increased medium exchange rates. This has, to our knowledge, not been previously 
reported in the literature.  
As demonstrated in chapter 3, butyrate addition significantly increases LV production. With the 
additional results for VG and VP titer kinetics in hand, additional observations concerning this 
‘butyrate effect’ could be made. It was observed that this effect is not primarily due to an increase 
of viral RNA/RNA containing particles in the culture supernatant. Although higher VG titers 
were observed with increasing butyrate concentration, the increase in functional LV was more 
significant and resulted in higher LV quality of almost 4-fold.  
On the one hand, it was found that protein production by transient transfection is generally 
limited by two main parameters: 1) events regulating the nuclear translocation of plasmid DNA 
and 2) protein expression, i.e. transcriptional competency and translational/post-translational 
processes (Carpentier, Paris et al. 2007). For PEI-based transfection, the same authors excluded 
the delivery of plasmid constructs to producer cells as a bottleneck for production; high numbers 
of plasmid copies (in the range of tens of thousands per cell) can be detected in producer cells at 
1 dpt. In the present case, which employs almost identical PEI-based transfection, it can be 
assumed that every cell received high amounts of plasmid DNA in the range of tens of thousands 
of copies per cell for each of the four LV-encoding constructs.  
On the other hand, LV production is generally limited by expression of the LV-encoding 
constructs. Gene silencing has been put forward as a reason for expression loss during LV 
production after transient transfection and also in stable packaging and producer cell lines (Kafri , 
van Praag et al. 1999; Ni, Sun et al. 2005; Jaalouk, Crosato et al. 2006; Sun, Goh et al. 2008). 
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Gene loss, in contrast, has been excluded as explanation for these observations as the gag-pol 
DNA can still be detected in stable packaging cell lines even without butyrate addition (Kafri, 
van Praag et al. 1999; Sparacio, Pfeiffer et al. 2001). Sodium butyrate is well described as a 
powerful inducer of LV production leading to, most often temporary, peak titers over a few 
consecutive days (Gasmi, Glynn et al. 1999; Karolewski, Watson et al. 2003; Jaalouk, Crosato et 
al. 2006). It acts on several levels, increasing expression in VSV-G, mRNA, CAp24 and vector 
RNA levels (Kafri, van Praag et al. 1999; Jaalouk, Crosato et al. 2006; Al Yacoub, Romanowska 
et al. 2007). It is generally observed that butyrate causes hyperacetylation of histones, leading to 
a higher transcription and an increased expression of transfected DNA (Altenburg, Via et al. 
1976; Kruh 1981; Gloger, Arad et al. 1985). Furthermore, it activates several promoter types and 
reduces effects caused by promoter interference (Gasmi, Glynn et al. 1999; Jaalouk, Crosato et al. 
2006). Yet, effects of butyrate in other transfection systems, such as the production of adeno-
associated virus (AAV) vectors or recombinant proteins, are not always beneficial and mixed 
effects on LV titers have also been reported ((Sena-Esteves, Tebbets et al. 2004) and unpublished 
results from our lab). There only seems to be a major effect on LV titers if the expression 
efficiency of the affected construct is non-optimal (Sena-Esteves, Tebbets et al. 2004). 
Based on our results, it cannot be excluded that butyrate also enhanced nuclear translocation after 
transfection but this mechanism has not been reported in the literature. Although our analysis was 
entirely based on quantification methods that only detect LV components in cell-free culture 
supernatants, a direct action on expression efficiency of the LV-encoding constructs is, in 
contrast, very likely and in particular supported by reports confirming the positive effect of 
sodium butyrate on stable packaging and producer cell lines. This suggests that either the 
volumetric expression in the transfected culture or the intensity of the ‘butyrate effect’ on 
expression of the LV-related proteins is not constant over time. 
This corrorobates with our findings showing that earlier addition of butyrate does not increase 
total LV yields (fig. AIV.13). This would, however, be expected if butyrate actively increased the 
translocation of plasmid DNA to the nucleus. 
A direct effect of sodium butyrate addition on LV stability can equally be excluded because 
functional LVs were showing identical half-lifes independent of harvest time and the addition of 
sodium butyrate (appendix I, fig. AI.1). 
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In chapter 3, it was hypothesized that the exponential decrease of LV titers at 3 and 4 dpt was 
caused by a loss of transfected producer cells due to the expression of the toxic LV proteins (in 
particular VSV-G and gag) (chapter 3.2.5). VSV-G has fusogenic activity and its expression in 
mammalian cells is known to result in scyncytia formation and cell death (Burns et al. 1993). 
These authors found that VSV-G expression is restricted to a short period before its presumed 
accumulation on the cell surface leads to cell death. The cytotoxicity of VSV-G is one of the 
major obstacles for the generation of stable LV packaging and producer cell lines as its 
constitutive expression prohibited in mammalian cells (Sinn, Sauter et al. 2005; Kafri, van Praag 
et al. 1999; Sparacio, Pfeiffer et al. 2001). Here, we made several additional observations 
concerning the ‘butyrate effect’ and cytotoxicity:  
1) without addition of butyrate cell density increased by up to 10-fold after transfection. In 
parallel, a 3-fold increase in VG titer was found after the maximum in functional titer at 3 dpt 
(appendix IV, fig. AIV.6 A) 
2) although the number of ELISA assays was limited, reproducible VP titer kinetics with a 
maximum after the functional titer maximum was found at around 3 dpt 
3) analysis of protein content in culture supernatants by SDS-PAGE and Western blot confirmed 
ELISA results and the presence of CAp24 until 4 days after transfection, with a maximum at 2-3 
dpt (results not shown); in contrast, while VSV-G was detected at 2-3 dpt, its amount was below 
the detection limit at 4 dpt 
4) the maximum cell density in small and bioreactor scale corresponds to the maximum in viral 
titer at 2 dpt (bioreactor: fig. 4.5; small-scale: appendix II, fig. AII.3) 
For the present system, it is consequently hypothesized that the expression of VSV-G is limiting 
LV production and that the maximum functional titer is found when expression of this protein is 
at its maximum. A subsequent loss of producer cells in particular due to the high expression 
levels of VSV-G is then leading to a decrease in functional LV titer at later time points. Future 
work will consequently need to analyze in detail if the non-functional particles produced in phase 
3 and 4 indeed lacked the VSV-G envelope. If so, it might be a possible avenue for process 
optimization to increase yields by converting these non-infectious virus-like particles to 
infectious forms via lipofection agents or VSV-G addition (Sharma, Murai et al. 1997; Abe, Chen 
et al. 1998). 
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4.4 Conclusion 
Reproducible LV production kinetics was found in all experiments under improved production 
kinetics. At the same time, LV quality varied significantly during the process, suggesting that 
expression kinetics of the LV components varied over time. Sodium butyrate addition was a key 
factor for improved production and the observed ‘butyrate effect’ translated into different kinetics 
of functional and total LV (VG, VP titer). We propose that the action of sodium butyrate is 
essentially related to viral protein expression. It would be of interest to further investigate in 
detail what mechanisms are behind these observations, ideally using methods analyzing cellular 
mRNA and protein levels.  
The observations mainly suggest, however, that alternative avenues at the molecular level should 
be considered for further process optimization. These could include the regulation of VSV-G or 
the use of other, less cytotoxic envelopes. 
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CHAPTER 5 MONITORING LENTIVIRAL VECTOR PRODUCTION 
KINETICS USING ONLINE PERMITTIVITY MEASUREMENTS 
5.1 Article Presentation 
This chapter presents the journal article “Monitoring Lentiviral Vector Production Kinetics 
Using Online Permittivity Measurements“. The chapter has been submitted to the Journal of 
Biotechnology.  
To follow the progression of the transient transfection process in real-time, monitoring methods 
that are able to directly monitor the viral release and production kinetics need to be identified. 
Such methods would facilitate process development and support process optimization as well as 
the implementation of PAT strategies for improved process robustness and in-process quality 
control.  
LVs are budding viruses and are thus similar to baculoviruses, causing dramatic physiological 
changes in the producer cells upon release. Permittivity measurements were thus evaluated as 
real-time monitoring tool during LV production. Previous studies have demonstrated that online 
permittivity measurements have great potential in process development of viral vector production 
processes. To analyze the online signal in detail, it was thus required to propose and validate an 
offline measurement method for the analysis of permittivity measurements. To that end and for a 
further understanding of the value and practical applications of online permittivity measurements, 
the reader is referred to appendix III in which the real-time signal is evaluated in HEK293 batch 
cultures. It was expected that the combination of the characterization of production kinetics by 
offline quantification of LVs (chapter 4) and the analysis of online measurements would help in 
the understanding and determination of critical process events. 
More specifically, it was assessed in the present chapter if it is possible to relate real-time 
monitoring signals and viral production kinetics and yields. It is demonstrated that permittivity 
measurements are an informative and, to some extent, quantitative tool for LV production 
monitoring and supervision. A direct use of the signal for process control and decision-making 
will enable process optimization and increase cost-effectivness of the process. The technology is 
consequently one of the key tools to consider when implementing PAT strategies.  
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The bioreactor runs presented in chapter 5 correspond to runs #2-5 (compare table AII.2). 
5.2 Monitoring Lentiviral Vector Production Kinetics using Online 
Permittivity Measurements  
Sven Ansorge1,2, Stéphane Lanthier1, Julia Transfiguracion1, Olivier Henry2 and Amine 
Kamen1,2* 
1
: National Research Council Canada, Biotechnology Research Institute, 
 6100 Royalmount Avenue, Montréal, Québec H4P 2R2, Canada  
2: École Polytechnique de Montréal, C.P. 6079, succ. Centre-ville, 
 Montréal, Québec H3C 3A7, Canada 
5.2.1 Abstract 
Lentiviral vectors (LVs) are effective delivery vehicles that are successfully used in gene and cell 
therapy. LVs are most commonly produced via transient transfection of several plasmid 
constructs in adherent cell cultures. Recently, we described an efficient and scalable LV 
production in serum-free suspension cultures. To further facilitate translation of LV-based 
interventions to the clinic, robustness of the production processes needs to be documented to 
ultimately achieve a specified quality and quantity of LV production lots. In this work, in situ 
real-time permittivity measurements were assessed to document LV production. Reproducible 
process phases that were closely associated with LV production kinetics were identified. The 
permittivity signal evolution was interpreted exploiting various independent online and offline 
monitoring measurements. The results suggest that cellular membrane properties and, to a lesser 
extent, cell size were the main factors contributing to the permittivity variations. It is concluded 
that the permittivity-related parameters can be used as reliable indicators for determination of the 
optimum harvest time, thereby allowing real-time assessment of process performance and greatly 
facilitating process optimization. 
5.2.2 Introduction 
The most advanced generations of lentiviral vectors (LVs) are safe and potent tools for gene and 
cell therapy interventions (Cockrell et al. 2007; Pluta et al. 2007). Most LVs are derived from 
human immunodeficiency virus type 1 (HIV-1) and they possess several advantages over other 
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virus-based gene delivery vehicles, such as a large packaging capacity, the ability to infect non-
dividing cells and the absence of transferred viral coding sequences (Vigna et al. 2000; Cockrell 
et al. 2007). However, despite recent progress in the field, mass production of LVs remains an 
important limitation for the translation of LV-based therapeutic strategies to the clinic (Ansorge 
et al. 2010b). The low production yields of LVs, in combination with a fast decay rate at 37°C 
(Higashikawa et al. 2001; Merten 2004), require further developments of efficient processes for 
large-scale LV production. For lentiviral (LV) but also other vectors, such as adeno-associated 
virus (AAV) vectors, transfection currently remains the most effective option for mass production 
due to the difficulty and time required to  generate stable producer cell lines (Throm et al. 2009; 
Wright 2009). Large-scale transient transfection has already been used for production of proteins 
and viral vectors to generate preclinical and clinical material in a timely manner (Park et al. 2006; 
Baldi et al. 2007; Durocher et al. 2007; Hildinger et al. 2007). Yet, these early generation 
processes are generally not well characterized due to the lack of detailed key process parameter 
monitoring and sub-optimal control conditions in bioreactors. One key avenue for optimization of 
transfection processes is therefore the identification, characterization and control of critical 
process parameters to ensure robustness and reduce batch to batch variability (Geisse 2009). 
Thus, to establish industrially viable LV production processes, reliable monitoring tools are 
required that either directly quantify the vectors and/or reflect their release from the producer 
cells. Concerning the at-line quantification of recombinant proteins, important progress was made 
in recent years (Chavane et al., 2008; Jacquemart et al., 2008). These methods might also be 
applicable to LV production but it remains to be demonstrated that they are industrially viable 
and able to measure, for example, vector functionality. 
In general, reliable monitoring methods are a fundamental element to characterize cell culture 
operations, facilitate their development and ensure process consistency and robustness during 
production (Junker et al. 2006). Although there has been a constant interest in monitoring and 
control technologies since the beginning of the industrial cell culture era, a renewed interest has 
been generated from the release of FDA’s guidance on process analytical technology (PAT). The 
PAT initiative proposes a shift of biomanufacturing quality control from the laboratory to the 
process site, ensuring a “Quality by Design”, resulting in a pre-defined, i.e. ‘built-in’, final 
product quality achieved by design. A successful application of a PAT-based strategy requires 
technologies and tools operating in situ, being non-invasive and generating online information 
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about multiple key bioprocess and/or metabolic variables (Teixeira et al. 2009). These monitoring 
tools should provide global, macroscopic bioprocess outputs ensuring their versatile and flexible 
utilization in different production systems. 
The biomass content is the most important variable to monitor and control in any cell culture 
process (Sonnleitner et al. 1992; Olsson et al. 1997; Kiviharju et al. 2007). Online in situ probes 
based on dielectric spectroscopy (permittivity measurements) are established tools for biomass 
monitoring. Unlike most other online approaches based upon the correlation of metabolic rates 
(e.g. OUR) with cell density, permittivity measurements provide a more direct information on the 
biomass content. They are easily transferable to different bioreactor scales and, as such, hold 
great promise for application in process development. Moreover, permittivity measurements have 
the potential to provide meaningful additional real-time information for process control and 
optimization. Their use to monitor critical transition points in cell culture processes was 
previously described during the production of baculovirus expression vectors (BEVs) (Zeiser et 
al. 1999; Zeiser et al. 2000) and, more recently, the technology has been further evaluated in 
other systems (Cannizzaro et al. 2003; Ansorge et al. 2010a). These transition points were 
typically related to significant changes in cellular dielectric properties, occurring when cell 
physiology, morphology or metabolism is altered. 
Upon viral infection, the initial release and the production of progeny virus are generally 
associated with significant physiological changes in the host cells. These physiological changes, 
in particular when taking place at the plasma membrane level, directly affect the dielectric 
properties of cells. Several studies describe the monitoring of these changes in single cells using 
techniques such as electrorotation (Archer et al. 1999; Berardi et al. 2009). Yet, the application of 
these findings, i.e. the use of permittivity measurements in virus or viral vector production, is to 
date limited to the BEV system. After infection of insect cell cultures with baculovirus, BEV 
replication results in changes of the host cell physiology and morphology, most notably a 
dramatic increase in the mean cell diameter. This change in cell size can be monitored in real-
time and used to predict the infection’s success and efficiency (Chico et al. 1998; Palomares et al. 
2001). The onset of BEV release by budding from the cell membrane is also reflected in the 
permittivity, in particular when the infection is synchronous (Zeiser et al. 1999; Zeiser et al. 
2000). These findings were also helpful in the analysis of more complex systems in which BEV 
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is used to produce AAV (Negrete et al. 2007; Cecchini et al. 2008), allowing real-time 
determination of the optimum harvest point.  
The goal of this study was to determine whether permittivity measurements could provide 
meaningful real-time information related to lentiviral vector production kinetics. LVs were 
produced by transient transfection of suspension-grown HEK293 producer cells using a perfusion 
process. The online permittivity data were correlated with changes in biovolume and cell 
diameter and were compared with viral production kinetics, changes in oxygen consumption and 
GFP expression. Significant changes in permittivity and β-dispersion parameters were indicative 
of the first viral release and the progress of LV production. Characteristic process phases were 
identified from the analysis of the pattern of the online data and were reproducibly observed 
during LV production under different operating conditions. The results suggest that online 
permittivity signal variations can be correlated with the total viral particle yield. As the signal 
allows the determination of lentiviral release in real-time, it is concluded that the permittivity 
measurements could be a useful tool to determine an optimal harvest time and provide an early 
assessment of process performance.  
5.2.3 Materials and Methods 
5.2.3.1 Cell Culture 
HEK293SF-3F6 cells were grown in suspension in HyQSFM4TransFx293 (HyQ) (Hyclone, 
Logan, UT) which was supplemented with Cell Boost 5 (CB5) at 5 % (v/v) (Hyclone, Logan, 
UT) when indicated (HyQ+). Subcultures were passaged every 2-3 days to keep the cells in their 
exponential growth phase. Hemacytometer counts using erythrosine B dye exclusion were used 
to assess cellular density (viable, total cell count per mL (vcc, tcc)) and viability.  
5.2.3.2 Bioreactor LV Production 
5.2.3.2.1 Transient Transfection 
The transfection protocol and process development for high-yield LV production have been 
previously described in detail (Ansorge et al. 2009). To produce LVs, a GFP-encoding self-
inactivating transfer vector (pCSII-CMV5-GFPq), third generation packaging plasmids 
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(pMDLg/pRRE#54 and pRSV-Rev) and a vector encoding the VSV-G envelope (pSVCMV-IN-
VSVg) (Dull et al. 1998; Broussau et al. 2008) were simultaneously transfected in HEK293 cells. 
A plasmid mass ratio of 1:1:1:2 (VSV-G: Gag-Pol: Rev: Lentiviral Transfer Vector) was used for 
polyethylenimine (PEI)-mediated transfection according to previous results from our group 
(Segura, Garnier et al. 2007). 
5.2.3.2.2 Bioreactor Cultures 
The bioreactor setup was identical to the one previously described (Ansorge et al. 2009). Cultures 
were grown in batch mode up to ~1-2x106 vcc when perfusion was started at 1 or 2 volume(s) of 
medium per reactor volume per day (VVD). After reaching the targeted cell density (5-8 x106 
vcc) in perfusion mode, the culture was transfected by the addition of polyplexes. After 
transfection, the LV-containing supernatant was kept at 4ºC until clarification and subsequently 
stored at –80ºC. 
Pure oxygen was pulse sparged into the culture at increasing flow rates (depending on the 
biomass content in the reactor) to control the dissolved oxygen at 40 % of air saturation. From the 
total oxygen volume sparged into the bioreactor, the oxygen sparging rate (OSR in mL/min) was 
calculated as an indicator of the volumetric oxygen consumption. 
5.2.3.3 Lentiviral Quantification  
5.2.3.3.1 Gene Transfer Assay (GTA) 
Functional viral titers were determined using a flow cytometry-based gene transfer assay (GTA) 
(Ansorge et al. 2009). The limit of detection of this assay is ~ 5101×  tu/mL. An in-house LV 
standard was used in all GTA experiments to minimize inter-assay variability. All final titers 
were calculated relative to this LV standard, which was found to be stable over a period of more 
than one year after storage at -80°C in culture medium. Transduction of selected samples was 
performed in the presence of AZT (SIGMA) to rule out pseudotransduction. 
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5.2.3.3.2 Total Viral Particle Quantification (VG titer) by Real-Time Polymerase Chain 
Reaction (RT-PCR) 
The VG titer, i.e. the amount of total viral particles expressed as viral genomes (vg)/ml), was 
determined using a SYBR-Green I (SGI) quantitative RNA PCR assay (Roche Applied 
Science, Laval, Qc). An in-house RNA standard was used to quantify LV in supernatants from 
production runs. After RNA purification from LV-containing supernatants using the High Pure 
Viral RNA kit (Roche Applied Science, Laval, Qc), samples were treated with DNAse (DNA-
free Kit, Applied Biosystems, Foster City, CA). RT-PCR was then performed in a Carousel-
based LightCycler (Roche Applied Science, Laval, Qc) or a Mastercycler ep realplex system 
(Eppendorff, Hamburg, Germany). Primers (P1, P2) targeting a sequence in the woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE) were selected using clone manager 
(Sci-Ed Software, Cary, NC). Each reaction had a volume of 20 µL with a concentration for each 
primer of 0.5 µM (P1: LVWPREF: AGT-TGT-GGC-CCG-TTG-TCA-GG, P2: LVWPRER: 
AGG-CGA-GCA-GCC-ATG-GAA-AG), amplifying a sequence in the WPRE element of 249 
bp. The RNA standard was produced using the MEGASCRIPT kit (Applied Biosystems, Foster 
City, CA). For this purpose, WPRE from the LV transfer vector (CSII-CMV-GFPq) was cloned 
into pUC19 T7. The resulting plasmid pUC19 T7-LVWPRE was then linearized and in-vitro 
transcribed. The transcript (RNA standard) with a length of 260 bases was purified 
(MEGACLEAR kit, Applied Biosystems, Foster City, CA), quantified by spectrophotometry and 
aliquoted at the final standard concentrations (1x109-1x104 copies/reaction) in DEPC-treated 
water. Specificity of the PCR reactions was confirmed by melting curve and agarose gel analysis. 
The lower detection limit of this method is in the range of 5x105 vg/mL. 
5.2.3.4 Cell Culture Samples Analyses 
5.2.3.4.1 Cell size measurement 
The volume weighted arithmetic mean cell diameter (d) was determined using a Z2™ Coulter 
Counter® (Beckman Coulter, Mississauga, ON) with an aperture diameter of 100 µm, followed 
by analysis of the size distributions with the Accucomp® software package (Beckman Coulter). 
The upper and lower analysis limits were 7.31 and 23.8 µm, respectively. To calculate d, the 
distributions were plotted as volume (%) against cell diameter (µm). The lower analysis limit was 
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then manually increased to select only that part of the distribution corresponding to viable cells 
for the calculation. 
Each value of d represents the average of at least two distributions. Using d and the viable cell 
count per mL (vcc), the biovolume (bv) was calculated using equation 5.1, assuming that the 
distributions were evenly scattered: 
vcc
dbv ××

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    (5.1) 
bv was then considered as an estimate of the volume fraction of cells P (equation 5.2 in section 
5.3.5). 
5.2.3.4.2 GFP measurement 
The total expression of GFP was measured on a SpectraMax Gemini EM plate reader (Molecular 
Devices, Sunnyvale, CA) in 96 well plates. 1x105 cells were distributed in each well and 
fluorescence was measured at wavelengths of 485/538/495 nm (excitation/emission/cutoff) after 
fixation with 4 % formaldehyde. 
5.2.3.5 Permittivity Measurements 
In this study, a Biomass System® (Fogale nanotech, Nîmes, France) as well as a Biomass 
Monitor 220 (Aber Instruments, Aberystwyth, UK) were employed for the measurement of 
permittivity across the β-dispersion frequency spectrum of ~0.1-10 MHz. Both systems provide 
the β-dispersion parameters (∆εmax, fc, α) after fitting the frequency spectra. In addition, the 
Biomass Monitor 220 (Aber Instruments, Aberystwyth, UK) measures the dual-frequency 
permittivity at 0.6 and 19.5 MHz, whereas the Biomass System/Biomass 400 (Fogale nanotech, 
Nîmes, France) routinely operates at 1 and 10 MHz, providing ∆εFC. The calculation of the β-
dispersion parameters was performed with commercially available software packages, either 
offline using AberScan (Aber Instruments) or in real-time with the Biomass 400 (Fogale 
nanotech).  
The underlying theory on the dielectric properties of biological cells has been described in detail 
elsewhere.(Kell et al. 1985; Harris et al. 1987a; Pethig et al. 1987; Markx et al. 1999) In brief, 
when placed in an alternating electric field, any given cell suspension shows a characteristic 
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decrease in permittivity with increasing frequency. This decrease, the β-dispersion, is caused by 
the polarization of cell membranes (fig. 5.1). The resulting dielectric/permittivity increment 
(∆εmax) is directly correlated to the membrane enclosed volume fraction (P) of the cell 
suspension. For spherical cells at high viability (and therefore a low membrane conductivity) and 
for moderate values of P (P < 0.2), one can mathematically define this decrease by three 
parameters (∆εmax, fC, α) and the equation of Schwan (eq. 5.2) (Schwan 1957; Harris et al. 
1987b): 
4
9
max
MCPr
∆ε
×××
=         (5.2) 
with 
∆εmax:  permittivity increment (F m-1)  
 r:  cell radius (m) 
P:  volume fraction of cells (biovolume); P = Nrpi ××× 3
3
4
   (5.2.1) 
 N:  cell density (cells m-3) 
CM:  capacitance per membrane area (F m-2) 
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Figure 5.1: Biological cells polarize in electrical fields, resulting in the β-dispersion when 
frequency is increased in the range of 0.1-10 MHz. 
See text in section 2.5 for details and further explanation 
 
The first parameter ∆εmax can be measured as the difference in permittivity at the low-frequency 
and the high-frequency plateau (permittivity increment). The second parameter, the characteristic 
frequency (fC), is the frequency at which the permittivity decreased by half. fC can be defined by 
the following simplified equation (eq. 5.3) (Schwan 1957; Harris et al. 1987b; Patel et al. 2008b): 

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with  
 σi: conductivity of the cytoplasm/intracellular conductivity (mS cm-1) 
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σm: conductivity of the medium (mS cm-1) 
As the value of σm is generally much higher than σi in typical cell culture experiments, this 
equation can be further simplified by omitting the term 
m2σ
1
 (Ansorge et al. 2010a).  
A third parameter describing the β-dispersion is α (also called: Cole-Cole α). It is an empirical 
parameter describing the decrease in permittivity with increasing frequency in the Cole-Cole 
equation (Cole et al. 1929). α is generally associated to changes in the distribution of cellular 
electrical properties (Davey 1993).  
5.2.4 Results and Discussion 
5.2.4.1 LV Production in Bioreactor Runs 
5.2.4.1.1 Identification of Process Phases 
LVs were produced by transient transfection in bioreactor cultures and the data of a 
representative experiment are shown in figure 5.2. In this culture, cells were transfected at a vcc 
of ~5x106 c/mL. After transfection, cell growth continued at a decreased rate until a maximum 
vcc of ~6x106 c/mL was reached ~40 hours post-transfection (hpt). 
LVs in the form of functional transducing units (tu/mL) and total viral particles (vg/mL) were 
first measured in the supernatant around 20 hpt. A maximum LV titer of ~4x107 tu/mL in the 
supernatant was found at around 48 hpt, followed by an exponential decrease. The VG titer 
profile showed a similar evolution from 20-40 hpt. However, after the maximum in functional 
viral particles was reached, the VG titer further increased to achieve a maximum at ~96 hpt. 
The small dilution of the cell suspension resulting from the addition of the polyplexes was 
reflected in the values of the permittivity ∆εFC and its increment (∆εmax)  Both values then 
reached a maximum around the time of the first viral release (~24hpt) with  ∆εmax exhibiting a 
more distinct maximum compared to ∆εFC. In contrast, the characteristic frequency (fc) achieved 
a minimum at the time of the maximum in ∆εFC and ∆εmax. 
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Figure 5.2: High-yield LV production in bioreactor scale. 
Dashed lines and numbers indicate characteristic process phases which were identified according 
to changes in permittivity and the related β-dispersion parameters 
 
The overall LV production profile was thus broken down into four distinct process transition 
phases, defined according to the observed changes in the aforementioned online permittivity 
signals (β-dispersion parameters). 
Phase 1 (0-24 hpt) was characterized by a relative increase in ∆εmax of 80%, whereas the 
characteristic frequency (fc) decreased by 13 % and reached a minimum at the time of the 
maximum in ∆εmax. During the second phase (24-50 hpt), ∆εmax was found to decrease by ~38 % 
while fc increased by ~28 %. This phase ended when fc reached its maximum which coincided 
with a slope change in the permittivity increment. During phase 3 (50-75 hpt), the values of ∆εmax 
and fc both decreased gradually. The onset of the last phase (75-120 hpt) corresponded to a 
second minimum in fc, paralleled by a slope change in ∆εmax.  
Although LV release in the form of transducing particles could be detected at low levels 
at the end of phase 1, significant amounts of viral titers, i.e. 10-100 % of the functional viral peak 
titer and up to 30 % of the VG peak titer in the bioreactor supernatant, were not detected before 
145 
 
the beginning of phase 2. It was therefore hypothesized that the extrema in ∆εmax and fc at the 
transition from phase 1 to phase 2 were related to this initial viral release after transfection. The 
subsequent changes also appeared to correspond with events related to LV production, such as 
the transition into phase 3 which coincided with the maximum in functional viral titer in the 
reactor. Finally, at the beginning of phase 4, functional LV titers had significantly decreased (<30 
%). In contrast, the VG titer remained stable, indicating that a large number of non-functional 
viral particles containing viral RNA were constantly produced after transfection.  
5.2.4.1.2 Analysis of Biovolume and Multifrequency Permittivity Measurements 
Only a few of the variables that affect the permittivity of the cell suspension can be measured by 
standard cell culture methods. These include the mean cell diameter (d) and the cell density (N), 
from which the biovolume (bv) can be calculated (equation 1). The biovolume can be used as an 
offline estimate of the online permittivity value, in particular during the exponential growth phase 
and when viability remains high (Zeiser et al. 1999; Ansorge et al. 2007). The value of bv reflects 
either the dual-frequency permittivity (∆εFC/∆ε0.6MHz) or, if multiplied by the cell radius (bv*r) the 
permittivity increment (∆εmax) (see equation 2). Before transfection, a good correlation (R2 = 
0.93) was observed between bv*r and the permittivity increment ∆εmax (fig. 5.3 A). However, the 
samples taken after transfection, i.e. during process phase 1 and phase 2 did not follow the same 
trend. In contrast, the samples from process phases 3-4 were again in-line with the correlation 
with the exception of those corresponding to the last day of the cultivation (90-114 hpt).  
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Figure 5.3: Regression lines for ∆εmax and bv*r (A) and fC and the inverse of the mean cell 
diameter (B); see equations 5.1-3 for the theoretical relationship of the variables.  
Regressions were in both figures calculated based only on samples from the exponential growth 
phase in batch and before transfection in perfusion (triangles); regression coefficients were: R2 = 
0.93 (A) and R2 = 0.6 (B). Dashed circles mark samples at the end of the culture; whereas dotted 
circles mark the samples after transfection in process phase 1/ the beginning of phase 2. The 
values from the perfusion culture correspond to the cultivation shown in 5.2 and 5.4 
The characteristic frequency (fc) is directly affected by changes in cell diameter, intracellular 
conductivity and membrane capacitance (equation 5.3). fc was consequently plotted against the 
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inverse of the offline measured cell diameter 





d
1
 measured offline (fig. 5.3 B). Although a linear 
relationship between the two variables is apparent, the regression coefficient for this cultivation 
was rather low (R2 = 0.6) even when the values obtained from process phases 1 and 2 and the late 
stages of the culture were excluded from the regression, as is further discussed later.  
To further investigate the changes in β-dispersion parameters and a possible relationship with 
initial LV release and production kinetics, the permittivity spectra were analyzed after mean 
centering and variance scaling. Attributing the same weight to the permittivity signals at the 
different frequencies allowed inferring which of the dielectric parameters most likely caused the 
observed changes in the spectrum (fig. 5.4). 
Before transfection, the permittivity showed the same response at all frequencies within the β-
dispersion range. After transfection, changes in the permittivity spectra occurred at 8-10 hpt when 
a first inflection point in the data became apparent. At that time, permittivity measured at low 
frequencies (0.3-1 MHz) increased at a much faster rate than measurement performed at high 
frequencies (2-10 MHz). A second inflection point was then observed at ~32-40 hpt, after which 
the permittivity at lower frequencies decreased more rapidly than at high frequencies. These 
inflection points were observed before the minimum in fc and after the maximum in ∆εmax, 
respectively.  
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Figure 5.4: Inflection points (marked by arrows) in the mean-centered and variance-scaled 
permittivity spectrum indicate changes in the dielectric properties of producer cells after 
transfection; grey dashed lines mark process transition phases 1-4 
 
The results from fig. 5.3 A and B indicate that neither a higher cell density with a slight increase 
in phase 1 and 2 only nor differences in cell diameter were solely responsible for the observed 
changes in the permittivity increment and characteristic frequency after transfection. That is, 
during phases 1 and 2, ∆εmax increased and fc decreased to a larger extent than was expected from 
the respective changes in vcc or d (fig. 5.3 A and B). Values for samples from the very end of the 
cultivation also deviated from the correlations, as the remaining cells showed a lower permittivity 
per biovolume. Although cell viability remained high until the end of the run (> 80 %), a 
considerable amount of cell debris was observed during phase 4, accompanied by an attachment 
of biomass to the inner surface of the bioreactor/shake flask and increased cell aggregation. 
Others reported that permittivity measurements cease to predict the biovolume at decreasing 
viability (Ducommun et al. 2001; Ducommun et al. 2002). In fact, in the case of decreasing 
viability, membrane conductance typically increases resulting in a lower cell-specific permittivity 
(Patel et al. 2008b). One also needs to take into account that cell viability is assessed differently 
in the three methods used to measure the biovolume (dielectric spectroscopy, dye exclusion for 
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viability measurements and cell size measurement). Deviations might therefore be expected 
towards the end of the cultivation. 
The analysis of permittivity spectra gave indications as to which of the dielectric parameters is 
responsible for the changes in the permittivity spectrum and the β-dispersion parameters. If no 
significant changes in cell diameter, intracellular conductivity and membrane capacitance occur, 
the response at all frequencies should be identical (equations 2 and 3). This is the situation 
observed prior to transfection, where only the amplitude of the β-dispersion (∆εmax), but not its 
shape (fc) changed. In principle, a decrease in σi, accompanied by constant values of CM and r, 
would result in a drop in permittivity at high frequencies and a decrease of fc and ∆εFC without 
affecting ∆εmax. Here, a variation in σi alone during phase 1 and 2 can consequently be excluded. 
Yet, it is still possible that σi changed in parallel to the variations in cell diameter and CM. In 
contrast, and as was observed here, an increase in CM or r would result in a higher permittivity 
signal at low frequencies without a significant effect on the response at high frequencies. 
Differences in the permittivity spectrum and in turn the dielectric properties of the producer cells, 
were monitored as early as ~10-12 hpt, with permittivity measured at the lower frequencies 
increasing at a faster rate than at higher frequencies. Based on the results presented in fig. 5.3A 
and B, the initial LV release causes an increase in the value of CM of 30-70 %. These variations 
were possibly caused by the LV budding process and responsible for the characteristic profile of 
the permittivity parameters observed during production. 
It was reported earlier that the production of HIV-forming proteins is initiated as early as 5-6 h 
after transfection (Jouvenet et al. 2008). This is consistent with the early changes observable in 
the permittivity spectra (fig. 5.4). CM was originally reported to be a biological constant with 
values in the range of 1 ± 0.5 µF/cm2 and described as a measure of the ‘wrinkliness’ of the cell 
membrane (Schwan 1957; Harris et al. 1987b; Patel et al. 2008b). More recent studies found, 
however, that CM changes after viral infection and overexpression of cation channels (Archer et 
al. 1999; Zimmermann et al. 2008). It therefore seems to be particularly affected by processes 
involving the cellular membrane properties, such as, for example, exocytosis (loss of microvilli), 
viral release, and apoptosis (Patel et al. 2008a; Patel et al. 2008b). Reductions in CM of 40-60 % 
were reported for several cell types after infection with different viruses, such as herpes simplex 
and polyomavirus. CM is affected as early as a few hours post-infection as a result of the loss of 
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membrane blebs and a more uniform membrane conformation or a membrane surface with more 
irregularities (Archer et al. 1999; Berardi et al. 2009). For HIV-1, from which LV are derived, it 
is hypothesized that the release of virus by membrane budding and fission takes place very 
shortly after the formation of particles (Goto et al. 1990).  
In contrast, studies on BEV-infected insect cell cultures have mainly focused on the ‘charging’ 
phase right after infection during which an increase in cell volume results in higher biovolume 
and permittivity values. Only two of the studies describing permittivity measurements in the BEV 
system used multifrequency technology for monitoring and only one of those analyzed changes 
in fc, which increased dramatically at the point of first baculovirus release (Ansorge et al. 2007). 
However, a key difference to the present LV system is that BEV-infected cells loose viability 
rapidly after the first viral release. 
5.2.4.1.3 Reproducibility and Comparison of Off- and Online Methods for Monitoring of 
LV Production 
Consistently, similar LV production kinetics and monitoring results were observed in several 
bioreactor perfusion cultures under different operating conditions (fig. 5.5) and could be 
described using the same phase distribution pattern. During process phase 1 (0-24 hpt) and the 
transition into phase 2 (24-50/70 hpt), a single maximum value for the oxygen sparging rate 
(OSR) was observed, coinciding with the maximum in biovolume and permittivity. In contrast, 
the total GFP expression attained high levels only in phases 3 and 4, with the culture at 1 VVD 
resulting in higher values than the cultivations at 2 VVD. 
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Figure 5.5: Monitoring results for high-yield LV production runs.  
Three independent experiments are shown for comparison. The culture in (B) is identical to the one presented in fig. 5.2 and 5.4. 
Operating conditions varied with:  
(A): perfusion rate in volume(s) of medium per reactor volume and day (VVD), vcc at time of transfection (Lao et al.): 1 VVD, 4.4 
x106 vcc; B: 2 VVD, 4.7 x106 vcc;  C: 2 VVD, 8x106 vcc; for cultivations shown in A and B the same medium composition (HyQ) was 
used, culture shown in C included additional supplementation with CB5 (HyQ+) 
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In all the cultures, the cell diameter was found to initially decrease after transfection, but 
eventually increased during the transition into phase 2. During the second phase, decreases in cell 
size, ∆εmax, ∆εFC/∆ε0.6MHz and OSR were also observed while viability remained high in all cases. 
The diameter returned to its value before transfection during phase 2 and increased significantly 
thereafter (until phase 4). For all cultures, similar permittivity spectra were obtained and the 
correlations between bv*r, bv and ∆εmax, ∆εFC/∆ε0.6MHz and between cell diameter and fc were, 
respectively, similar (regressions not shown for all cultures).  
Also, the changes in cell diameter (d) clearly played a role in the evolution of ∆εmax and fc. A first 
maximum in d was observed from the transition of phase 1 to phase 2 at the beginning of the 
initial viral release and was in-line with the maximum in ∆εmax/the minimum in fc. The second 
inflection point in the permittivity spectrum (fig. 5.5) coincided with the minimum in cell 
diameter and/or CM.  
The maximum in OSR might also be used as an indicator of the initial lentiviral release and the 
onset of the production phase. Changes in oxygen consumption after viral infection are well 
documented in the literature (Kussow 1995; Kamen et al. 1996; Lecina et al. 2006). During LV 
production however, monitoring of OSR alone seemed to provide considerably less direct 
information specific to the titer kinetics than ∆εmax and fc.  
If GFP is the transgene encoded by the viral vector construct, monitoring GFP expression can 
also provide indication on the infection and production kinetics of viral vectors (Henry et al. 
2004; Kamen et al. 2004). This also holds for the production of VSV-G pseudotyped LVs in 
which self-infection of the producer cells results in high transgene expression once LV are 
released (Farson et al. 2001; Bagnis et al. 2009). In small scale experiments, the peak in 
production after 48 hpt and the GFP expression measured at 72 and 96 hpt correlated well over a 
wide titer range (results not shown). In bioreactor-scale cultivations, a lower perfusion rate 
resulted in less GFP expression in the producer cells, possibly due to an increased residence time 
of functional particles in the vessel. The use of in situ probes could therefore be explored during 
LV production (Gilbert et al. 2000). However, the value of these measurements will be most 
likely limited because information on functional viral titer would only be available with a delay 
of 1 or 2 days. More importantly, once GFP will be replaced by a different transgene of interest, 
this method will be inapplicable. 
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5.2.4.1.5 Changes in Online Permittivity Signals as Indicators of LV Yield 
The ratio of functional to total particles is generally low during LV production with the 
expression of LV proteins such as gag or VSV-G being sufficient for the release of non-
functional enveloped particles (Haglund et al. 2000; Göttlinger 2001; Higashikawa et al. 2001; 
Sherer et al. 2003; Mitta et al. 2005; Pichlmair et al. 2007). All of these species bud off from the 
membrane and would hence affect its properties. They were also found to contain viral or cellular 
DNA/RNA (Pichlmair et al. 2007; Zhao et al. 2008) and lead to an overestimation of VG titer. 
We therefore evaluated if the relative changes in the two key β-dispersion parameters, fc and 
∆εmax, could give indications on the total LV yield from bioreactor runs. We found a good 
correlation of the relative changes in fc and ∆εmax (during phase 2) and the total VG yield from 
bioreactor LV productions (fig. 5.6). However, these results will need to be confirmed by future 
cultures with a wider range in viral yield. In contrast to the VG titer evolution, the permittivity 
signal and the production of functional particles continuously decreased starting in phase 2. In 
control experiments, SDS-PAGE and western blot revealed that 4 days after transfection, the 
expression of VSV-G had dramatically decreased in LV-containing culture supernatants (results 
not shown). Cytotoxic effects of the envelope protein VSV-G were observed by others (Li et al. 
1993; Quinonez et al. 2002; Pichlmair et al. 2007; Zhao et al. 2008). Lysis of producer cells 
induced by these toxic effects might explain why the kinetics observed for VG titer and 
functional viral particles varied in particular during phase 3 and 4 (section 5.2.4.1.1, fig. 5.2 and 
5.5).  
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Figure 5.6: Relative changes during phase 2 in permittivity-related parameters (∆εmax and fC ) 
indicate total process yield. 
∆εmax: R2 = 0.9741; fC: R2 = 0.9332. Similar high regression coefficients were found when 
plotting the total yield after 2 dpt (not shown); one value for ∆εmax for a culture at low yield in 
which the maximum was related to a cease in cell growth was omitted in the graph 
5.2.5 Conclusions 
To our knowledge, this study is the first presenting permittivity measurements as online 
monitoring tools for the detection of viral release after transfection. Previous reported 
observations were made for systems in which viral vectors are produced after infection of 
producer cells. Based on online permittivity data, four distinct and reproducible process transition 
phases were identified during LV production and were shown to be related to the initial release of 
LVs and the kinetics of functional viral particle titers. Extrema and slope changes in the β-
dispersion parameters (∆εmax, fc) indicated the first viral release at the end of phase 1 (~24 hpt), 
the maximum functional viral titer in the culture supernatant during phase 2 (~48 hpt) and the 
optimal harvest time after phase 3/during phase 4 (>72-96 hpt). These characteristic features were 
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observed for different operating conditions, including differences in perfusion rate, cell density at 
transfection and media composition (fig. 5.5). 
Before transfection, a good correlation was found between offline biovolume measurements and 
online permittivity signals (R2>0.9). In contrast, samples taken during the initial viral release 
phase (phase 1-2) exhibited higher permittivity values per biovolume and a decreased 
characteristic frequency (fc) per cell diameter. After analysis of the permittivity spectra and 
comparison with other off- and online measurements, it was inferred that membrane capacitance 
(CM) must have increased significantly after transfection and around the time of first viral release. 
The measured changes in cell size alone were, on the other hand, not sufficient to explain the 
differences in ∆εmax, ∆εFC and fc, suggesting that LV budding could be detected by permittivity 
measurements. However, the changes of cell membrane properties (CM) during LV production 
were not directly measured and it is consequently possible that other parameters (such as the 
intracellular conductivity) were also affected. The use of methods such as dielectrophoresis or 
electrorotation should be of interest in this context to shed light on the events occurring at the 
cellular level and to better understand the impact of LV release on the dielectric properties of 
cells. Yet, it is not necessary to unambiguously identify the dielectric parameter(s) affected 
during LV production to use our observations for process characterization and control.  
Compared to other methods (oxygen consumption, total GFP expression), dielectric spectroscopy 
appeared to be the most sensitive and informative tool for online monitoring of LV production. 
The use of changes in ∆εmax, ∆εFC and fc as guiding variables for the real-time identification of 
action points or as a direct tool for perfusion rate control and final harvest should allow 
optimizing LV production processes.  
Interestingly, the relative changes in ∆εmax and fc correlated with the yield in total viral particles 
(VG titer), suggesting that the method might be used for the real-time estimation of process yield. 
These findings should not only facilitate LV production process characterization and 
modelization but also enable advanced process control. The monitoring of parameters that are 
indicative of process efficiency in real-time should greatly facilitate and speed up process 
development and allow prediction of process performance and eventually failure. Such tools are 
therefore invaluable to further support the establishment of robust lentiviral vector production 
processes in large-scale. 
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Also, it is expected that the findings reported herein could be translated to other viral vector and 
vaccine production processes based on transient transfection and infection.  
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CHAPTER 6 OVERALL DISCUSSION, CONCLUSIONS AND 
RECOMMENDATIONS  
Lentiviral vectors are currently under investigation as gene delivery vehicles in more than 20 
clinical trials. Meanwhile, the molecular architecture of the vector system remains under 
development. Improvements and possible modifications of the system will depend on the 
acceptance and success of these ongoing clinical trials.  
For LV mass manufacturing of final commercial material, it can be anticipated that stable 
packaging and producer cell lines will be employed. However, it is questionable if the efforts to 
produce a stable packaging or producer cell line are beneficial in early stages of an LV-based 
therapy development when different or modified vector components often need to be evaluated. 
To that end, transient transfection has advantages in terms of flexibility and shorter time to 
product. To date, yields from both production strategies are equivalent. It is therefore expected 
that both technologies will be used in parallel in the foreseeable future. 
Although time-consuming and subject to large variability, current production protocols using T-
flasks or culture dishes provide sufficient yields for small scale research applications. 
Improvements in benchscale LV production protocols could increase yields significantly but the 
approaches almost exclusively used adherent cell lines. A comparison of results from different 
groups is generally difficult due to the variety of production protocols and titration methods 
found in the literature. Optimization approaches guided by bioprocess engineering principles are 
only rarely reported.  
However, to avoid production constraints in later evaluation phases, robust and readily scalable 
suspension based approaches need to be in place for pilot and large-scale productions, ideally 
before preclinical studies and phase 1 clinical trial are being contemplated.  
This thesis deals with the production of LVs by transient transfection and describes their scalable 
production. Some of the parameters that are critical for efficient LV production were identified 
and monitored or controlled to improve process yields. Using a suspension-grown cell line for 
production in perfusion mode, the issue of low LV stability was successfully addressed and 
previous constraints concerning the scalability of production methods were solved. More 
specifically, the present work demonstrated that LV production is amenable to the 3 L bioreactor 
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scale. Beyond that, it is hypothesized that production in larger scales is feasible without major 
changes in the production setup. 
As a result of the perfusion strategy, the cell density limitation of common transfection protocols 
was circumvented by producing LVs at high cell density (HCD) of 5x106 c/mL. This strategy 
should be transferable to other systems and advantageous for unstable products for which the 
production process needs to be performed in perfusion. 
Optimization of transfection conditions further increased LV titers. In our hands, best results 
were obtained for a PEI:DNA mass ratio of 2:1 and when 0.4-0.6 µg of total DNA/ 610  cells was 
used for transfection in HyQ medium. This strategy reduces toxic effects of PEI and increases the 
cost-effectiveness of the method.  
The addition of sodium butyrate had the most significant impact on LV production. At a 
concentration of 5 mM, sodium butyrate altered the production kinetics and increased total yields 
by 15-fold.  
The LV production kinetics after transient transfection in perfusion mode was analyzed in detail. 
It was found that productivity of functional LVs and the ratio of functional to total LV particles 
(LV quality) were changing during the process. Production kinetics and the ratio of functional 
(GTA) and total LV particles (VG/VP titer) were found to differ from intial conditions when 
using improved production conditions. Optimum expression of all four plasmid constructs for LV 
production took in the latter case place at 2 dpt, resulting in highest functional titers and LV 
quality. This ‘butyrate effect’ was attributed to an increase in the overall expression of the LV-
encoding constructs. VSV-G seemed to be critical under improved production conditions and it 
was hypothesized that its expression is limiting production yields and confines the generation of 
functional LV at high yield to transient production of a few days. If these findings hold true, this 
might also have implications for the development and use of stable cell lines, as these systems 
would then also be intrinsically limited to short LV production windows. 
Enriched medium formulations (LC-SFM GL, HyQ, HyQ+) outperformed standard medium 
formulations (LC-SFM L, HyQ). LV production is thus also a function of the nutrient availability 
of the culture. Further work is however required to understand the influence of the cell’s 
physiological state on production yields. Preliminary results did not allow determining if further 
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process improvements were limited by metabolic constraints or the efficiency of transfection at 
high cell density. 
Overall, the optimization strategy resulted in improved production conditions delivering 100-150 
fold higher total yields compared to routine small scale conditions. These conditions were then 
validated at the 3-L bioreactor scale, resulting in an increase of ~75-fold compared to a bioreactor 
production performed under initial conditions. A continuous harvest strategy and storage of LV at 
low temperature outside the reactor allowed for the efficient rescue of functional LV. 
Even when using improved production conditions, the cell-specific productivity of functional 
viral vector remained low (60-120 tu/cell). This can in part be explained by the low ratio of 
functional to total LV particles (GTA:VG titer) of 1-4 %. Due to differences in production 
protocols, titration methods and plasmid constructs, a direct comparison of cell-specific yields 
with other groups is not always possible. The yields observed here, with a maximum of >1x108 
tu/mL in non-concentrated supernatants should nevertheless be superior to what has been so far 
reported by other groups.  
We note that the process strategy developed in this work is flexible and can consequently be 
easily modified to rapidly respond to the requirements defined by the final application for which 
LV are generated. As a general recommendation for efficient LV production it is pointed out that 
the choice of the ideal production strategy is a function of several parameters including: 
• total LV quantity needed 
• downstream processing (DSP) strategy  
o are functional LVs separated from total particles/is this required for the final 
application? 
o production yield (volume and titer) vs DSP capacity per day 
• the importance of LV quality for the final application 
In small-scale, i.e. for a total targeted production yield of 0.5-1x1010 tu (for the model system) the 
optimum production strategy would consist of LV production at 5-10x106 c/mL at 2 DMD, 
ensuring high total yields and LV quality. Culture supernatants could then either be frozen for 
subsequent purification or directly concentrated by ultracentrifugation. 
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In bioreactor scale, i.e. for a targeted production yield of >1x1011 tu, the choice of medium 
exchange rate highly depends on the capacity and resources of the downstream facilities and the 
importance of LV quality. 2 VVD resulted in higher LV quality than production at 1 VVD. 
However twice the amount of LV-containing supernatant is generated and LV-containing 
supernatants can, due to the low LV stability, only be stored for limited periods (at 4°C) whereas 
freezing of large volumes is challenging. The DSP strategy is thus determining if production at 
high medium exchange rates is advantageous. 
It must be noted that total LV yields are known to be a function of the LV system and the 
transgene of interest; absolute yields might therefore differ significantly from the values observed 
for the model system used throughout this work. Our described LV production platform should 
be ideal for the testing of improved LV constructs and their evaluation from bench to bioreactor 
scale. The scalable perfusion strategy will also facilitate the development of LV-related 
production and manufacturing technologies, such as large scale downstream processing which 
was previously limited by the inability to rapidly generate large volumes of highly concentrated 
LV supernatants.  
Current LV quantification methods are an important constraint for process development. Most 
methods are time-consuming, standardization is urgently needed and assay result variability is 
generally high. Further development of novel quantification methods for lentiviral vectors and 
other enveloped viruses is consequently needed. In that context, precision and time-to-result of 
the different methods is instrumental to facilitate process development. To date, the 
quantification of VG titer by RT-PCR seems to be the most advantageous direct method to assess 
total particle numbers. Concerning indirect methods, our results indicate that it will be of 
particular importance to control the passage numbers of target cells as this might significantly 
decrease variability of functional LV titers. 
Optimized operation and LV yield maximization of the bioreactor perfusion process require tools 
that convey information on vector production in real-time. For that purpose, we sought to link LV 
production kinetics to online measurement signals. As a first step, suitable real-time tools for the 
monitoring of LV production needed to be identified. Despite the, in comparison to other viral 
vectors, low productivity of functional lentiviral vectors after transfection, online in situ 
permittivity measurements were identified as the most informative tool for the rapid 
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characterization of bioreactor productions. Based on the real-time permittivity data, four distinct 
and reproducible process transition phases were identified during LV production. The monitoring 
results consistently reflected LV production kinetics during several bioreactor perfusion cultures 
under different operating conditions. Changes in the signals were related to the initial release of 
LVs and the kinetics of functional viral particle titers. In addition, relative changes in the β-
dispersion parameters (fc and ∆εmax) correlated with the total VG yield from bioreactor LV 
productions. In conclusion, the technology is of great value for the screening of different 
production conditions and process development. It is also recommended as a PAT tool for 
process characterization which is in turn a prerequisite for performance optimization. 
Despite the significant increase in LV yield when using the improved production conditions 
reported here, viral vector titers were low compared to what is reported for other viral constructs 
and production systems. For capsid virus-based vectors, such as adenoviral and adeno-associated 
viral vectors, cell-specific yields in the range of 103-104 infectious viral particles per cell are 
generally observed in HEK293 cells (Kamen, Henry 2004; Aucoin, Perrier et al. 2008). 
Baculovirus expression vectors, which are similar to LVs budding from the producer cells can be 
produced in insect cells at yields of up to 104 infectious particles/cell (Carinhas, Bernal et al. 
2009). Such comparisons are, however, generally difficult because of differences in viral (capsid 
vs budding virus) and/or host cell (insect vs mammalian cells) biology. Nevertheless, even for 
production of influenza virus which is, supposedly, the closest system compared to LV 
production, resulted in higher infectious particle yields of 102-103 IVP/cell in non-optimized 
bioreactor batch productions (Le Ru, Jacob et al. 2010).  
It is thus expected that there is still a possibility to further improve current LV production 
processes significantly. On the other hand, it is concluded that the dramatic effect of butyrate on 
production yields and kinetics is at the same time a limitation for further process improvement. 
The overexpression of LV-related proteins limits production windows. This is supported by our 
findings that the time point of butyrate addition has no positive effect on total LV yields. The 
extension of production windows seems to be a promising strategy to achieve higher yields. This 
would be possible if the loss of functional titers in later process stages could be avoided. For 
example, sequential transfection with the VSV-G plasmid might be explored as well as the 
reversible inhibition of the fusogenic properties of VSV-G during production.  
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At this point, most significant improvements can, however, be expected from modifications at the 
molecular level, such as an increase in functional LV stability, a decrease in envelope 
cytotoxicity or regulation strategies for VSV-G.  
Alternative LV envelopes have been described and their use would likely result in higher 
functional vector yields (Verhoeyen and Cosset 2004; Cronin, Zhang et al. 2005). Yet, LVs that 
are not pseudotyped with VSV-G are limited to specific applications and target cells.  
Beyond these improvements, another avenue for process optimization is a further analysis of the 
HEK293 metabolism in HyQ medium with the goal to identify and develop a) strategies to 
further increase cell density at the time of transfection without loss in specific productivity and b) 
optimized medium formulations for the production of LVs. 
Therefore, more work integrating recent advances in metabolic engineering and medium 
optimization is required to further increase LV production yields. Only preliminary data are 
available on the impact of the physiological state and the nutrient availability at the time of 
transfection on LV production yields. An example is that lactate concentrations at inhibiting 
concentrations were observed in some of the bioreactor perfusion cultures. Due to the limitations 
of LV quantification methods, it is recommended to perform this evaluation using suitable 
transfection model systems for which the protein product can be more reliably quantified.  
Specific to LV production is an analysis of the importance of lipids and lipid metabolism. 
Extensive work related to the production of retroviral vectors suggests that cellular lipid content 
and metabolism play a critical role in vector production (Merten 2004; Coroadinha, Alves et al. 
2006; Coroadinha, Ribeiro et al. 2006; Coroadinha, Silva et al. 2006). As lipid content in the 
produced vectors appears to determine their stability, it will be particularly in that context 
instrumental to deconvolute effects on LV production and stability (Beer, Meyer et al. 2003; 
Carmo, Faria et al. 2006; Coroadinha, Alves et al. 2006). 
Further work and in particular the demonstration of improved process performance when using 
the real-time signals for process control and decision-making is required. For example, the 
permittivity signals could be used to directly control the harvest rate and for further advanced 
process control or supervision to optimize the process and maximize yields. Preliminary results 
also suggest that the feed could be controlled based on real-time permittivity signal before 
production, which would minimize medium consumption. 
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Overall, it is difficult to anticipate to what degree these strategies and their combination would 
further improve LV production yields using the model system. Another avenue for future work 
would thus be to evaluate if the critical parameters identified here are applicable and transferable 
to other LV systems. 
This work demonstrates that mass production of LV using suspension cultures is feasible in large 
scale. Our findings will make the application of these vectors cost-effective, facilitate their 
experimental and clinical evaluation and eventually render LVs more accessible to patients. The 
strategies developed in this work provide unprecedented yields of 1010-1011 tu/L corresponding to 
1012-1013 vg/L of production supernatant. Although many aspects require further research and 
development and process optimization efforts, the progress in LV production described here 
should enable the cost-effective and simple mass production of clinical LV material under GMP 
conditions in the near future.  
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APPENDICES 
The appendix contains preliminary and additional experimental observations that facilitate the 
understanding of the results presented in the main part of this thesis.  
In appendix I, the stability of LV is assessed in cell culture supernatants. Appendix II summarizes 
the efforts undertaken to further improve LV yields in the production system beyond the yield 
improvements described in chapter 3. This part points out the limitations of the current 
production strategy. Finally, complementary experiments for the respective chapters as well as 
additional information are presented in appendix III.  
 
APPENDIX I- A Preliminary Study on the Stability of LVs in Culture 
Supernatants 
As was summarized earlier (section 1.2.4, 2.1.3), the stability of functional LV is generally low, 
with a half-life of only 3-18 h at 37 °C (Higashikawa and Chang 2001; Watson, Kobinger et al. 
2002; Croyle, Callahan et al. 2004). Yet, literature does not provide sufficient data on the 
stability of lentiviral vectors in cell culture supernatants. In most cases, pre-purified or 
concentrated LVs are used to evaluate LV stability in final preparations. Here, it was of particular 
interest to assess the viral decay during production. According to the results presented here, the 
harvest strategy was modified, i.e. higher medium exchanges rates of 2 DMD/VVD were tested 
to further increase process yields (appendix II and chapter 5). 
198 
 
 
AI.1 Stability of functional LV produced in small-scale experiments 
 
Figure AI.1: LV stability in small scale culture supernatants at 37°C 
(A) LV decay in supernatants harvested from cultures transfected using improved production 
conditions and 2 DMD 
(B) Modification of production conditions (sodium butyrate addition) does not significantly 
affect LV stability 
 
The stability of functional LVs was evaluated after harvest of supernatants from cultures using 
improved production conditions in small scale experiments. Figure AI.1 presents the kinetics of 
LV decay after incubation at 37°C. No significant differences in LV stability were found for 
harvests at varying production days (2-4 dpt) (fig. AI.1 A). The time point of butyrate addition 
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did not affect LV stability (fig. AI.1 B). In all cases, the loss in transducing units at 37°C 
followed an exponential decrease. The half-life (t1/2) of LVs was in most conditions between 8-10 
h (refer to table AI.1 for half-life values). Variations in t1/2 were, however, quite high (standard 
deviations not shown), due to the fact that the analysis was based on GTA. Subsequently, LVs 
harvested during a bioreactor perfusion culture (run #3) were analyzed (fig. AI.2). A higher 
number of samples allowed for a more reliable estimation of t1/2 which was calculated at ~12-13 
h. No difference was found for t1/2 of LVs in supernatants harvested on 2 and 3 dpt, respectively. 
At a reduced temperature of 4°C, the degradation of LVs was slowed down and followed a linear 
decay (t1/2  of ~ 100 h). 
In contrast, the viral decay based on VG titer was similar at 4 and 37°C (t1/2 of 40-50 h). This 
indicates that viral RNA degradation was not responsible for the rapid loss in the decay of 
functional LVs. Similar kinetics for viral genome degradation of VSV-G pseudotyped LVs were 
observed by others. The same authors excluded enzyme inactivation and viral degradation as 
responsible for the fast loss in LV infectivity and hypothesized that the loss in functional LV is 
associated to a loss in the capacity to perform reverse transcription (Carmo, Panet et al. 2008).  
In conclusion, the t1/2 of functional LVs was found to be in the range of 8-13 h. Higher variations 
were observed during the analysis of supernatants produced in small scale cultures but these 
could not be attributed to the modifications in production conditions. It also needs to be noted 
that lower t1/2 values for PCR analysis compared to GTA results were found at 4°C indicating 
that further experiments are required to assess decay kinetics with higher confidence. 
Nevertheless, the results provide a good indication on viral degradation during the process and 
suggest production at increased medium exchange rates for yield optimization (appendix II). In 
contrast, as these studies were performed in cell-free supernatants, the results do not allow 
conclusions on the loss of functional LV due to retransduction of producer cells. Those events do, 
however, most likely occur, as GFP expression during production attained high levels and 
correlated with maximum LV titers (chapter 4). The significance of retransduction events for 
production yields would thus need to be evaluated in additional studies. 
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AI.2 Stability of functional LV produced in bioreactor cultures 
 
 
Fig AI.2: LV stability at 37°C in cell free harvest from bioreactor supernatants; supernatants were 
harvested from continuous bioreactor cultures at 2 and 3 dpt, bioreactor run corresponds to run # 
3; (A) decay analyzed by GTA at 4 and 37 °C, note that this figure is identical to fig. 2.2; (B) 
decay at 4 and 37 °C analyzed by PCR  
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Table AI.1: LV stability in different production scales and conditions 
Improved Production Conditions Modified Production Conditions  
 
ExperimentI/ 
Harvest DayII 
Small Scale 
(GTA, 
37°C) 
Exp #1IV 
Bioreactor 
ScaleIII (GTA, 
37 °C), run #3 
Bioreactor 
ScaleIII (GTA, 
4 °C), run #3 
Bioreactor 
ScaleIII (PCR 
4/37 °C), run #3 
Harvest  
(hpt), 
butyrate 
addition 
(hpt) 
Small Scale 
(GTA, 37 °C) 
Exp #2V 
Harvest  
(hpt), 
butyrate 
addition (hpt) 
Small Scale 
(GTA, 37 °C) 
VI 
1 dpt (starting 
titer, (tu/mL) t1/2, 
R2) 
8.1x106, 
8.4, 0.99. n.a. n.a. n.a. 16, 0 
1.3x107 
6.35, 0.99   
2 dpt (starting 
titer, 
(tu/mL/vg/mL) 
t1/2, R2 ) 
7.1x108, 
10, 0.99 
5.2x107, 
12.85, 0.99 
4x107, 
109.2, 0.96 
1.5x109,  
54, 0.91 
9.5x108, 
 38, 0.97 
40, 0 2.14x10
8
, 
5.66, 0.99, 
48, no 
butyrate 
2.3x107, 
10.44, 0.99 
3 dpt (starting 
titer, (tu/mL) t1/2, 
R2) 
1.8x108, 
9.3, 0.99 
7.6x107, 
13.34, 0.99 
8.66x107, 
88.46, 0.91 n.a. 24, 6 
7.3x107, 
8.1, 0.99 
72, no 
butyrate 
4x107, 15.3, 
0.99 
4 dpt (starting 
titer, (tu/mL) t1/2, 
R2) 
2.85x107, 
10.7, 0.99 n.a. n.a. n.a. 40, 6 
2.14x108, 
9.66, 0.89   
t1/2 : half-life  
I: scale (quantification method, temperature, experiment #) 
II: harvest time (LV starting titer, half-life, regression coefficient) 
III: harvest from cell-free supernatant (perfusion harvest), run #3, improved production conditions in bioreactor, 1 VVD 
IV: experimental conditions: improved production conditions, 2 DMD 
V: experimental conditions: improved production conditions, butyrate addition at different time points  
VI: transfection at 5x106 c/mL, no butyrate addition 
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APPENDIX II- Exploring Process Limits in LV Production:  
Operation Windows for High Cell Density Transfection in Small and 
Bioreactor Scale 
AII.1 INTRODUCTION 
The production of viral vectors is typically performed at low cell densities only (refer to 
references in chapter 1 and 3). In other viral vector production systems, productivity highly 
depends on the physiological state of the producer cells at the time of infection (Henry, Dormond 
et al. 2004; Kamen and Henry 2004; Henry, Kamen et al. 2007b). This phenomenon is now 
commonly described as the cell density effect which was first identified during the production of 
adenoviral vectors (Garnier, Coté et al. 1994; Nadeau, Garnier et al. 2003). Perfusion strategies 
have been demonstrated to alleviate unidentified nutrient limitations and byproduct inhibitions, 
thereby enabling the production at higher cell densities (Henry, Kamen et al. 2007a). Similarly, 
routine transfection protocols for the production of recombinant proteins employ low cell 
densities only (Durocher, Perret et al. 2002; Derouazi, Girard et al. 2004; Pham, Kamen et al. 
2006). Transfection at high cell density in perfusion mode has now also been described (Sun, Hia 
et al. 2008). However, for most recombinant products, production in perfusion is not 
economically justifiable. Perfusion processes are generally associated to a higher contamination 
risk, are more complex to operate, more difficult to validate because of longer process times and 
require dedicated facilities and skilled personnel to ensure a robust operation. In contrast, fed-
batch cultures can now be considered the industry standard, mainly due to the success of 
monoclonal-antibody based therapeutics which are almost exclusively produced in this process 
mode (Wurm 2004). Consequently, production in perfusion mode is generally avoided as long as 
product stability and titers are sufficiently high to allow for product accumulation in the reactor 
over several days. In the case of LVs, however, the low stability of functional particles requires 
production with frequent harvest and medium replacement ((Merten 2004); refer to appendix I for 
LV stability data). As it is the case for other labile biologicals, such as FVIII but also for some 
monoclonal antibodies (Chu and Robinson 2001), continuous production in perfusion mode is 
therefore the strategy of choice for LVs. 
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In chapter 3, a perfusion strategy for the high-yield production of LV was described. Frequent 
harvest of LVs by medium replacement allowed operating at increased cell densities of up to 
5x106 c/mL, superior to what was described earlier in routine transfection protocols.  
This part of the appendix will summarize our efforts undertaken to further improve LV yields in 
the production system. It was the goal to explore and define process limits for LV production at 
high cell density. The first part of the results (appendix II.3.1) presents results for LV production 
in small-scale experiments. It was then evaluated to what extent these process conditions could be 
transferred to bioreactor scale (appendix II.3.2).  
AII.2 Materials and Methods 
All materials and methods used in this chapter were described previously (chapter 2)  
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AII.3 Results and Discussion 
AII.3.1 LV production in small-scale experiments 
AII.3.1.1 LV Production at 1 DMD 
 
Figure AII.1: LV production in small scale at 1 discontinuous medium exchange per day (DMD).  
(A) LV production at 5x106 c/mL with 1 DMD leads to a total LV yield of >5x109 tu at 4 dpt 
(average of 3 independent experiments is shown); LV production in batch mode was performed 
after transfection at the same cell density of a culture taken from bioreactor run #3 (see chapter 4 
and section appendix II.3.2; data shown in figure are identical to what is shown in fig. 4.1) 
(B) Increase in cell density at 1 DMD; productions were performed using the same transfection 
(polyplex) mix for all cultures at 1 and 2 DMD, respectively, i.e. the volume of polyplex amount 
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varied from 4-40 % of the final culture volume; values represent data from 3 independent 
experiments 
 
LV production employing improved conditions at 1 discontinuous medium exchange per day 
(DMD) identified in chapter 3 resulted in reproducible production kinetics with high total yields 
of >5x109 tu after 4 dpt per 20 mL shake flask (fig. AII.1 A). After transfection at a cell density 
of 5x106 c/mL, the maximum functional titer was observed 2 dpt, followed by an exponential 
decrease thereafter. In contrast, transfection at the same cell density without subsequent medium 
exchange, i.e. in batch mode, gave total yields which were at least 2-3 fold lower. 
Subsequently, a further increase in cell density was explored at the time of transfection (fig. AII.1 
B). Cell densities of up to 2x107 c/mL were tested but resulted in only slightly increased 
functional titers with similar kinetics at 1 DMD. At the same time, specific productivity 
decreased dramatically from ~60 to ~20 tu/cell (fig. AII.1 B).  
 
AII.3.1.2 Production at 2 DMD Results in Higher Total LV Yields 
The study on the stability of infectious LVs in culture supernatants revealed that their half-life is 
in the range of 8-13 h, a value independent of the time of harvest during production (see appendix 
I for details). Accordingly, the optimum harvest rate for LV should be about twice a day. It was 
therefore investigated if production at an increased medium exchange rate of 2 DMD resulted in 
higher total yields of functional LV (fig. AII.2). Operation at 2 discontinuous medium exchanges 
per day (DMD) was expected to result in constant functional titers (tu/mL) and increased total 
yield due to the doubling of the harvested volume. LV production kinetics were indeed similar, 
increasing the total yield to >1x1010 tu corresponding to a specific productivity of ~120 tu/cell.  
In comparison to production at 1 DMD, 2 medium exchanges per day resulted in a drop in LV 
titers on 3 and 4 dpt. It is possible that the discontinuous exchange of medium by centrifugation 
and resuspension had detrimental effects on or led to a loss in producer cells. Furthermore, in 
particular at cell densities >5x106 c/mL a high degree of cell clumping made it difficult to 
resuspend the cell pellet after centrifugation on 3 and 4 dpt (see fig. AIV.16-17 for pictures). At 1 
and 2 DMD, the viable cell density increased slightly after transfection at 5x106 c/mL and 
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reached a maximum at ~7x106 c/mL at 2 dpt (fig. AII.3). The cell density then decreased until the 
end of production at 4 dpt. Count errors for these samples were high, resulting in a high standard 
deviation for the average of several experiments, probably because of the observed significant 
cellular aggregation. 
 
 
 
Figure AII.2: LV production using improved production conditions in small scale at 1 and 2 
DMD 
The values correspond to average values from n = 3 independent experiments at 1 DMD and n = 
5 at 2 DMD; error bars represent the respective standard deviations. 
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Figure AII.3: Cell density and viability during small-scale LV production at 1 and 2 DMD. 
Improved production conditions with transfection at 5x106 c/mL were used. Error bars represent 
standard deviations from independent experiments (1 DMD: n = 3; 2 DMD: n = 5). 
 
As a higher medium exchange rate also increases the nutrient supply to the culture, a cell density 
increase at the time of transfection was then explored at 2 DMD. Higher titers and total yields 
were achieved at cell densities superior to 5x106 c/mL (fig AII.4 A). Yet, when increasing the cell 
density beyond 5x106 c/mL, a decrease in specific productivity by ~30 % was observed. During 
these experiments, the polyplex volume varied (similar to what was previously presented in fig. 
AII.1 B), corresponding to 40 % of the final culture volume for transfection at 2x107 c/mL.  
 
AII.3.1.3 Effect of Medium Supplementation on LV Production and Constraints for Scalability 
Previously, it was observed that the use of an enriched medium composition (HyQ) had a positive 
effect on LV production. It was hypothesized that this was due to an improved nutrient 
availability and physiological state of the culture at the time of transfection (see chapter 3, fig. 
3.2). It was consequently tested if additional supply of nutrients could further improve 
productivity and LV yields. A commercial medium supplement (cell boost 5 (CB5 reg)), 
developed for fed-batch cultivations, was used in subsequent experiments. In previous work and 
preliminary experiments (unpublished results from our group; fig. AIV.11), it could be shown 
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that the addition of CB5 reg at a concentration of 5 % (v/v) significantly improved growth of the 
HEK293 cell line. A significant increase in proliferation rate during the post-exponential growth 
phase was observed, thereby reaching higher maximum cell densities in batch cultures. As 
supplementation of the medium with up to 10 % (v/v) of CB5 reg did not lead to a further 
increase in cell density, supplementation with 5 % (v/v) of CB5 reg was evaluated for LV 
production. 
For this part of process yield optimization, the comparison of total yields and specific 
productivity turned out to be challenging due to the intrinsic variability of the GTA assay (see 
section 2.2, table 2.2). Due to the high standard deviation of this assay, it was difficult to detect 
effects of production conditions that resulted in differences smaller or equal to 2-fold. For 
subsequent experiments, an internal standard, i.e. a shake flask which was transfected using 
improved production conditions at 2 DMD (HyQ medium, 0.4 µg of total DNA per 1x106 cells, 
addition of 5 mM butyrate at 16 hpt) was therefore included. In all experiments, the results were 
then normalized to this condition. 
When CB5 reg was added post-transfection, i.e. starting with the first medium exchange at 16 
hpt, the increase in yield was small compared to the regular HyQ formulation (fig. AII.4 A) 
Supplementation of HyQ with CB5 reg before transfection was not feasible because transfection 
was dramatically inhibited, resulting in no functional virus particles that were detectable by GTA 
after transfection (data not shown). This inhibition was overcome by using CB5 mod and the 
HyQ+ medium formulation (see methodology). Subsequent experiments were then performed at 
increasing cell densities and 2 DMD (fig. AII.4 B).  
In addition, to ensure scalability of the production conditions to the bioreactor scale, the polyplex 
volume was subsequently kept constant for all conditions at 10 % of the final culture volume. In 
particular due to the specifications of the level control device, the bioreactor system used in this 
work allows robust operation in perfusion only in a limited culture volume range. This means that 
an increase in 10 % of culture volume by polyplex addition is considered as maximal if the small 
scale conditions should be readily scalable.  
Using HyQ+ and a constant polyplex volume of 10 %, transfection at cell densities of up to 1x107 
c/mL resulted in higher total yields although specific productivity decreased when transfection 
took place at densities beyond 5x106 c/mL (fig. AII.4 B).  
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Figure AII.4: LV production in small-scale at 2 DMD is a function of the cell density at the time 
of transfection; CB5 reg.: regular formulation of cell boost which is inhibitory for transfection; 
HyQ+: HyQ medium supplemented with CB5 mod, a modified formulation of cell boost that 
does not inhibit transfection 
(A) LV production at increased cell density at 2 DMD using variable polyplex volumes which 
were increased as a function of the cell density and correspondend to 4-40 % of final culture 
volume; CB5 reg was added only post-transfection 
(B) LV production at increased cell density at DMD and constant polyplex volume (10 % of the 
final culture volume)  
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Figure AII.5: Comparison of LV production at 2 DMD in HyQ (at 5x106 c/mL) and HyQ+ (at 
1x107 c/mL) medium  
 
However, when comparing transfection at 1x107 in HyQ+ and 5x106 c/mL in HyQ, the gain in 
viral titer and total LV yield did not formally reach statistical significance (fig AII.5). On the one 
hand, this means that under these production conditions and with the described constraints, the 
process limit was reached. On the other hand, LV production based on transfection was 
reproducibly leading to functional LV titers that were superior to 1x108 tu/mL in small scale, 
corresponding to >1x1010 tu per experiment. The reasons for why these limitations were observed 
remain unknown. Two major hypotheses need to be discussed in this context.  
First, it is possible that nutrient limitations were responsible for the decrease in specific 
productivity. Nevertheless, major nutrients (such as glucose and amino acids) were not depleted 
in any of the small-scale experiments. Similarly, byproducts such as lactate and ammonium were 
far below or at the lower limit of what has been reported as inhibiting concentrations, with the 
exception of lactate concentration 1 day-post transfection at 1 DMD (see fig. AIV.8).  
Second, according to our results, in particular the concentration range in which polyplexes are 
efficiently formed seems to require a further evaluation. Strategies that use high cell densities to 
increase productivity after transient transfection are not often described in the literature. Transient 
transfection in medium that supports high transfection efficiencies at cell densities as high as 
evaluated here has not yet been reported. Only one study described that the culture volume in 
which the polyplexes are prepared does affect transfection efficiency during transfection at 1x107 
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c/mL (Sun, Hia et al. 2008). The operation windows of these processes are generally not well 
defined. We note that high cell density transfection with polyplexes prepared at routine 
concentrations resulted in higher LV yields (fig. AII.4 A). However, the cell suspension was also 
significantly diluted with the addition of polyplexes. An isolated analysis of this concentration 
effect was therefore impossible. More work is thus needed to establish robust transfection 
protocols at high cell density. The present LV system, with its intrinsic constraints and variations 
of viral quantification methods, does not seem to be the ideal system to further investigate this 
problem.  
With respect to scalability, one of the constraints of the present bioreactor system was that the 
polyplex volume could not exceed 10 % of the final culture volume. Perfusion reactors which 
allow for higher flexibility might therefore be advantageous for LV production. 
Alternatively, direct addition of DNA to the culture, followed by PEI addition could be another 
option for transfection at high cell density. This method has first been described as one way to 
overcome inhibitory properties of culture media that are not suitable for transfection (Backliwal, 
Hildinger et al. 2008). Although the direct sequential addition of DNA and PEI simplifies the 
production protocol by avoiding a priori polyplex formation, large-scale reproducibility of the 
method remains to be demonstrated. Another major drawback of this strategy is that the 
associated costs would be significantly increased, as higher amounts of purified DNA are needed 
to achieve comparable transfection efficiencies (Backliwal, Hildinger et al. 2008, and 
unpublished results  from our group). 
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AII.3.1.4 Comparison of Functional LV Yields and Direct Particle Quantification Methods 
Table AII.1:LV yields from productions at high cell density (5x106 c/mL) at different operating conditions in small-scale 
 Functional titer (GTA) VP titer (ELISA) VG titer (PCR) 
operating 
condition/ 
parameter 
1 DMD I 2 DMD II 2 DMD, HyQ+ III 1 DMD
 IV
 
2 
DMDIV 
2 DMD, 
HyQ + 
IV
 
1 DMDV 2 DMDVI 2 DMD, HyQ + 
maximum 
titer 
(LV/mL) 
1.6x108 3.1x108 6x108 2x1010 9x109 1.4x1010 4.5x109 4.2x109 VII n.a. 
Total yield 
(LV) 
6.8 +/- 1.6 
x109 
1.17 +/- 0.75 
x1010 
2.14 +/-1.08 
x1010 1x10
12
 6.4x1011 1.1x1012 1.8 +/-0.6 
x1011 
3 +/- 0.45 
x1011 n.a. 
Spec. prod. 
(tu/cell) 70 +/-16 117 +/- 77 214 +/- 108 10300 6400 11000 1800 +/- 600 3000 +/- 450 n.a. 
n.a.:  results not available  
I:  average values from n = 3 experiments 
II: average values from n = 6 experiments 
III:  average values of n = 2 experiments 
IV:  values were based on a small number of data points; VP titers for 1 dpt were not available 
V:  average values from n = 3 experiments 
VI:  average values from n = 2 experiments 
VII:  constant values from 2-5 dpt 
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Table AII.1 summarizes the results for LV yields as assessed by direct (GTA) and indirect 
(CAp24 ELISA, PCR) quantification methods. An increase in specific productivity of functional 
LVs was found as result of an increased medium exchange rate (from 1 to 2 DMD) but also the 
improvement of nutrient availability (from 2 DMD (HyQ) to 2 DMD (HyQ+). VG titer yields 
were higher at 2 DMD while there was a decrease in VP titer from 1 to 2 DMD. The number of 
experiments for which ELISA results were available was, however, too low to allow for a final 
conclusion on the differences in VP titers. In general, the improvements in titer were lower than 
what was observed during the first part of process improvement (chapter 3). As a consequence, 
some of the modification in production conditions did not formally reach statistical significant 
titer differences. 
 
In summary, higher cell densities at the time of transfection resulted in increased total LV yields. 
Beyond 1x107 c/mL, however, no increase in LV titer was observed when transfection was 
performed in readily scalable conditions at 2 DMD (constant polyplex volume at 10 %). This 
observation seems to correspond to previous results for other systems (cell density effect) 
(Garnier, Côté et al. 1994; Nadeau, Garnier et al. 2003; Henry, Kamen et al. 2007). Nevertheless, 
in the present production system, an advanced medium formulation combined with a high 
medium exchange rate for LV harvest allows operating at significantly increased cell density. 
Our results do not allow to infer the reasons behind the limitations in production yield. LV 
production might be either limited by lower transfection efficiencies at densities beyond 1x107 
c/mL and/or unidentified nutrient limitations and inhibitions. 
The operation window for efficient LV production was thus defined to be in the range of 5-
10x106 c/mL at the time of transfection. This value served as starting point for the transfer of the 
production conditions to bioreactor scale.  
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AII.3.2 Transfer of LV production to bioreactor scale 
The second part of this section presents the analysis of LV production in bioreactor cultures. 
Based on batch growth results (appendix III), it was in general concluded for the subsequent LV 
productions in bioreactor scale that initial batch growth should not be extended beyond a cell 
density of ~2x106 c/mL. Growth in perfusion mode should then ensure that the culture remains in 
its exponential growth phase and in a favourable metabolic state before transfection. In chapter 3, 
the scalability of production conditions has already been demonstrated by two bioreactor 
perfusion cultures (using starting and improved production conditions corresponding, 
respectively, to run #2 and #3). Here, it was sought to further characterize LV production in 
bioreactor scale by comparing total yields from small and bioreactor scale experiments as well as 
changes in growth and metabolic rates.  
In addition to previously discussed data, LV production in bioreactor scale employing improved 
production conditions was evaluated in a total of three perfusion cultures (see table AII.2 for 
operating and production conditions).  
AII.3.2.1 Comparison of Yields from Small and Bioreactor Scale Experiments 
When comparing the LV yields from small-scale and bioreactor experiments, it was found that 
yields from all bioreactor experiments were lower (table AII.2 B). This finding was already 
briefly discussed for run #3 in chapter 3 (section 3.2.5). Taking the volume difference to shake 
flask cultures (20 mL) into account, bioreactor cultures were expected to generate 1-3x1012 tu per 
culture. In contrast, although all bioreactor cultures gave consistently high total LV yields 
(>3x1011 tu), the total functional titers were 2.5-10 fold lower than in the comparable small scale 
conditions. On the other hand, the VP and VG titer yields were closer to the values observed in 
small-scale and increased with each improvement in production conditions from run #2-5 (fig. 
AII.5). 
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Table AII.2:  Comparison of bioreactor runs conducted in this work 
(A) Experimental conditions for bioreactor scale cultures in which HyQ medium was used 
  (B) LV yields from bioreactor cultures and comparison to corresponding small scale experiments 
A 
 
Culture 
Operation 
(mode, 
perfusion 
rate) 
Transfection 
at cell density of 
(c/mL), after 
cultivation time of 
(h) 
Growth rateI (µ(vcc), µ(perm); 
(batch, pre-transfection) (d-1) Medium, Remarks 
Run #1 batch - , - 0.67II +/- 0.18; 0.6 +/- 0.15 HyQ, no transfection; batch culture; 
see appendix III for process evolution 
Run  #3 perfusion, 1 VVD 4.4x10
6
, 96 0.73 +/- 0.07, 0.36 +/- 0.03;  
0.69 +/- 0.16, 0.42 +/- 0.16 
HyQ, process kinetics shown in 
chapter 3 (fig. 3.5) and 4 (fig. 4.2-4 B 
and 4.5 (1 VVD)) 
Run #4 perfusion, 2 VVD 4.7x10
6
, 96.5 
0.72 +/- 0.08, 0.34 +/- 0.05; 
0.83 +/- 0.16, 0.56 +/- 0.15 
HyQ, see chapter 4 (fig. 4.2-4 B and 
4.5 (2 VVD) for process kinetics 
Run  #5 perfusion, 2 VVD 8x10
6
, 120.5 
0.61 +/- 0.04, 0.55 +/- 0.09; 
0.74 +/- 0.08, 0.56+/- 0.08 
HyQ+ (medium composition included 
5 % (v/v) of supplement mixture), see 
chapter 5 for kinetics 
Refer to chapters 3 and appendix II.2 for the identification of production conditions 
I: average values in d-1; pre-transfection refers to phase of process after perfusion start and before transfection 
II: average value for exponential growth phase only (in batch culture) 
One bioreactor culture performed in starting conditions using medium composition LC-SFM L (run #2) is not shown in the table; refer to fig. AII.5, AIV.6, as 
well as chapter 3, fig. 3.4 for functional titer kinetics 
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B Functional titer (GTA) VP titer (ELISA) VG titer (PCR) 
Operating 
condition/ 
Parameter 
1 VVD, 
run #3 
2 VVD, 
run #4 
2 VVD, 
HyQ+, 
run #5 
1 VVD, 
run #3III 
2 VVD, 
run #4 
2 VVD, 
HyQ+, 
run #5 
1 VVD, 
run #3 
2 VVD, 
run #4 
2 VVD, 
HyQ+, 
run #5 
Maximum 
titer (LV/mL) 7.7x10
7
 3.0x107 3.1x107 2.2 x1010 2.85x109 n.a. 5.61x109 3.7x109 4.6x109 
Total yield 3.6x1011 4.25x1011 3x1011 1.4x1014 2.4x1013 n.a. 2.3x1013 5x1013 8x1013 
Spec prod 
(tu/cell) 30 33 14 11500 1900 n.a. 2000 3900 3600 
Relative to total 
expected yield 
(%) IV 
38.5 26.5 10.2 100.2 27.3 n.a. 93 121 n.a. 
III: ELISA results possibly overestimated but from same assay as values for run #3 
IV: based on total yields from small scale experiments 
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Figure AII.5: Functional (tu) and total particle (vg) yield from bioreactor scale LV production 
runs 
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Figure AII.6: Viable cell density, permittivity, cell diameter and growth rates during LV 
production in bioreactor scale perfusion cultures. Values for three independent cultures are shown 
(see runs #3-5 in table AII.2). None of the values (cell counts, growth rates, permittivity) were 
corrected for loss of cells when perfusion was started. 
(A) growth rate and vcc 
(B) growth rate (based on biovolume) 
(C) mean cell diameter  
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AII.3.2.2 Growth rates and evolution in cell diameter 
The observation that all bioreactor cultures gave lower functional yields than expected based on 
small-scale results suggested that there was a systematic reason behind this finding. In contrast to 
small-scale cultures, in which producer cells were concentrated in fresh medium before 
transfection, the cultures were in bioreactor conditions were grown in batch and perfusion mode 
(at the targeted LV harvest rate (1 or 2 VVD)) to the targeted cell density without discontinuous 
medium exchange (see chapter 2). It can thus be assumed that nutrient availability and byproduct 
concentrations differed at the time of transfection. The importance of the cell’s physiological 
state at the time of infection during viral vector production has been demonstrated by others 
(Henry, Dormond et al. 2004; Henry, Kamen et al. 2007). The same authors also reported 
increased metabolic rates during the viral vector production phase. 
We therefore analyzed growth and, as the continuous medium exchange allowed for a reliable 
calculation, the metabolic rates in the bioreactor cultures. The goal was to identify potential 
limitations in the current process and propose strategies for further improvement of bioreactor 
scale LV production. 
Similar values were found for the average growth rate calculated using offline cell counts (µ(vcc) 
or the online permittivity signal µ(perm) in perfusion mode (table AII.2). The apparent growth 
rates during perfusion were in all cases lower than during initial batch growth (table AII.2, fig. 
AII.6), which was partly due to a small loss of cells during the onset of perfusion. We also note 
that cell size was larger compared to batch cultures after perfusion was started and cell diameter 
thus remained rather constant during the perfusion phase (compare to batch culture in appendix 
III, fig. AIII.1 A). The cell size increase was also reflected in higher growth rates based on the 
permittivity signal (µ(perm)) compared to µ(vcc). 
During two of the three perfusion cultures (run #3 and #4), the growth rates (µ(vcc) and µ(perm) 
reached their maximum (of ~0.8 d-1 and 1 d-1, respectively) during batch growth (fig. AII.6). The 
situation was similar for (µ(perm) of run # 5 while the maximum in µ(vcc) was reached here after 
perfusion was started. (µ(perm) remained almost constant in the pre-transfection phase in all 
cultures (~0.5-0.6 d-1) while a local maximum was in all cases reached for µ(vcc)  after the 
perfusion start. At the time of transfection, µ(vcc) was in all cases at around 0.4-0.5 d-1, 
corresponding to the values found at the end of exponential growth phase in batch cultures (see 
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appendix III, fig. AIII.3). All cultures were, except run #5, transfected at the maximum in growth 
rate in perfusion mode (µ(vcc)). 
Although operated at different medium exchange rates, run #3 and 4 were showing very similar 
growth rate profiles. Nevertheless, differences in the cell size evolution were observed between 
the two cultures (fig. AII.6 C). In addition, more cells were lost in the harvest during the start of 
perfusion of run #4 resulting in a drop in growth rate from -60-50 hpt. Run # 5 was showing a 
very similar cell size evolution than run #4, with a cell diameter increase after perfusion start and 
subsequent constant values before transfection. The evolution of metabolic rates was then 
analyzed during the bioreactor cultures. Because of the observed differences in cell diameter, i.e. 
the increase in cell size when perfusion was started at 2 VVD, those rates were calculated based 
on the permittivity (qperm; refer to chapter 5 for qperm values in batch mode). 
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Figure AII.7: Metabolic rates for LV production in bioreactor cultures; arrows indicate the time 
of perfusion start for runs #3-5; dashed lines mark the time of transfection 
(A) glucose consumption rate 
(B) molar ratio lactate/glucose and lactate concentration 
 
During the batch growth phase, the glucose consumption rate was during all three cultures at 
~0.08- 0.1 mmol*cm/pF (corresponding to 0.2-0.3 µmol/106 cells*h) during all three cultures 
(fig. AII.7). Those values were similar to what was observed in batch cultures (see appendix III, 
table AIII.1). After the perfusion start, the specific glucose consumption rate (qperm (glc)) 
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increased by almost 2-fold at 2 VVD while similar values compared to batch growth were 
observed during run #3 (at 1 VVD). At the time of transfection, qperm (glc) had then decreased 
to ~0.07 mmol*cm/pF (runs # 4 and 5) while it was significantly lower at 1 VVD (0.03 
mmol*cm/pF). After transfection, a maximum was then reached at 16-30 hpt in all three cultures.  
At 1 VVD, the lactate concentration during the complete culture remained at low levels with a 
maximum at ~5 mM (fig. AII.7 B). Much higher concentration were reached at 2 VVD, with 
maxima at 15 (run #4) and ~20 mM (run #5). 
As the specific production rates of lactate were showing different kinetics than glucose 
consumption, the molar ratios of lactate and glucose Y(lac/glc) varied significantly during the 
three cultures. Maxima in the molar ratio were observed either before (runs # 3 and 5) or at 
around the time of transfection (run #4). For run #3 and 5, minima in the molar ratio were 
observed at around 48 hpt while run #4 was showing an almost constant value from 24- 72 hpt. 
Y(lac/glc) was in all cultures lower after transfection than in the growth phase, indicating a more 
efficient metabolism with less lactate production from glucose. Overall similar observations were 
made for all cultures for the metabolic rates and ratios of glutamine and ammonium (results not 
shown). 
In summary, the metabolic profile of run #3 suggests that perfusion was started after the 
beginning of the metabolic shift (compare chapter 5) because lactate production ceased before the 
perfusion start. This was confirmed by the decrease in cell diameter during batch growth that was 
indicating reduced metabolic activity in batch cultures (compare appendix III, fig. AIII.1). We 
also note that the response to the increased glucose concentration (due to the start of perfusion) 
was lower in that culture. On the other hand, perfusion start for run #4 and 5 took place before the 
metabolic shift with Y(lac/glc) at positive values of 0.6 and 0.2, respectively. In these two 
cultures, a significant response (increase in qperm(glc)) was observed after perfusion start. Yet, 
during run #4 and 5, lactate concentrations of 15-20 mM were reached. This means that in 
particular for the case of run #5, this concentration could have been inhibiting before transfection. 
Only in run #3, the metabolic rates were low compared to initial batch growth at the time of 
transfection. In the two subsequent cultures (run #4 and 5), the rates were similar to maximum 
values during batch growth. If the observations from batch cultures are directly applicable to 
these two cultivations in perfusion mode, online (fc) and offline monitoring (cell size) indicated 
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constant metabolic activity after the perfusion start as both values remained unchanged in the pre-
transfection phase (see chapter 5 for a further discussion on the relationship of these variables in 
HEK293 cell cultures).  
AII.4 Overall Summary, Discussion and Recommendations  
In small-scale experiments, maximum functional LV titers and total yields were found after 
increase of the cell density at transfection to 5-10x106 and 2 DMD with HyQ or HyQ+ medium. 
The cell suspension was concentrated by centrifugation and precultures were resuspended in 
fresh medium before transfection. After transfection, none of the analyzed nutrients (glucose, 
amino acids) was limiting in these conditions and byproduct concentrations (ammonium, lactate) 
were below inhibiting concentrations. A further increase in cell density did not result in higher 
LV yields. The reasons for the limitations of production beyond 1x107 c/mL remain unknown, 
with transfection efficiency or (unidentified) nutrient limitations or inhibitions as possible 
explanations.  
In bioreactor scale, cells were initially grown in batch mode and perfusion was used to reach the 
targeted cell density without discontinuous medium exchange or concentration. It was generally 
expected that continuous and controlled process conditions in perfusion would result in higher 
LV yields. The total functional yields from these experiments were, however, 2.5-10 fold lower 
than in the comparable small-scale conditions. In contrast to small-scale LV production, specific 
productivity decreased with ‘improvement’ in production conditions from run #3-5. This was 
suggestive for systematic metabolic limitations or inhibitions that occurred at high cell density.  
Comparing small-scale and bioreactor cultures, we noted first that specific growth rates were 
similar during batch growth in both cases (fig. AIII.3 and supplementary figure AIII.1/AIV.12). 
The concentrations of byproducts were significantly lower during small-scale LV production 
compared to the bioreactor cultures (continuous vs discontinuous medium exchange). Whereas 
no depletions of nutrients could be identified in small-scale, the continuous operation in 
bioreactors allowed the calculation of specific metabolic rates. Interestingly, a local maximum in 
glucose consumption rate was observed after transfection and at around the time of the first viral 
release, indicating increased metabolic acitivity of the culture at that time. As they were observed 
for qperm(glc), these changes were not related to increases in cell size but seemed to be rather 
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attributed to production of LV-related proteins. This should be further investigated to uncover the 
specific requirements of cells producing LVs.  
It was also assumed that the metabolic rates are indicative of the physiological state of the 
cultures at the time of transfection. Only for the production at 1 VVD (run #3), a significantly 
reduced metabolic activity was observed in comparison to batch cultures. In contrast, no 
significant decrease in metabolic activity was observed at increased medium exchange rates of 2 
VVD. It is thus hypothesized that the lower LV yields in bioreactor scale were due to a 
combination of byproduct inhibition (at 2 VVD) and a lower nutrient availability (at 1 VVD). 
A straightforward explanation for why lower titers were found in bioreactor scale remained 
nevertheless difficult. In other studies, extracellular accumulation of byproducts and factors that 
would down regulate the overall metabolic activity was put forward as limitation for cultivation 
at high cell densities (Carinhas et al.). It is consequently concluded that further optimization of 
LV production in bioreactor scale, based on the analysis of HEK293 metabolism, is required.  
To that end, our results can provide general recommendations for the development of high-yield 
HEK293 perfusion processes at high cell density in the current medium formulation 
(HyQ/HyQ+):  
1. a rational approach is needed to improve the understanding on the impact of physiological 
state of the cell line on LV yields after transfection; this should be ideally done employing 
a less complex system for which quantification methods with a lower intrinsic variability 
are available (e.g. production of GFP or secreted alkaline phosphatase (SEAP) only) 
2. in the present work, small-scale conditions (including the concentration of cells before 
transfection) were set to ease the practical execution of experiments and increase 
experimental throughput; however, the resulting differences in production strategy, i.e. 
concentration in small-scale and continuous cultivation of cells in bioreactor perfusion 
made a direct translation of production conditions (at constant productivity) difficult  
3. the perfusion start at a high medium exchange rate of 1 or 2 VVD is possibly non-optimal 
and leads to high byproduct concentrations; lower medium exchange rates should be 
tested in small-scale or (see 4.) 
4. a reduction in glucose concentration in the feed could be tested to avoid high glucose 
concentrations and high lactate production before transfection 
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5. the findings from chapter 5 concerning the online monitoring of the metabolic activity 
could be helpful during the development of improved process strategies 
 
Beyond the observations concerning the physiological state of the cultures, further work is 
needed to establish robust transient transfection protocols for production at high cell density and 
in bioreactor scale. Several independent experiments (n>10) resulted in consistently high LV 
titers and total yields. Using improved production conditions, a maximum functional titer of 
>1x108 tu/mL with total yields of 0.5-2x1010 tu was found in all experiments. Yet, it could not be 
excluded that transfection efficiency at high cell density was a constraint when cell densities were 
higher than 1x107 c/mL in small-scale. In addition, the number of cultures was limited in 
bioreactor scale and inter-experimental variations in the transfection process might have 
contributed to yield differences from the different cultures. It is generally possible that 
transfection in bioreactors and at cell densities beyond 1x107 c/mL is consistently less efficient 
than in small-scale or routine conditions. On the other hand, we exclude events associated to the 
distribution of polyplexes in the reactor or inactivation of virus by bioreactor-specific cultivation 
conditions (such as the acoustic filter or agitation), as shake flask controls, which were taken 
from the bioreactor before/after transfection and transfected outside/inside the reactor with the 
identical polyplex mix, resulted in similar LV titers than the respective mother culture (data not 
shown). For a further rational optimization of high-cell density transfection, several challenges 
will need to be addressed: 
1. whereas the preparation in small-scale appears to be highly reproducible, mixing of large 
volumes for bioreactor cultures (in particular when larger scales than studied here are 
targeted) needs to be evaluated for its consistency; ideally, this would include the use of 
well-defined conditions in a stirred external unit (in contrast to formation of polyplexes 
by manual shaking as performed here) 
2. the optimum concentrations at which polyplexes are formed needs to be evaluated; this is 
of particular importance for cultures that are transfected at cell densities beyond 1x107 
c/mL 
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3. the identification of a suitable method for evaluation of polyplex quality would thus be of 
great value (for 1. and 2.); one of the most promising parameters to evaluate and which 
should be also easily accessible is polyplex size (Guillem et al. 2004) 
4. transfection of high cell density cultures according to the ‘direct method’ (direct addition 
of DNA followed by PEI without a priori polyplex formation) would circumvent several 
of these challenges and should consequently be evaluated 
AII.4 Final Remarks and Conclusion  
It is concluded that the developed process for LV production is readily scalable (see chapters 1 
and 3 for a further discussion on the subject). For a further improvement in process yields, 
optimization of bioreactor production is, however, needed. This should comprise further analysis 
of the HEK293 cell metabolism in HyQ medium and optimization of high cell density 
transfection. 
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APPENDIX III: Practical Applications of Online Permittivity Signals: 
Characterization of HEK293 Batch Growth and Identification of Metabolic 
Shifts 
This chapter presents the characterization of HEK293 growth in batch cultures and introduces 
permittivity measurements as an online monitoring tool. It is presented as a draft manuscript for 
submission as a short communication in a peer reviewed scientific journal.  
Following FDA’s Process Analytical Technology (PAT) initiative, real-time monitoring tools 
gained considerable momentum within the biotech community in recent years (Read, Park et al. 
2010). Evidently, identification and evaluation of suitable PAT tools are the first step towards a 
successful application of this strategy which pursues the goal to develop well-defined and 
controlled processes that deliver products of predefined quality. Ideal PAT tools provide 
macroscopic data at-line, i.e. in the case of bioprocessing use in situ online probes. 
Within this section, the growth of the producer cell line HEK293SF (clone 3F6) is characterized 
in preliminary batch experiments using online permittivity measurements. This cell line is used 
with the goal to produce LVs by transient transfection throughout the entire work related to this 
thesis. As the HyQ medium formulation allowed attaining high LV yields, this composition was 
chosen to characterize bioreactor batch cultivations employing the same methods later used to 
analyze the cultures during LV production. We first point out the practical value of permittivity 
measurements in batch cultivations and conclude that the technology provides information on the 
biovolume content and, at the same time, the physiological state of the HEK 293 cell cultures.  
In this context, the experiments presented here had the following specific objectives: 
In contrast to LVs, most of the viral vectors, vaccines and proteins produced in HEK293 have a 
sufficient stability to favour production in batch or fed-batch mode. Fed batch mode has been 
reported to dramatically increase yields after transient transfection (Sun, Goh et al. 2006). 
Feeding strategies for the HEK293 system thus need to be developed to reach higher cell 
densities and improve volumetric productivity. As a starting point for rational process and 
feeding strategy optimization in future work, a detailed characterization of the producer cell 
metabolism is hence needed. Recent literature reports demonstrate that the permittivity signal is a 
tool that can be used beyond the simple estimation of biomass as it also reflects the physiological 
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state of cell cultures (Ansorge, Esteban et al., 2010 a and b). As an online tool indicating the 
cellular state in real-time would largely facilitate the development of feeding strategies, it was 
explored if growth and metabolic rates are reflected in the online permittivity signal. More 
specifically, we assessed if there is a link between cellular metabolism and the online permittivity 
parameters.  
In addition, the offline measurement method for the analysis of the permittivity signal needed to 
be validated. The goal was to use this method for comparison and analysis of the permittivity 
signal during LV production to monitor viral production kinetics (chapter 5). 
Finally, for the establishment of an efficient process for LV production in perfusion mode, it was 
fundamental to characterize growth and metabolic behaviour of the producer cell line in batch 
cultures. As perfusion is in this work primarily used to harvest LV, the main parameter that 
needed to be determined was the cell density at which perfusion needs to be started to ensure 
exponential growth until the time of transfection.  
The bioreactor batch cultivation presented in this chapter corresponds to run #1 in appendix II. 
It needs to be noted that this part of the appendix contains only a shortened section on the 
background on permittivity measurements to avoid repetition with chapters 2 and 5. A final 
version of this draft manuscript will contain a short paragraph on the theory behind permittivity 
measurements (similar to section 5.2.3.5). 
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CHARACTERIZATION OF HEK293 BATCH GROWTH AND IDENTIFICATION OF 
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Montréal, Québec H3C 3A7, Canada 
 
AIII.1 Abstract 
Permittivity measurements are becoming a routine tool for cell culture process monitoring. Their 
advanced use for process control is, however, still limited by a lack of understanding of the 
complex information reflected in the permittivity-related parameters. Permittivity measurements 
monitor the evolution of biovolume content in real-time and can in parallel also reflect the 
metabolic activity of mammalian cells. 
To identify how permittivity measurements could be practically used, the technology was 
evaluated for the characterization of HEK293 in bioreactor batch cultivations. The analysis of 
batch growth gave insights on what information can be obtained from the permittivity signals. 
The dual-frequency permittivity signal and the dielectric increment correlated well with the 
offline measured biovolume (from offline cell counts and cell diameter measurements). In 
addition, the characteristic frequency was correlated with the decrease in metabolic activity and 
its online signal could be used for the early identification of a metabolic shift at the end of 
exponential growth. The technology should thus be considered as a monitoring tool to support the 
design and implementation of improved feeding strategies. 
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AIII.2 Introduction 
Routine cell culture experiments and production runs include sampling from the bioreactor once a 
day only. Parameters that are then commonly measured offline comprise cell density, viability 
and metabolite concentrations. This significantly prolongs the response time to process variations 
and events. Process-related actions, such as feed additions, are therefore mostly scheduled in a 
strictly time-based manner. This also holds for most industrial fed-batch cultivations and can be 
also explained by the fact that current real-time sensor technology does not allow uncovering the 
intracellular state of cell cultures (Henry et al. 2007b). Rational, i.e. process/event-based control 
strategies are thus challenging. Online monitoring offers a virtually unlimited sample number and 
provides a continuous signal that reflects the status of the bioprocess. This holds great advantages 
compared to classical offline sampling. It can be assumed that an approach based on the 
continuous signal from one or, ideally, several combined online monitoring measurements on 
when to perform an action critical for the production will result in a more robust and reproducible 
process. Efficient monitoring techniques have therefore been described as instrumental for the 
rapid development and optimization of bioprocesses (Kamen et al. 2004; Lecina et al. 2006; 
Henry et al. 2007b). In that context, in particular the direct online monitoring of the biomass 
content and the metabolic activity would allow for early fault detection of cultures and improved 
process control strategies.  
In part due to the renewed interest in process analytical technology (PAT), online in situ 
permittivity measurements are on the way to become a routine tool to monitor cell culture 
processes. The technology holds particular promise for the monitoring and characterization of 
viral vector production (Zeiser et al. 1999; Zeiser et al. 2000; Negrete et al. 2007). It has also 
been reported that permittivity measurements indicate the metabolic activity of mammalian cells, 
in particular when physiological changes occur during the cultivation (Noll et al. 1998; 
Cannizzaro et al. 2003; Ansorge et al. 2010a). An advanced exploitation of the signal, beyond a 
basic descriptive monitoring of cultures is, however, still limited by a lack of understanding of 
the complex information reflected in the permittivity-related parameters. This can, in part, be 
explained by the difficulty of the assessment of the cellular dielectric properties by routine cell 
culture methods.  
   
 
231 
To that end, the significance of permittivity measurements was evaluated as a monitoring tool in 
batch cultures of HEK293 cells to identify the practical value of the technology beyond simple 
biomass estimation. The suspension-grown HEK 293 cell line, in combination with HyQ 
medium, has already demonstrated promising potential for the high-yield production of 
recombinant proteins and viral vectors by transient transfection (Durocher et al. 2007; Tom et al. 
2007; Ansorge et al. 2009). Other viral vectors and viruses, such as AdV and influenza, can also 
be efficiently generated using this platform (unpublished results from our group, (Le Ru et al. 
2010). The transfer to further systems and subsequent process optimization to further increase 
yields is therefore required. Real-time monitoring tools indicating metabolic activity online 
would facilitate process development (e.g. feeding strategies). It was thus of particular interest to 
investigate if changes in cellular metabolism are reflected in the online permittivity parameters.  
AIII.3 Materials and Methods 
AIII.3.1 Cell Culture 
HEK293SF-3F6 cells were grown in suspension in HyQSFM4TransFx293 medium (HyQ) 
(Hyclone, Logan, UT). Subcultures were passaged every 2-3 days to keep the cells in their 
exponential growth phase. Hemacytometer counts using erythrosine B dye exclusion were used 
to assess cellular density (viable, total cell count per mL (vcc, tcc)) and viability.  
AIII.3.2 Cell Culture Sample Analysis 
The volume weighted arithmetic mean cell diameter (d) was determined using a Z2™ Coulter 
Counter® (Beckman Coulter, Mississauga, ON) with an aperture diameter of 100 µm, followed 
by analysis of the size distributions with the Accucomp® software package (Beckman Coulter). 
The upper and lower analysis limits were 7.31 and 23.8 µm, respectively. To calculate d, the 
distributions were plotted as volume (%) against cell diameter (µm) and only the part of the 
distribution corresponding to viable cells was considered for the calculation. 
Each value of d represents the average of at least two distributions. Using d and the viable cell 
count per mL (vcc), the biovolume (bv) was calculated using equation AIII.1, assuming that the 
distributions were evenly scattered: 
vcc
dbv ××





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3
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4
   (AIII.1) 
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bv was then considered as an estimate of the volume fraction of cells P (equation 5.2 in section 
5.3.5). 
AIII.3.3 Bioreactor Setup 
The bioreactor setup was identical to the one previously described (Ansorge et al. 2009). In brief, 
cultures were performed in in a controlled 3.5 L Chemap CF-3000 bioreactor (Mannedorf, 
Switzerland). Agitation rate was set to 85 rpm, pH was controlled in the range of 7.1-7.2 by 
addition of CO2 via the surface or sodium bicarbonate addition. The vessel (working volume 2.7 
L) was equipped with probes to measure and control pH, DO, temperature. Permittivity was 
acquired with a Biomass 400 system (Fogale nanotech, Nîmes, France). The DO was controlled 
at 40 % of air saturation by sparging pure oxygen in pulse mode. 
AIII.3.4 Permittivity Measurements 
In this study, a Biomass 400 system (Fogale nanotech, Nîmes, France) was employed for the 
measurement of permittivity across the β-dispersion frequency spectrum of ~0.1-10 MHz. The 
system measures the dual-frequency permittivity signal ∆εFC at 1 and 10 MHz and additionally 
provides the β-dispersion parameters (∆εmax, fc, α) in real-time after fitting the frequency spectra.  
AIII.3.5 Calculation of Growth and Metabolic Rates 
Growth and metabolic rates were calculated using standard equations (Henry et al. 2004) after 
filtering of the raw data (online and offline measurements). Offline raw data were fitted using the 
smoothing spline regression function of the kyplot software. Online data were treated with 
Matlab (The MathWorks, Natick, MA). The calculation or specific rates was based either on the 
viable cell count (vcc) or the online dual-frequency permittivity signal (∆εFC). 
AIII.4 Results and Discussion 
AIII.4.1 Characterization of HEK293 Batch Growth 
When HEK293 were grown in bioreactor batch cultures, the exponential growth phase started 
after a short lag phase, lasting for ~90 h until a viable cell count (vcc) of ~ 2.5-3x106 c/mL was 
reached (fig AIII.1 A; see also table AIII.1). Cell growth continued subsequently at a reduced rate 
and a slightly lower viability over a period of 125 h until death phase started and viability 
decreased rapidly. The maximum vcc was reached at 1.3x107 c/mL after 215 h of culture. The 
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cell diameter (d) remained almost constant during exponential growth and then decreased 
significantly from 16.5 to 13.5/14.0 µm during the post-exponential growth and death phase.  
The concentrations of metabolites and byproducts (glutamine, glucose, lactate, ammonium) for 
this batch cultivation are shown in figure AIII.1 A. Glucose and glutamine concentrations 
decreased during exponential growth phase, until a slope change in their consumption was 
observed at residual concentrations of 22 mM and 1.5 mM (glucose and glutamine, respectively). 
Both metabolites were then further consumed until glucose was depleted at ~220 h whereas the 
concentration of glutamine stabilized at ~0.6 mM. The concentrations of the byproducts lactate 
and ammonium increased until around 100 h after incubation. Subsequently, the concentration of 
ammonium decreased from 1.6-1 mM before it slightly increased towards the end of the 
cultivation. Lactate concentration levelled/reached a plateau for 2-3 days (95-160 h) at 18 mM 
after the end of the exponential growth phase, further increased up to 26 mM and finally 
decreased during the last two days of the cultivation.  
Overall, similar observations were made in control shake flask cultures which were directly 
drawn from the bioreactor culture (representative culture shown in supplementary figure 
AIII.1/Figure AIV.12). 
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Figure AIII.1: Batch cultivation of HEK293 cells in 3L bioreactor scale 
(A) viable cell count (vcc), total cell count (tcc), cell diameter, viability 
(B) metabolite and byproduct concentrations 
AIII.4.2 Biovolume Measurements Are Reliable Indicators of Online Permittivity 
Measurements 
It was subsequently investigated if offline measurement of the biovolume (from vcc and d) were 
correlating with the online permittivity signal during batch cultures. The biovolume (bv) includes 
variations in cell density and cell diameter, providing a value which can be correlated to either 
the dual-frequency permittivity (∆εFC) or, if multiplied by cell radius with the permittivity 
increment (∆εmax). In this batch cultivation, the permittivity signal (∆εFC and ∆εmax) followed the 
biovolume well, resulting in a high regression coefficient, in particular for the values of the 
exponential growth phase and when viability was high (figure AIII.2, table AIII.1). Yet, the slope 
and the regression coefficient decreased with increasing culture time. Samples from late stages of 
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the process showed comparatively smaller permittivity values. This observation was attributed to 
changing dielectric properties of the remaining viable cells with decreasing viability (Ansorge et 
al. 2010c). It seems to be a general finding that the accuracy of permittivity measurements in 
predicting vcc is lower when viability decreases (Opel et al. 2010). Nevertheless, all samples at 
high viability fell on the same trend line being thus independent of variations in nutrient and 
byproduct concentrations and cell diameter. 
 
Figure AIII.2: Correlation of biovolume and permittivity in HEK293 bioreactor batch culture; 
note that the values for ∆εmax are not shown in the figure (refer to table 5.1 for regression 
parameters); thick line: regression for exponential growth; dashed line: regression for high 
viability only; dotted line: regression for all samples 
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Table AIII.1: Correlation of permittivity signal (∆εFC)/dielectric increment (∆εmax) and 
biovolume(bv)/bv*r 
 ∆εFC vs bv,  
             (Y)     (X) 
∆εmax vs bv*r 
(Y)        (X) 
culture phase/ 
regression 
parameter 
R2 slope (pF/cm/µl/ml) R
2
 
slope 
(pF/cm/um*µl/ml) 
exponential 
growth  0.99 0.76 0.99 1.60 
high viability 0.98 0.71 0.97 1.68 
complete 
culture 0.96 0.68 0.94 1.54 
In all cases, the regression was calculated with the constraint that the trend line had to pass 
through the origin 
 
The strong correlation of offline biovolume measurements (from hemacytometer cell counts 
mean cell diameter) and online values (∆εmax, ∆εFC) validated the approach for the analysis of 
online permittivity data. This is consistent with findings by others according to which the 
biovolume measured by the electrical sensing zone method (Coulter principle) follows, in 
comparison with other methods, the evolution of permittivity measurements best. This seems to 
be a finding which holds for several cell types, in particular for the exponential growth phase 
(Zeiser et al. 1999; Zeiser et al. 2000; Ansorge et al. 2007b; Ansorge et al. 2010a). 
 
AIII.4.2 Monitoring of the Characteristic Frequency Allows Identification of Metabolic Shifts 
AIII.4.2.1 Metabolic Shift Identification at the End of Exponential Growth  
The end of the exponential growth phase at ~90 h was identified after computing the growth rate 
from the offline cell counts (fig. AIII.3 A). The decrease in growth rate from 0.6 d-1 to 0.29 d-1 
was consistent with results obtained from online monitoring. No rapid changes were observed in 
the permittivity signal (∆εFC) (fig. AIII.3 B). The value increased until the beginning of death 
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phase, reaching a maximum at around 220 h. At around 90h, ∆εFC continued to increase at a 
reduced slope.  
Two approaches were then used to calculate the specific growth rates: either the calculation was 
done specific to the viable cell count (µ(vcc)) (fig. AIII.3 A) or, alternatively, to obtain a value 
which includes possible variations in cell size, specific to the online dual-frequency permittivity 
signal (∆εFC) that represents the biovolume (µ(perm)). Both approaches resulted in similar 
growth rate values and trends. As expected due to the decrease in cell diameter (fig. AIII.1 A), 
µ(perm) decreased faster towards the end of the exponential growth and was additionally 
showing a lower value of 0.18 d-1 compared to µ(vcc) (0.29 d-1) during the post-exponential 
growth phase (fig. AIII.3 A and B, table AIII.1).  
Accordingly, similar observations were made for the specific lactate and glucose 
production/consumption rates calculated using either vcc (q(lac); q(glc)) or permittivity (∆εFC) 
(qperm(glc); qperm). These values showed a similar decrease than the growth rates from 50 h 
until the beginning of death phase (see table 5.1 for average values), resulting in a strong linear 
correlation (R2>0.95; regressions not shown). The consumption/production rates for 
glutamine/ammonium (NH3) showed an almost constant decrease during exponential growth, 
followed by values close to zero in later stages of the cultivation .  
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Figure AIII.3: Growth for batch cultivation of HEK 293 cells. Arrows indicate end of exponential growth and beginning of death 
phase, respectively 
(A): growth rate calculated based on vcc; offline bv values (circles) shown for comparison 
(B): calculation of growth rate from the online permittivity signal ∆εFC 
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Table AIII.2: Growth and metabolic rates for HEK293 batch culture; average values for each 
culture phase are shown 
 
parameter exponential growth 
post-
exponential 
growth 
death phase 
time (h) 0-90 90-215 215-285 
µ(vcc) (d-1) 0.67 +/- 0.18 0.29 +/- 0.07 -0.064 +/- 0.018; 
µ (perm) (d-1) 
0.6 +/- 0.15 
 
0.18 +/- 0.04 
 
-0.04 +/- 0.04 
qglc (µmol/106* h); 
qperm(glc) 
(µmol*cm/pF*h) 
0.15 +/- 0.05; 
0.07 +/- 0.03 
0.02 +/- 0.005; 
0.02 +/- 0.005 
0.003 +/- 0.001; 
0.004 +/- 0.004 
qlac (µmol/106* h); 
qperm 
(µmol*cm/pF*h) 
0.22 +/- 0.10; 
0.12 +/- 0.05 
0.007 +/- 0.01; 
0.007 +/- 0.009 
0.01 +/- 0.01; 
-0.01 +/- 0.01 
qgln (µmol/106* h); 
qperm(gln) 
(µmol*cm/pF*h) 
0.02 +/- 0.013; 
0.010 +/- 0.06 
0.001 +/- 0.0013; 
0.001 +/- 0.001 0; 0 
qNH3; qperm(NH3) 
(µmol*cm/pF*h) 
0.02 +/ - 0.02; 
0.01 +/- 0.01 
-0.001 +/- 
0.001; -0.001 
+/- 0.001 
0; 0 
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Figure AIII.4: Evolution of the molar ratios for lactate/glucose and NH3/glutamine 
 
Significant changes in the lactate/glucose and ammonium/glutamine molar ratios confirmed a 
metabolic shift starting at around 90 h or when 12 mM/1.5 mM of glucose or glutamine were 
consumed and 15 mM/1.2 mM of lactate and ammonium were produced, respectively (fig. 
AIII.4). This change in cellular metabolism was most clearly observable for the values of the 
lactate/glucose molar ratio which gave negative values from 100-170 h.  
The end of exponential growth was thus in this culture marked by a metabolic shift, when the 
consumption of glucose and glutamine decreased while lactate and ammonium production ceased 
for several days (table AIII.1, fig AIII.1). The change in metabolism was linked to the significant 
drop in growth rate from 50-90 h. The specific metabolite consumption and production rates, in 
particular of glucose and lactate were indicative for the reduced metabolic activity and were 
strongly correlating with growth rate until the beginning of the death phase. The depletion of 
glucose finally resulted in the beginning of death phase after 215-220 h of cultivation. It is also 
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noted that the byproduct concentrations of lactate and ammonium at the time of the metabolic 
shift were below or at the lower end of the concentrations that are reported to be limiting for 
HEK 293 cultures (>20 mM for lactate and 1-2.5 mM for ammonium (Hassell et al. 1991; 
Nadeau et al. 1996). It is therefore likely that other, unidentified medium components or 
byproducts were limiting or inhibiting at the end of the exponential growth phase. 
AIII.4.2.2 Changes in Characteristic Frequency (fc) as Indicator for Metabolic Activity  
Online permittivity measurements provide primarily a measure of the biovolume (∆εFC). 
Multifrequency permittivity measurements give additional real-time information on the state of 
the cell suspension via the β-dispersion parameter fc. In most cases, fc is used as an indicator for 
cell size changes, assuming that both the intracellular conductivity (σi) and cell membrane 
capacitance (CM) remain constant during the cultivation. For most mammalian cell culture 
experiments, fC can be defined by a simplified form of equation 5.3 (Schwan 1957; Harris et al. 
1987; Patel et al. 2008a; Patel et al. 2008b; Ansorge et al. 2010a): 
i
M
C
σ
Crpi
f 12
1
××××
=
       (AIII.1) 
fc is therefore a function of cell radius, membrane capacitance and intracellular conductivity.  
During the present cultivation, d and fc did, however, not correlate following one single linear 
relationship (fig. AIII.5). In contrast, smaller cell diameters seemed to correlate with the drop in 
fc during the first part of the cultivation. This correlation was thus contradictory to the theoretical 
relationship according to which fc increases with decreasing diameter if it is assumed that CM and 
σi remain constant (eq. AIII.1). In general, we noted a decrease in cell diameter with increasing 
culture time. This decrease corresponded to a reduction in cellular volume of up to 30 % and 
started towards the end of the exponential growth phase. Reduction of cell size for the same and 
other cell lines during batch cultures has been reported in other studies (Ramirez et al. 1990; 
Ansorge et al. 2007a; Ansorge et al. 2010a). Several studies describe cell size to be one of the 
parameters reflecting the physiological state of a culture (Fantes et al. 1977; Frame et al. 1990 ; 
Stocker et al. 2000) (Lloyd et al. 2000; Berdichevsky et al. 2008). For example, multifrequency 
permittivity measurements in CHO cell perfusion cultures revealed that large cells disappeared 
once nutrient availability decreased (the feed was stopped), causing changes in the permittivity at 
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low frequencies (Cannizzaro et al. 2003). The cell diameter during batch cultures of HEK293 
cells might therefore be considered as an indicator of cellular metabolic activity. 
 
Figure AIII.5: Characteristic frequency (fc) and cell diameter correlated following two distinct 
linear correlations.  
Regression coefficients were high in both cases with R2 = 0.91 during the entire growth phase 
(<120 h) and R2 = 0.95 during post-exponential growth phase (150-215 h)  
 
Concerning the relationship of characteristic frequency and cell diameter, only the values for d 
and fc during the post-exponential growth, i.e. from 150-215 h, were consistent with the 
theoretical relationship (fig. AIII.5). For the regression, values from death phase (>215 h) were 
not included because of the decreased viability during that phase (see AIII.1 A). Taken together, 
these observations suggested that the mean cell diameter was not the only variable that changed 
during the exponential growth phase.  
A recent literature report could link the occurrence of a metabolic shift in CHO cell batch 
cultures, as a result of the depletion in glutamine, with a dramatic decrease in characteristic 
frequency (fc) which was caused by a drop in intracellular conductivity (σi) (Ansorge et al. 
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2010a). σi was thus described to be linked to the physiological state and the nutrient availability 
of the cell suspension. These findings were also confirmed in fed-batch cultivations of the same 
and a second CHO cell line during which responses to discontinuous feed additions in OUR and 
fc were monitored (Ansorge et al. 2010b). The authors did, however, not directly correlate the 
changes in fc with a specific metabolic parameter.  
The evolution of fc was further analyzed in the present cultivation. During the exponential growth 
phase, the value of fc decreased starting at around 50 h, reaching a minimum at ~115 h and 
increased thereafter until the end of the culture. (see fig AIII.6 A). In comparison, the growth, 
metabolic rates and fc showed a similar decline from 50-100 h, the values (fig. AIII.6 A), 
correlating with high regression coefficients (R2 >0.95; regressions not shown). Even when the 
changes in cell diameter towards the end of the exponential growth rate were taken into account 
(see equation AIII.2 in the figure legend and fig. AIII.6 B), fc correlated with the metabolic rates 
(lactate and glucose) with a high regression coefficient (R2>0.95) until 90 h. During the post-
exponential growth and death phase, the values for the metabolic rates were almost constant at 
very low levels (see table AIII.1). For that time, a good correlation of cell diameter (1/d) and fc 
was observed (see fig. AIII.5). 
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Figure AIII.6: During the exponential growth phase, the characteristic frequency correlates with 
the metabolite consumption and production rates. 
(A): metabolic rates (qglc and qlac) and characteristic frequency show similar evolutions until the 
end of exponential growth phase 
(B) Correlation of fc*r and the inverse of glucose consumption and lactate production show that 
fc is an indicator of the metabolic activity, most likely because of changes in intracellular 
conductivity (σi). Data were plotted according to equation AIII.1 which can also be written: 
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 (equation AIII.2) and assuming that CM remained constant during 
exponential growth. Regression coefficients were as follows:  
1/qlac: R2 = 0.94; 1/glc: R2 = 0.92 
 
The characteristic frequency, which can be directly acquired in real-time, is thus a parameter 
providing information on the metabolic activity of the cell suspension. If it is assumed that the 
membrane capacitance (CM) was constant during the exponential growth phase, changes in 
intracellular conductivity (σi) must have been responsible for this correlation. This confirms that 
previous findings for CHO cells (Ansorge et al. 2010a; Ansorge et al. 2010b) are transferable to 
other cell types. Whereas depletion in glutamine resulted in that case in a levelling of the 
biovolume and a decrease in permittivity (∆εFC), the situation for the batch cultivation of 
HEK293 cells was in the present study less dramatic, i.e. metabolic rates decreased but cell 
growth and biovolume increase continued, although at reduced rates. Therefore, it cannot be 
excluded that CM also changed, although its value was in several reports found to be mainly 
affected during processes involving trafficking through the membrane or other dramatic 
morphological changes of the cell membrane (Archer et al. 1999; Patel et al. 2008a; Patel et al. 
2008b; Zimmermann et al. 2008). In addition, Ansorge et al. (2010) refuted earlier assumptions 
according to which CM varies with changes in metabolic rates (Noll et al. 1998). Instead, 
variations in intracellular conductivity were put forward as reason for the correlation of fc, 
permittivity and nutrient availability. To date, a direct demonstration for why the intracellular 
conductivity varies with nutrient availability has however not been reported, mainly because this 
parameter is not accessible with routine cell culture methods. 
AIII.4 Summary and Conclusion 
The HEK293 cell line which was studied here grows to high cell densities of up to 1x107 c/mL in 
batch mode. Exponential growth lasts, however, only up to a cell density of 2.5-3 x106 c/mL 
when a metabolic shift occurs, accompanied by, as the most characteristic change, a cease in 
lactate production. The specific metabolic rates of glucose and lactate were indicative for the 
reduced metabolic activity. Online measurement of the permittivity (∆εFC and ∆εmax) allowed 
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monitoring of cell growth in real-time, calculation of the growth rate based on the online values 
and thereby identification of the exponential growth phase. Offline biovolume measurements 
were evaluated during the bioreactor batch culture and identified as a suitable tool to follow the 
evolution of the permittivity signal. In combination with the values for cell size, this information 
enables the analysis of permittivity variations in detail. In contrast to routine offline analyses of 
culture samples, online in situ permittivity measurements offer the advantage to monitor the 
evolution of the biovolume in real-time with a quasi-continuous signal. Growth rate (based on the 
biovolume) is then directly accessible from this online signal. However, the use of this ‘online 
growth rate’ (as derivate of ∆εmax or ∆εFC) for process control (e.g. feed additions) would face the 
challenge that its value is likely to be highly affected by noise on the online signal. In addition, 
the dual-frequency signal can also be affected by changes in the dielectric properties (CM and σi) 
of the cells.  
The β-dispersion parameter characteristic frequency fc, on the other hand, also provides 
information related to the metabolic activity and correlated with metabolic consumption and 
byproduct production rates during the exponential growth phase. These findings will need to be 
validated in other systems. In contrast to metabolite analysis, fc is available in real-time. The 
virtually unlimited ‘sample’ number of permittivity measurements consequently results in a 
higher degree of confidence concerning the state of the culture. Yet, as the permittivity signals 
provide complex information and several parameters may affect the dielectric properties of a cell 
suspension, the use of the technology should be supported by offline cell size measurements. This 
is required for a first characterization of the system, to uncover the mechanisms behind the signal 
variations and an in-depth analysis of the signal if various operating conditions are investigated. 
Cell size measurements are the most useful parameter to determine offline as they allow 
calculating the biovolume and the analysis based on dielectric theory (see equations 5.1-3). In 
addition, cell size seems to be indicative of the metabolic activity and belongs to the set of the 
parameters that define the physiological state of a culture. Nevertheless, cell size appears to be a 
parameter that is often overlooked when analyzing cell culture processes with literature on the 
subject being scarce.  
It is concluded that our observations might be of value for the development of fed-batch 
strategies or for transfer time determination in production seed trains.  
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APPENDIX IV: Complementary Experiments, Supporting Information and 
Experimental Observations 
ADDITIONAL DATA FOR CHAPTER 2 
 
Figure AIV.1: Sodium butyrate does not compromise results from GTA assays. LVs were 
produced without butyrate addition using HyQ medium. Before titration, the LV containing 
supernatants were subjected to 5 mM of sodium butyrate and incubated for 15 min at 37°C  
 
 
Figure AIV.2 : The number of functional LV is low (< 3% of LV titer before harvest) 
immediately after resuspension of the cell pellet during small-scale experiments. LVs were 
produced using improved production conditions, comparison was done 2 dpt. These data were 
submitted as supporting information to Ansorge et al. (2009) 
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ADDITIONAL DATA FOR CHAPTER 3 
 
Figure AIV.3 : Control titrations in the presence of 100 µM AZT result in significantly reduced 
functional LV titers. LV was produced using improved production conditions at 1 DMD 
ADDITIONAL DATA FOR CHAPTER 4 
Alternative LV Quantification Methods 
This section briefly summarizes additional alternative methods that were evaluated for LV 
quantification/titer estimation within this work.  
LV Quantification by HPLC 
Current protocols for the quantification of lentiviral vectors (GTA, RT-PCR, ELISA) are time-
consuming (Sastry et al. 2002) (chapter 2, table 2.2). These methods are thus not suitable for a 
rapid at-line monitoring of LV titers. In addition, none of the previously described methods is 
based on the direct quantification of physically intact lentiviral particles. In contrast, anion-
exchanged high-performance liquid chromatography (HPLC) can specifically and efficiently 
resolve viral particles from other contaminants. The LV-containing fraction can then be precisely 
quantified. The method has been proven to have large potential for the quantification of retroviral 
total particle numbers (Transfiguracion et al. 2004). The detection limit of the method can be 
increased by the use of fluorescent dyes such as SYBR Green I to label the viral genomic DNA 
or RNA. The feasibility of this approach has been demonstrated for the most commonly used 
viral vectors (Transfiguracion et al. 2005). An adaptation of this method to the LV system has 
been successful. Detection of the intact LV particles takes place after labeling the viral RNA 
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genome with SYBR Green I followed by HPLC separation from sample contaminants. A full 
description of the developed method would go well beyond this scope of this work and a 
publication concerning this subject is ongoing work in our group (Transfiguracion, 2010, 
manuscript in preparation). 
Preliminary HPLC quantification results were made available (fig AIV.4). Analysis of bioreactor 
supernatants from run #3 at 1 VVD  resulted in almost constant concentrations in the range of 
1x1010-1x1011 total viral particles (tp/mL) from 2-5 dpt (see table AII.2 for summary of 
bioreactor runs). Viral release could also be observed 1 dpt. However, before this method can be 
routinely used for LV quantification, further optimization of the method is required (ongoing 
work and unpublished results). 
 
Figure AIV.4 :  Comparison of LV quantification methods for a bioreactor perfusion culture at 1 
VVD (run #3) 
Data obtained so far are promising but challenges such as a high detection limit and specificity to 
LV related particles need to be overcome (see table AIV.1). 
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Table AIV.1: Novel LV quantification method based on HPLC 
LV Quantification Assay/ 
assay parameter HPLC 
method in-house, Transfiguracion et al manuscript in preparation 
Assay standard in-house, 50x concentrated, semi-purified LV preparation 
Inter-assay-variabilityI <2 % 
Intra-assay variabilityII <10 %VI 
Time to result/throughput 
per dayIII 1-3 h, ~50 
Labor intensityIV ++/+++VII 
FlexibilityV ++ 
Detection limit (DL) 5x108 tp/mL 
Remarks method still under development 
VI: variability if a large number of samples is analyzed and labelling time is increased up to 24 h 
VII: depending on sample pre-treatment 
Refer to table 2.2 for further explanations and remarks I-V 
Measurement of Total GFP Expression in Producer Cells During LV Production 
During the production of VSV-G pseudotyped LVs, a high level of transgene expression in 
producer cells is typically observed (Farson et al. 2001; Bagnis et al. 2009). It was thus assessed 
if the total GFP expression at 3 and 4 dpt would indicate the amount of functional LV particles. 
In small scale experiments, a linear trend between LV titer and GFP expression was found, 
although the regression coefficients were quite low and inter-experimental variations were high 
(fig. AIV.5). 
   
 
258 
 
Figure AIV.5 :  Total GFP expression on 3 and 4 dpt is indicative for the maximum functional 
LV titer.  
Results represent 61 data points for 3 and 4 dpt, respectively, corresponding to 15 independent 
experiments at 1 or 2 DMD and in different medium compositions. Regressions for samples from 
3 and 4 dpt gave: R2= 0.7 and R2 = 0.6, respectively 
 
One of the limitations of the method was that the total GFP expression signal is a function of the 
number of producer cells distributed in the well prior to measurement. Any variation in cell 
density (obtained from manual counting) is thus reflected in the GFP signal (unpublished 
observation). In addition, control cultures which were transfected either without the VSV-G or 
the Gag-Pol encoding plasmid and did not generate functional vector particles, also resulted in 
significant GFP expression, suggesting that the transgene is also directly expressed of the transfer 
vector plasmid (plasmid construct CSII-CMV5-GFPq alone; refer to section 2.1.2 for details on 
plasmid constructs) after transfection.  
Whereas the value of the method, in particular with respect to LVs carrying other transgenes is 
limited, the advantage of the GFP expression measurement during LV production is, however, 
that it value is rapidly available during the experiment. The method is therefore a valuable 
indicator for process development.  
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Figure AIV.6 :  Viral production kinetics and permittivity monitoring for bioreactor run #2; (A) 
cell, density, functional LV and VG titer, dashed line indicates time of transfection; (B) 
monitoring results (permittivity), dashed lines mark process phases 1 and 2; (compare chapter 6 
(bioreactor run in starting conditions), appendix II, figure AII.5 and table AIII.1) 
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Figure AIV.7 : Addition of Synthechol (SC) or valproic acid (VPA) do not have positive effects 
on LV production 
VPA (SIGMA P4543, prepared at a stoch concentration of 500 mM in MilliQ water) was added 
16 hpt at 5 mM. VPA was described as a potent alternative histone deacetylase inhibitor 
(Backliwal, Hildinger et al. 2008); SC (SIGMA S5442; was added to HyQ medium at a 
concentration of 1:1000 which was determined to be the maximum concentration without 
negative impact on viability). Cholesterol was found in several studies to act as an enhancer or 
LV infectivitiy (Chen, Ott et al. 2009). 
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ADDITIONAL DATA FOR CHAPTER 5 
Table AIV.2: Identification of process transition phases in bioreactor runs 
Process transition points (PTP) were identified based on online monitoring data and used to define the process phases 1-4 (see chapter 
6) 
Culture Titer,  
GTA (max)3, 
PCR (max) 3; 
Total yield4  
(GTA, PCR) 
Operation  
(mode, 
perfusion rate, 
cell density at 
time of 
transfection,  
# of PTP; 
culture medium; 
Remarks) 
PTP 1 
 
PTP 2 
 
PTP 3 PTP 4 
   
Identification Criteria;  
Time (hpt); Titer  
(tu/mL, %);  
Process Phase 
 
Change in 
∆εmax  
(rate pF/cm/h, 
%));  
Change in fc 
(kHz, %) 
Identification Criteria;  
Time (hpt); Titer (tu/mL, 
%);  
Process Phase 
 
Change 
in ∆εmax  
(rate 
pF/cm/h, 
%));  
Change 
in fc (kHz, 
%) 
Identification Criteria;  
Time (hpt); Titer  
(tu/mL, %);  
Process Phase 
 
Change in ∆εmax  
(rate pF/cm/h, %));  
Change in fc (kHz, 
%) 
Identification 
Criteria;  
Time (hpt); Titer  
(tu/mL, %);  
Process Phase 
 
Change in ∆εmax  
(rate pF/cm/h, %));  
Change in fc (kHz, 
%) 
Run #1 none Batch, -,-, 3, 
HyQ; no 
transfection 
batch culture 
Decrease in fc, change 
in slope of ∆εFC; 0-80 
hinoc; 
n.A.; Exponential 
growth phase 
12 pF/cm/80 
h;780-700, 
10% 
decrease 
over > 3 d 
Increase ∆εmax, fc; 80-220h; 
n.A.;  
Linear growth at high 
viability, maximum in 
oxygen consumptino 
1234.5 
/140 h; 
700-630-
730 
 
Decrease ∆εmax, 
increase fc; 220-280 h; 
n.A.; Death phase, 
decrease in viability 
34-26.1; 720-800   
Run #2 Low yield, 
8x105, 3.3x108, 
5.6x109, 
3.1x1012 
 
Perfusion, 2 
VVD, 1x106, 3, 
LC-SFM L, 
results acquired 
with Aber B220 
Increase ∆εmax, fc 
constant; -68-40 hpt; 
n.a./2-3%;  
Exponential growth 
phase/ pre-production 
1-10; 
~7002 
Slope change in ∆εmax; 40-
108; 7x105; 
Production phase at 
maintained exponential 
growth, slope change in 
oxygen consumption. 
10-40; 
700  
625, 11 
% 
Minimum in fc, slope 
change in ∆εmax; 
leveling of fc; 108-144; 
3-4x105; Decrease in 
viral titer/harvest time 
40-50, +25 %; 625-
700, 12 % 
  
Run #3 High yield, 
7x107, 
5.6x109, 
3.6x1011, 
2.3x1013 
Perfusion, 2 
VVD, 4.4x106, 4, 
HyQ; results 
acquired with 
Aber B220 
increase ∆εmax after 
transfection, decrease 
in fc; 0-25; 105-6, <10 
%; 
Charging and 
induction, phase post 
transfection/pre-
production 
23.5-34 
pF/25 h; 44.7 
%; 480-425-
515, 11% 
drop, 21 % 
increase 
Increase in fc: decrease in 
∆εmax; 25-70 hpt; 1x107-
~7x107, 10%-100 %;  
Viral release, start of 
production 
34-28, - 
17.6 % 
decrease; 
515-615-
530, 19.4 
% 
Change in slope ∆εmax 
and minimum in fc; 70-
96 hpt; 3.5-1.6x107, 
<20-40 %;  
Decrease in viral 
titer/harvest time 
31-28.5, -8 %; 615-
540, -12 % 
Increase in fc, 
decrease ∆εmax; end 
of process ; 96 – 
process end, titer: < 
20 % 
∆εmax <20 
fc >600 
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Run #4 High yield,  
4x107,  
3.8x109,  
4.25x1011,  
5x1013 
Perfusion, 2 
VVD, 4.7x106, 4, 
HyQ 
increase ∆εmax; 
decrease in fc; 
maximum in ∆εmax, 
minimum in fc; 0-24; 
<6x105, <1.5 %; 
Charging/induction, 
phase post 
transfection/pre-
production 
35 64/24 h; 
83 %, 
(aber: 30-
48/24 h; 60 
%); 
720 625, -
13%; 1030- 
920, 10.6%) 
decrease in ∆εmax, increase 
in fc; change in slope ∆εmax, 
maximum fc; 24-50 hpt; 
3.8x107-3.5x107; Viral 
release and peak titer, 
maximum in oxygen 
consumption 
64-40; -
37.5 %; 
(Aber: 
48—33; -
31.25 %; 
615-790, 
28 % 
increase; 
(Aber: 
920-1090, 
18.5% 
Slope change in ∆εmax 
/slope change in fc; 50-
75 (fc)-84 (∆εmax); 2.8-
1e7, 74-35 %;  
Decrease in viral 
titer/harvest time 
40-28/31.5, 30 %; 
770-715/73,-8 % 
Decrease of ∆εmax 
until; end of 
process; 75/84 hpt – 
process end, 
<30 % 
∆εmax <30, fc = 730 
Run #5 High yield, 
3x107, 
4.6x109, 
3x1011, 
 8x1013 
Perfusion, 2 
VVD, 8x106, 4; 
HyQ+ 
Increase ∆εmax after tf, 
decrease in fc; 
maximum in ∆εmax; 
minimum in fc; 
0-24; <1e4, <1.5;  
Charging/induction, 
phase post 
transfection/pre-
production; maximum 
in oxgen consumption 
73110/24h; 
50 %; 
(Aber: 94-
128/24 h, 
36%); 
635 525, 
17%; 
(Aber: 380-
330, 13%) 
1: decrease in ∆εmax, 
increase in fc; 2: change in 
slope ∆εmax, maximum fc; 
 24-45/50;3.1x107 (max), 
6.5-100-70 %; 
Viral release and peak 
titer, maximum in oxygen 
consumption 
110 
(24h)-55 ; 
50 %; 
(Aber: 
128-64, 
50 %); 
525-825, 
57 % 
increase; 
330- 540; 
63 % 
 
Slope change in ∆εmax; 
50-70 hpt, 172-192 h 
inoc; 2.2-1.4x107, 70-
45/40 %; Decrease in 
viral titer/harvest time 
55-44pf/cm/26 h , 20 
%; 825-780, 5.5 % 
Decrease of ∆εmax 
until, end of 
process; 70 hpt – 
process end, 
< 30 % 
∆εmax <40, 
fc = 760-720 
PTP: process transition points 
Remarks for Table AIV.2 : 
1: LV titer GTA in bioreactor supernatant sample 
2: high variation in fc at beginning of culture due to low biomass level 
3: maximum titer in reactor supernatant 
4: after 5 dpt 
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ADDITIONAL DATA FOR APPENDIX II: 
 
Figure AIV.8: Nutrient and byproduct concentrations (glucose, glutamine, lactate) in small scale 
LV production. Culture were transfected using improved production conditions at 2 DMD and 
two different cell densities (5x106 c/mL and 1x107 c/mL). All concentrations remained below 
limiting or inhibiting values, except for lactate concentration before the first medium exchange 
 
Figure AIV.9: Functional LV titer evolution is identical in bioreactor and shake flask control 
cultures; experiment shown corresponds to run # 5. Control 1 was taken from the bioreactor 3.5 h 
before transfection and transfected in the shake flask with the identical polyplex preparation than 
the mother culture; control 2 was taken from the bioreactor 1.5 h after transfection; both control 
cultures were subject to 2 DMD  
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Figure AIV.10: Characteristic frequency and glucose consumption rate do not correlate during 
bioreactor LV production. Data correspond to run #4; dashed line indicates the time of 
transfection. The decrease in fc after transfection, paralleled an increase in glucose consumption 
rates indicates that the changes in fc is not linked with decreasing metabolic activity (as observed 
in chapter 5 for batch cultivation) 
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Figure AIV.11: Shake flask cultures in different medium compositions. Cultures were inoculated 
at cell density of ~3x105 c/mL and grown in regular medium (HyQ) and at supplement (CB5 reg) 
concentrations of 5 and 10 % v/v 
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ADDITIONAL DATA FOR APPENDIX III 
Practical applications of Online Permittivity Signals: Characterization of HEK293 Batch Growth 
and Identification OF metabolic Shifts 
Supplementary Figure AIII.1/Figure AIV.12: 
Control shake flask cultures (sample taken from 
the bioreactor 1.5 h after inoculation) showed 
similar metabolic and growth profiles compared 
to the mother culture in the bioreactor; arrows 
mark the end of the exponential growth and 
beginning of death phase, respectively. The 
death phase began earlier in shake flask control 
cultures, most likely because of elevated lactate 
concentrations, causing a decrease in pH. At the 
end of the culture, (~250 h, the pH of control 
was determined at 6.3. 
 
(A) vcc and growth rates 
(B) glucose concentrations and consumption 
rates 
(C) lactate concentrations and production rates 
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THE EFFECT OF SODIUM BUTYRATE ADDITION TIME POINT ON LV 
PRODUCTION 
 
Figure AIV.13: The addition of sodium butyrate at different time points post-transfection (0, 2, 6, 
16 hpt) was evaluated using transfection at 5x106 c/mL in HyQ+ medium.  
Impact of butyrate was previously observed (see chapter 3) to act as a strong inducer of LV 
production, resulting in yield improvement of ~15-fold at a concentration of 5 mM. When adding 
butyrate at different time points post-transfection (0-16 hpt), the LV release with titers >1x107 
was shifted to earlier harvest points. The first harvest (16 hpt), which typically contained only 
small amounts of LV under improved production conditions, contained >1x107 tu/mL when 
butyrate was added as early as 0-2 hpt; simmilarly, the second harvest (24 hpt) also showed 
significantly increased titers). Yet, the overall yield was not improved in any of the tested 
alternative production conditions with the addition of butyrate at 16 hpt resulting in highest LV 
yields. 
The addition of an even later addition of butyrate might therefore be evaluated. However, it needs 
to be kept in mind that this might further delay LV release/ i.e. prolong the overall process and, 
with regards to production in bioreactor, perfusion time. 
The results also indicate that although the intial plasmid uptake is a fast process leading to high 
functional LV titers as early as 16 hpt, expression of all LV-encoding proteins at highest 
efficiency takes only places at later time points, i.e. 1-3 dpt. A further analysis of expression 
kinetics could this be useful to further optimize muli plasmid transfection systems. 
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ADDITIONAL OBSERVATIONS DURING LV PRODUCTION 
  
Figure AIV.14: LV production with and without the addition of sodium butyrate at 5 mM. In 
these initial experiments in LC-SFM L medium, the butyrate stock was not neutralized and pH 
<<7. This was corrected in later experiments (chapter 3). 
 
 
Figure AIV.15: High total GFP expression at 4 dpt in bioreactor perfusion culture (picture taken 
during run #4) 
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Figure AIV.16: Small scale LV production 4 dpt. Cultures were transfected using improved 
production conditions at different cell densities: (1): 2x106; (2): 5x106; (3): 1x107; (4) 2x107 
c/mL. Note the dramatic and increasing cell ring formation at the inner shake flask surface 
 
Figure AIV.17: Qualitative evolution of cellular aggregation during bioreactor perfusion culture 
(run #4). Figure legends indicate the time post-transfection. Immediately after inoculation (A), 
almost no cellular aggregates were observed. Aggregation then increased progressively after the 
perfusion start (B) and reached high levels at 2 (C) and 4 dpt (D) 
